Functionalized long chain hydrocarbon monocarboxylic and dicarboxylic acids useful for prevention or treatment of disease
Through the administration of specific compounds, the existing problem of reducing triglyceride levels in type IIb hyperlipidemia and other diseases has been solved, and the effects of reducing triglycerides and improving high-density lipoprotein cholesterol are achieved, reducing inflammation and fiber Progress in the development of cardiovascular disease has reduced the risk of cardiovascular disease.
Patent Information
- Application Number
- CN202410969586.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-17
- Filing Date
- 2020-07-23
- Publication Date
- 2024-11-08
AI Technical Summary
There are limited existing drugs for the treatment of type IIb hyperlipidemia, especially ineffective in reducing triglyceride levels, and are poorly tolerated by common drugs, with drug interactions and severe myotoxicity risks, and are used to reduce triglyceride treatments Options such as fish oil require frequent use and cause discomfort symptoms.
Provided is a compound and a pharmaceutically acceptable salt and solvate thereof for the treatment or prevention of various diseases including type IIb hyperlipidemia, by administering an effective amount of the compound to reduce plasma of the subject or Specific index concentrations in the serum can reduce triglyceride levels and increase high-density lipoprotein cholesterol concentration.
Effectively reduce triglyceride levels, increase high-density lipoprotein cholesterol concentration, reduce inflammation and fibrosis progression, reduce cardiovascular disease risk, and have good tolerance and safety.
Smart Images

Figure CN118903087A_ABST
Abstract
Description
[0001] This application is a divisional application of a Chinese patent application filed on July 23, 2020, with application number 202080052472.5, and invention name “Functionalized long-chain hydrocarbon mono- and dicarboxylic acids that can be used to prevent or treat diseases”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 878,852, filed on July 26, 2019, and U.S. Provisional Application No. 62 / 901,739, filed on September 17, 2019, the disclosures of each of which are incorporated herein by reference in their entirety. Technical Field
[0004] The present invention provides compounds of Formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA) and (IIIB) and pharmaceutically acceptable salts and solvates thereof, and compositions thereof. The present invention further provides methods for preventing or treating diseases, including but not limited to liver disease or abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); malignant or benign tumors of the lung, liver, gallbladder, bile duct or digestive tract; intrahepatic or extrahepatic bile duct disease; lipoprotein disorders; lipid and metabolic disorders; cirrhosis; fibrosis; glucose metabolism disorders; cardiovascular or related vascular disorders; diseases caused by steatosis, fibrosis or cirrhosis; diseases associated with increased inflammation (such as liver inflammation or lung inflammation); hepatocyte ballooning; peroxisome proliferator activated receptor-associated disorder; ATP-citrate lyase disorder; acetyl-CoA carboxylase disorder; obesity; pancreatitis; or kidney disease. Background of the Invention
[0006] Hepatocellular carcinoma (HCC) is one of the most common primary liver malignancies. Patients with chronic liver diseases (such as cirrhosis and fibrosis) have an increased risk of developing HCC. Therefore, the development of HCC in patients with chronic liver diseases should be closely monitored. The risk factors for HCC include cirrhosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), long-term alcohol abuse, hepatitis B and C, IIb type hyperlipidemia, mixed dyslipidemia, obesity and type 2 diabetes.
[0007] Patients with type IIb hyperlipidemia are at high risk for developing NAFLD and nonalcoholic steatohepatitis (NASH), which develop due to excessive production and accumulation of hepatic triglycerides. Elevated levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides are associated with mixed dyslipidemia (including type IIb hyperlipidemia characterized by elevated apolipoprotein B), very low-density lipoprotein cholesterol (VLDL-C), intermediate-density lipoprotein cholesterol (IDL), and small dense low-density lipoprotein (LDL) levels, as well as elevated levels of LDL-C and triglycerides.
[0008] The treatment options for treating type IIb hyperlipidemia are currently limited. Although statins can effectively reduce LDL-C and reduce inflammation, they are generally not very effective in reducing triglyceride concentrations. In addition, high-dose statin therapy is generally poorly tolerated because it can cause muscle pain (myalgia) and increase the risk of severe muscle toxicity (such as rhabdomyolysis) in patients. Moreover, conventional triglyceride-lowering agents used in combination with statins are generally poorly tolerated. When used together with statins, it is known that fibrates have drug-drug interactions, thereby causing an increase in the risk of statin blood drug levels, myalgia, muscle toxicity, and an increase in safety risks. In fact, the interaction of the statin Baychol (cerivastatin) with the fibrate gemfibrozil causes severe muscle toxicity and death, and causes safety concerns, causing Baychol to withdraw from the U.S. market. Fish oils that have been used to reduce triglyceride levels need to be taken multiple times a day, and can cause fish oil aftertaste, hiccups, or nausea. Niacin can cause flushing, especially when taken in combination with statins.
[0009] Hepatocellular adenomas are benign liver tumors whose genetics and pathophysiology are not fully understood. These lesions pose diagnostic and therapeutic challenges, and survival after treatment remains challenging. Bile duct adenomas pose the same therapeutic challenges. Digestive system adenomas are sporadic tumors arising from the glandular epithelium of the stomach, small intestine, bile duct, colon, and rectum.
[0010] Gastrointestinal (digestive) cancers are cancers that affect the gastrointestinal tract and other organs within the digestive system. Gastrointestinal stromal tumors (GIST) are a rare type of sarcoma that develops along the gastrointestinal tract but primarily begins in the stomach or small intestine. The origin of digestive cancers is closely related to chronic inflammation of the organs through a series of progressions that depend on the histopathological stage of the affected organ. For cancers of the gastrointestinal tract or GIST, surgery may be recommended to remove the tumor and / or help maintain normal function. Other treatment options are radiation therapy, chemotherapy, hormone therapy, or targeted therapy.
[0011] Therefore, there is a need for a safe and effective therapy to treat or prevent cancer (such as gastrointestinal cancer, hepatocellular carcinoma or cholangiocarcinoma); malignant or benign tumors of the lung, liver, gallbladder, bile duct or digestive tract; liver disease or liver disorder, intrahepatic or extrahepatic bile duct disease; lipoprotein disorders; lipid and metabolic disorders; cirrhosis; fibrosis; glucose metabolism disorders; cardiovascular or related vascular disorders; diseases caused by steatosis, fibrosis or cirrhosis; diseases associated with increased inflammation (such as liver inflammation or lung inflammation); hepatocellular ballooning; peroxisome proliferator-activated receptor-related disorders; ATP-citrate lyase disorders; acetyl-CoA carboxylase disorders; obesity; pancreatitis; or kidney disease. Summary of the invention
[0012] The present invention provides compounds of Formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK), (IL), (II), (III), (IIIA) and (IIIB) and pharmaceutically acceptable salts and solvates thereof (each compound, pharmaceutically acceptable salt and solvate is a "compound of the present invention").
[0013] The present invention also provides compositions comprising i) an effective amount of a compound of the present invention and ii) a pharmaceutically acceptable carrier or vehicle (each a "composition of the present invention").
[0014] The present invention further provides a method for treating or preventing a disease, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof, wherein the disease is a liver disease or abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); malignant or benign tumors of the lung, liver, gallbladder, bile duct or digestive tract; intrahepatic or extrahepatic bile duct disease; lipoprotein disorders; lipid and metabolic disorders; cirrhosis; fibrosis; glucose metabolism disorders; cardiovascular or related vascular disorders; diseases caused by steatosis, fibrosis or cirrhosis; diseases associated with increased inflammation (such as liver inflammation or lung inflammation); hepatocyte ballooning; peroxisome proliferator-activated receptor-related disorders; ATP-citrate lyase disorders; acetyl-CoA carboxylase disorders; obesity; pancreatitis; or kidney disease.
[0015] The present invention further provides a method for treating or preventing a disease, wherein the disease is cancer, lipid and metabolic disorders, liver disorders, cirrhosis, fibrosis, glucose metabolism disorders, peroxisome proliferator-activated receptor-associated disorders, malignant or benign tumors of the lung, liver, gallbladder and digestive tract, ATP-citrate lyase disorders, acetyl-CoA carboxylase disorders, obesity, pancreatitis, kidney disease, hepatocyte ballooning, liver inflammation or lung inflammation.
[0016] The present invention further provides a method for reducing the C-reactive protein (CRP) concentration, serum amyloid A (SAA) concentration, alanine aminotransferase (ALT) concentration, aspartate aminotransferase (AST) concentration, alkaline phosphatase (ALP) concentration, gamma-glutamyl transferase (GGT) concentration, serum creatinine concentration, 7α-hydroxy-4-cholesten-3-one (C4) concentration, protein: creatinine ratio, creatine kinase concentration, angiopoietin-like protein 3 concentration, angiopoietin-like protein 4 concentration, angiopoietin-like protein 8 concentration, fibrinogen concentration, total cholesterol concentration, low-density lipoprotein cholesterol concentration, low-density lipoprotein concentration, very low-density lipoprotein cholesterol concentration, very low-density lipoprotein concentration, non-HDL cholesterol concentration, non-HDL concentration, apolipoprotein B concentration, lipoprotein (a) concentration or serum triglyceride concentration of a subject in the subject's plasma or serum, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0017] The present invention further provides a method for reducing triglyceride concentration in the liver of a subject, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0018] The present invention further provides a method for increasing the concentration of high-density lipoprotein cholesterol or high-density lipoprotein in the plasma or serum of a subject, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0019] The present invention further provides a method for treating a disease, comprising administering an effective amount of a compound of the present invention to a subject in need thereof, wherein the disease is a gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) or an autoimmune disease.
[0020] The present invention further provides a method for regressing, reducing the rate of progression, or inhibiting the progression of fibrosis, hepatocyte ballooning, and liver inflammation, comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0021] The present invention further provides a method for inhibiting, reducing or delaying the development of lipid synthesis, hepatic steatosis, hepatocyte ballooning or inflammation, liver fibrosis, pulmonary fibrosis or cirrhosis in a subject, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0022] The present invention further provides a method for reducing the risk of a subject developing or suffering from atherosclerosis, coronary heart disease, peripheral vascular disease, stroke or restenosis, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0023] The present invention further provides a method for increasing the HDL concentration in the serum or plasma of a subject, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0024] The present invention further provides a method for inhibiting NF-kB or stellate cell activation, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0025] The present invention further provides a method for activating PPAR (peroxisome proliferator-activated receptors), which comprises administering an effective amount of a compound of the present invention to a subject in need thereof.
[0026] The present invention further provides a method for reducing the fat or cholesterol content of livestock meat or poultry eggs, which comprises administering an effective amount of the compound of the present invention to the livestock or poultry.
[0027] The present invention further provides a method for modulating, directly inhibiting or allosterically inhibiting ATP citrate lyase in a subject, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0028] The present invention further provides a method for modulating, directly inhibiting or allosterically inhibiting acetyl-CoA carboxylase 1 or acetyl-CoA carboxylase 2 in a subject, the method comprising administering to the subject an effective amount of a compound of the present invention.
[0029] The present invention further provides a method for treating or preventing a disease, the method comprising administering an effective amount of a composition of the present invention to a subject in need thereof, wherein the disease is cancer, lipid and metabolic disorders, liver disorders, cirrhosis, fibrosis, glucose metabolism disorders, peroxisome proliferator-activated receptor-associated disorders, malignant or benign tumors of the lung, liver, gallbladder and digestive tract, ATP-citrate lyase disorders, acetyl-CoA carboxylase disorders, obesity, pancreatitis, kidney disease, hepatocyte ballooning, liver inflammation or lung inflammation. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figures 1A-1D The inhibitory effects of compounds I-32, I-61, I-1 and III-1 on mouse primary hepatocyte lipogenesis are shown respectively, expressed as a percentage of the control group.
[0031] Figures 2A-2D The antiproliferative effects of compounds I-32, I-61, I-1 and III-1 on Hepa1-6 cells are shown, respectively, as a percentage of vehicle control.
[0032] Figures 3A-3DThe antiproliferative effects of compounds I-32, I-61, I-1 and III-1 on Hep3B cell proliferation are shown, respectively, as a percentage of vehicle control.
[0033] Figures 4A-4D The anti-clonogenic effects of compounds I-32, I-61, I-1 and III-1 in Hepa1-6 cells are shown, expressed as a percentage of vehicle control.
[0034] Figures 5A-5D The anti-clonogenic effects of compounds I-32, I-61, I-1 and III-1 in Hep3B cells are shown, respectively, as a percentage of vehicle control.
[0035] Fig. 6A The antiproliferative effects of compound 1-32 and sorafenib in Hep3B cells in the presence or absence of other compounds are shown. Figure 6B The antiproliferative effects of compound 1-32 and lenvatinib in Hep3B cells in the presence or absence of other compounds are shown. Figure 6C The antiproliferative effects of compound 1-61 and sorafenib in the presence or absence of other compounds in Hep3B cells are shown. Fig.6D The antiproliferative effects of compound 1-61 and lenvatinib in the presence or absence of other compounds in Hep3B cells are shown.
[0036] Fig. 7A The antiproliferative effects of compound 1-32 and sorafenib in Hepa1-6 cells in the presence or absence of other compounds are shown. Figure 7B The antiproliferative effects of compound 1-32 and lenvatinib in the presence or absence of other compounds in Hepa1-6 cells are shown. Figure 7C The antiproliferative effects of compound 1-61 and sorafenib in the presence or absence of other compounds in Hepa1-6 cells are shown. Fig.7D The antiproliferative effects of compound 1-61 and lenvatinib in the presence or absence of other compounds in Hepa1-6 cells are shown.
[0037] Fig. 8A The synergistic anti-proliferative effect of compound I-32 and sorafenib in Hep3B cells was shown. Figure 8B The synergistic anti-proliferative effect of compound 1-32 and lenvatinib in Hep3B cells was shown. Figure 8C The synergistic anti-proliferative effect of compound I-61 and sorafenib in Hep3B cells was shown. Fig.8DThe synergistic anti-proliferative effect of compound I-61 and lenvatinib in Hep3B cells was shown. DETAILED DESCRIPTION
[0038] definition
[0039] The term "about" when immediately preceding a numerical value means ± to 20% of the numerical value. For example, "about" a numerical value means ± to 20% of the numerical value, in some embodiments, ± to 19%, ± to 18%, ± to 17%, ± to 16%, ± to 15%, ± to 14%, ± to 13%, ± to 12%, ± to 11%, ± to 10%, ± to 9%, ± to 8%, ± to 7%, ± to 6%, ± to 5%, ± to 4%, ± to 3%, ± to 2%, ± to 1%, to less than ± 1%, or any other value or range of values therein.
[0040] Throughout this specification, numerical ranges of certain numbers are provided. These ranges include all subranges therein. Thus, a range "from 50 to 80" includes all possible ranges therein (e.g., 51 to 79, 52 to 78, 53 to 77, 54 to 76, 55 to 75, 60 to 70, etc.). In addition, all values within a given range may be endpoints of the range thus covered (e.g., a range of 50 to 80 includes ranges with endpoints, such as, for example, 55 to 80, 50 to 75, etc.).
[0041] The term "pharmaceutically acceptable salt" includes both acid and base addition salts. Pharmaceutically acceptable salts can be obtained by reacting the compounds of the present invention acting as a base with an inorganic or organic acid to form a salt, such as salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, etc. Pharmaceutically acceptable salts can also be obtained by reacting the compounds of the present invention acting as an acid with an inorganic or organic base to form a salt, such as salts of sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, ammonia, isopropylamine, trimethylamine, etc. Those skilled in the art will further recognize that pharmaceutically acceptable salts can be prepared by reacting the compounds of the present invention with a suitable inorganic or organic acid or base via any one of a variety of known methods.
[0042] The term "solvate" refers to a solvated complex. A solvate may be formed by solvation (a combination of solvent molecules with a molecule or ion of the invention), or a solvate may be an aggregate comprising a solute ion or molecule or a solvent molecule. The solvent may be water, in which case the solvate is a hydrate. Examples of hydrates include, but are not limited to, hemihydrates, monohydrates, dihydrates, trihydrates, hexahydrates, and the like. Solvates may be formed via hydration (including via absorption of water). Pharmaceutically acceptable salts may also be solvates. In the case where a solvate is obtained via crystallization from a solvent, the solvent may be an alcohol, such as methanol or ethanol; an aldehyde; a ketone, such as acetone; or an ester, such as ethyl acetate.
[0043] The compounds of the present invention may have one or more asymmetric centers and may therefore be mirror image isomers, racemates, diastereomers, other stereoisomers, and mixtures thereof. The compounds of the present invention include all such possible isomers (including geometric isomers), as well as racemic and optically pure forms thereof, whether or not specifically described herein. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques such as chromatography and fractional crystallization. Conventional techniques for preparing or separating individual mirror image isomers include chiral synthesis from appropriate optically pure precursors or resolution of racemates using, for example, chiral high pressure liquid chromatography (HPLC). When the compounds of the present invention contain an olefinic double bond or another center of geometric asymmetry, and unless otherwise specified, the compounds include E and Z geometric isomers. Likewise, the compounds of the present invention include all tautomeric forms.
[0044] "Effective amount" when used in conjunction with a compound of the present invention means an amount of the compound of the present invention that, when administered to a subject alone or with another pharmaceutically active agent, is effective in treating or preventing a disease.
[0045] "Effective amount" when used in conjunction with another pharmaceutically active agent, means an amount of the other pharmaceutically active agent that, alone or in combination with the compounds of the present invention, is effective in treating or preventing a disease.
[0046] A "subject" is a human or non-human mammal, such as a cow, horse, cat, dog, rodent, or non-human primate. A human can be male or female, a child, adolescent, or adult. A female can be premenstrual or postmenstrual.
[0047] "Mammal" includes humans, livestock such as laboratory animals (e.g., mice, rats, rabbits, monkeys, dogs, etc.) and domestic pets (e.g., cats, dogs, pigs, cows, sheep, goats, horses, rabbits), and non-domesticated wild animals.
[0048] Unless otherwise indicated, all weight percentages (ie, "weight %" and "wt. %" and w / w) referred to herein are relative to the total weight of the mixture or composition, as the case may be.
[0049] As used herein, the following terms have the following meanings unless otherwise indicated:
[0050] "Halo", "Hal" or "halogen" refers to Br, Cl, F or I.
[0051] "Alkyl" refers to a fully saturated straight or branched hydrocarbon chain having from one to twelve carbon atoms and connected to atoms by single bonds. Alkyl groups having a carbon number ranging from 1 to 12 are included. Alkyl groups having 1 to 12 carbon atoms are C1-C 12 Alkyl, alkyl having 1 to 10 carbon atoms is C1-C 10 Alkyl, alkyl having 1 to 6 carbon atoms is C1-C6 alkyl and alkyl having 1 to 5 carbon atoms is C1-C5 alkyl. C1-C5 alkyl includes C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl and C1 alkyl (i.e. methyl). C1-C6 alkyl includes all the above parts about C1-C5 alkyl, but also includes C6 alkyl. C1-C 10 Alkyl includes all of the above mentioned moieties regarding C1-C5 alkyl and C1-C6 alkyl, but also includes C7, C8, C9 and C 10 Similarly, C1-C 12 Alkyl includes all of the aforementioned moieties, but also includes C 11 and C 12 Alkyl. C1-C 12 Non-limiting examples of alkyl include methyl, ethyl, n-propyl, isopropyl, sec-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, tert-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl and n-dodecyl. Unless otherwise specified, alkyl may be unsubstituted or substituted with substituents disclosed herein.
[0052] "Alkylene" refers to a fully saturated straight or branched chain divalent hydrocarbon having from one to twelve carbon atoms. 12 Non-limiting examples of alkylene groups include methylene, ethylene, propylene, n-butylene, etc. Each alkylene end is connected to an atom with a single bond. The connection point of the alkylene chain can be one or two atoms. Unless otherwise indicated, the alkylene chain can be unsubstituted or substituted with a substituent disclosed herein.
[0053] "Alkenyl" refers to a straight or branched hydrocarbon chain having two to twelve carbon atoms and having one or more carbon-carbon double bonds. Each alkenyl group is connected to the atom by a single bond. Alkenyl groups having a number of carbon atoms ranging from 2 to 12 are included. Alkenyl groups having 2 to 12 carbon atoms are C2-C12 Alkenyl, alkenyl having 2 to 10 carbon atoms is C2-C 10 Alkenyl, alkenyl having 2 to 6 carbon atoms is C2-C6 alkenyl and alkenyl having 2 to 5 carbon atoms is C2-C5 alkenyl. C2-C5 alkenyl includes C5 alkenyl, C4 alkenyl, C3 alkenyl and C2 alkenyl. C2-C6 alkenyl includes all the above parts about C2-C5 alkenyl, but also includes C6 alkenyl. C2-C 10 Alkenyl includes all of the above moieties for C2-C5 alkenyl and C2-C6 alkenyl, but also includes C7, C8, C9 and C 10 Similarly, C2-C 12 Alkenyl includes all of the aforementioned moieties, but also includes C 11 and C 12 Alkenyl. C2-C 12 Non-limiting examples of alkenyl groups include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), isopropenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, 3-nonenyl, 4-nonenyl, 5-nonenyl, 6-nonenyl , 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless otherwise specified, an alkyl group may be unsubstituted or substituted with a substituent disclosed herein.
[0054] "Alkenylene" refers to a straight or branched divalent hydrocarbon chain radical having from two to twelve carbon atoms and having one or more carbon-carbon double bonds. 12Non-limiting examples of alkenylene include vinylene, propenylene, butenylene, etc. Each end of the alkenylene chain is connected to the atom with a single bond. The connection point of the alkenylene chain can be through one or two atoms. Unless otherwise indicated, the alkenylene chain can be unsubstituted or substituted with a substituent disclosed herein.
[0055] "Alkynyl" refers to a straight or branched hydrocarbon chain radical having from two to twelve carbon atoms and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the atom by a single bond. Alkynyl groups having a number of carbon atoms ranging from 2 to 12 are included. Alkynyl groups having 2 to 12 carbon atoms are C2-C 12 Alkynyl, alkynyl having 2 to 10 carbon atoms is C2-C 10 Alkynyl, alkynyl having 2 to 6 carbon atoms is C2-C6 alkynyl and alkynyl having 2 to 5 carbon atoms is C2-C5 alkynyl. C2-C5 alkynyl includes C5 alkynyl, C4 alkynyl, C3 alkynyl and C2 alkynyl. C2-C6 alkynyl includes all the above parts about C2-C5 alkynyl, but also includes C6 alkynyl. C2-C 10 Alkynyl includes all of the above mentioned moieties for C2-C5 alkynyl and C2-C6 alkynyl, but also includes C7, C8, C9 and C 10 Similarly, C2-C 12 Alkynyl includes all of the aforementioned moieties, but also includes C 11 and C 12 Alkynyl. C2-C 12 Non-limiting examples of alkenyl include ethynyl, propynyl, butynyl, pentynyl, etc. Unless otherwise specified, an alkyl group may be unsubstituted or substituted with substituents disclosed herein.
[0056] "Alkyne" refers to a straight or branched divalent hydrocarbon chain radical having from two to twelve carbon atoms and having one or more carbon-carbon triple bonds. 12 Non-limiting examples of alkynylene include ethynylene, propynylene, butynylene, etc. Each end of the alkynylene chain is connected to the atom with a single bond. The connection point of the alkynylene chain can be through one or two atoms. Unless otherwise indicated, the alkynylene chain can be unsubstituted or substituted with a substituent disclosed herein.
[0057] "Alkoxy" refers to a group of the formula -OR a A group in which R a is alkyl, alkenyl or alkynyl as defined herein. Unless otherwise specified, an alkoxy group may be unsubstituted or substituted with a substituent disclosed herein.
[0058] "Aryl" refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 18 carbon atoms and at least one aromatic ring. Aryl can be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which can include fused or bridged ring systems. Aryl includes, but is not limited to, aceanthrylenyl, acenaphthenyl, acephenanthrylenyl, anthracenyl, azulenyl, chrysenyl, fluoranthenyl, fluorenyl, as-dicyclopentadienylphenyl, s-dicyclopentadienylphenyl, dihydroindenyl, indenyl, naphthyl, perbenzonaphthyl, phenanthrenyl, phenyl, pleiadenyl, pyrenyl and triphenylene. Unless otherwise indicated, aryl can be unsubstituted or substituted with substituents disclosed herein.
[0059] "Arylene" refers to a divalent aromatic radical, wherein the aromatic radical is as defined herein. Unless otherwise specified, an arylene radical may be unsubstituted or substituted with substituents disclosed herein.
[0060] "Arylalkyl" refers to a group of the formula -R b -R c A group in which R b is an alkylene group as defined herein and R c is an aryl group as defined herein, for example, benzyl, diphenylmethyl, and the like. Unless otherwise specified, an arylalkyl group may be unsubstituted or substituted with a substituent disclosed herein. "Arylalkenyl" refers to a radical of the formula -R b -R c A group in which R b is alkenylene as defined herein and R c is an aryl group as defined herein. Unless otherwise specified, an arylalkenyl group may be unsubstituted or substituted with substituents disclosed herein.
[0061] "Arylalkynyl" refers to a group of the formula -R b -R c A group in which R b is an alkynylene group as defined herein and R c is an aryl group as defined herein. Unless otherwise specified, an arylalkynyl group may be unsubstituted or substituted with substituents disclosed herein.
[0062] "Cycloalkyl" refers to a non-aromatic monocyclic or polycyclic fully saturated hydrocarbon group consisting of carbon and hydrogen atoms, including fused or bridged ring systems, having from three to twelve carbon atoms, preferably from three to ten carbon atoms and connected to the atom by a single bond. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decahydronaphthyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, etc. Unless otherwise indicated, cycloalkyls may be unsubstituted or substituted with substituents disclosed herein.
[0063] "Aryloxy" refers to a radical of the formula -O(aryl), wherein aryl is as defined herein. Aryloxy includes, but is not limited to, phenoxy (-O(phenyl)). Unless otherwise indicated, aryloxy may be unsubstituted or substituted with substituents disclosed herein.
[0064] "Cycloalkenyl" refers to a non-aromatic monocyclic or polycyclic group consisting of carbon and hydrogen atoms and having one or more carbon-carbon double bonds. Cycloalkenyl may include a fused or bridged ring system having from three to twelve carbon atoms (in some embodiments, from three to ten carbon atoms). Cycloalkenyl is connected to the atom with a single bond. Monocyclic cycloalkenyl includes, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, etc. Polycyclic cycloalkenyl includes, for example, bicyclo [2.2.1] hept-2-enyl, etc. Unless otherwise indicated, cycloalkenyl may be unsubstituted or substituted with a substituent disclosed herein.
[0065] "Cycloalkynyl" refers to a non-aromatic monocyclic or polycyclic hydrocarbon group consisting only of carbon and hydrogen atoms having one or more carbon-carbon triple bonds, which may include a fused or bridged ring system having from five to twelve carbon atoms (in some embodiments, from five to ten carbon atoms), and which is connected to the rest of the molecule by a single bond. Monocyclic cycloalkynyls include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise indicated, cycloalkynyls may be unsubstituted or substituted with substituents disclosed herein.
[0066] "Cycloalkylalkyl" refers to a group of the formula -R b -R d A group in which R b is an alkylene group as defined herein and R d is a cycloalkyl group as defined herein. Unless otherwise indicated, a cycloalkylalkyl group may be unsubstituted or substituted with a substituent as disclosed herein. "Cycloalkylalkenyl" refers to a group of the formula -R b -R d A group in which R b is alkenylene as defined herein and R dis a cycloalkyl group as defined herein. Unless otherwise specified, a cycloalkylalkenyl group may be unsubstituted or substituted with a substituent as disclosed herein. "Cycloalkylalkynyl" refers to a group of the formula -R b -R d A group in which R b is alkynylene as defined herein and R d is a cycloalkyl group as defined herein. Unless otherwise specified, a cycloalkylalkynyl group may be unsubstituted or substituted with substituents disclosed herein.
[0067] "Cycloalkenylalkyl" refers to a group of the formula -R b -R d A group in which R b is an alkylene group as defined herein and R d is a cycloalkenyl group as defined herein. Unless otherwise indicated, a cycloalkenylalkyl group may be unsubstituted or substituted with a substituent as disclosed herein. "Cycloalkenylalkenyl" refers to a group of the formula -R b -R d A group in which R b is alkenylene as defined herein and R d is a cycloalkyl group as defined herein. Unless otherwise specified, a cycloalkenylalkenyl group may be unsubstituted or substituted with a substituent as disclosed herein. "Cycloalkenylalkynyl" refers to a group of the formula -R b -R d A group in which R b is alkynylene as defined herein and R d is a cycloalkyl group as defined herein. Unless otherwise specified, a cycloalkenylalkynyl group may be unsubstituted or substituted with substituents disclosed herein.
[0068] "Cycloalkynylalkyl" refers to a group of the formula -R b -R d A group in which R b is an alkylene group as defined herein and R d is a cycloalkynyl group as defined herein. Unless otherwise specified, a cycloalkynylalkyl group may be unsubstituted or substituted with a substituent as disclosed herein. "Cycloalkynylalkenyl" refers to a group of the formula -R b -R d A group in which R b is alkenylene as defined herein and R d is a cycloalkyl group as defined herein. Unless otherwise specified, a cycloalkynylalkenyl group may be unsubstituted or substituted with a substituent as disclosed herein. "Cycloalkynylalkynyl" refers to a group of the formula -R b -R d A group in which R b is alkynylene as defined herein and R dis a cycloalkyl group as defined herein. Unless otherwise specified, a cycloalkynylalkynyl group may be unsubstituted or substituted with substituents disclosed herein.
[0069] "Carbocyclyl", "carbocyclic ring" or "carbocycle" refers to a ring structure in which each of the atoms forming the ring is carbon. A carbocyclyl, carbocyclic ring or carbocycle may contain from 3 to 20 carbon atoms in the ring. Carbocyclyl, carbocyclic ring or carbocycle include aryl, cycloalkyl, cycloalkenyl and cycloalkynyl as defined herein. A carbocyclyl, carbocyclic ring or carbocycle may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused, bridged and spirocyclic systems. Unless otherwise indicated, a carbocyclyl, carbocyclic ring or carbocycle may be unsubstituted or substituted with substituents disclosed herein.
[0070] "Haloalkyl" refers to an alkyl group, as defined herein, substituted with one or more halo groups, as defined herein, for example, trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc. Unless otherwise specified, a haloalkyl group may be unsubstituted or substituted with substituents disclosed herein.
[0071] "Haloalkenyl" refers to an alkenyl group as defined above substituted with one or more halo groups as defined herein, for example, 1-fluoropropenyl, 1,1-difluorobutenyl, etc. Unless otherwise specified, a haloalkenyl group may be unsubstituted or substituted with substituents disclosed herein.
[0072] "Haloalkynyl" refers to an alkynyl group, as defined herein, substituted with one or more halo groups, as defined herein, for example, 1-fluoropropynyl, 1-fluorobutynyl, etc. Unless otherwise specified, a haloalkenyl group may be unsubstituted or substituted with substituents disclosed herein.
[0073] "Heterocyclyl" refers to a 3-20 membered non-aromatic partially unsaturated or aromatic ring radical comprising two to twelve carbon atoms and from one to six nitrogen, oxygen or sulfur heteroatoms. Heterocyclyl includes heteroaryl as defined herein. Unless otherwise indicated, heterocyclyl may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, including fused, bridged and spiro ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl may be partially or fully saturated. Examples of heterocyclyl include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuranyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless otherwise specified, heterocyclyl may be unsubstituted or substituted with substituents disclosed herein.
[0074] "Heterocyclylalkyl" refers to a group of the formula -R b -R e A group in which R b is an alkylene group as defined herein and R e is a heterocyclyl group as defined herein. Unless otherwise specified, a heterocyclylalkyl group may be unsubstituted or substituted with a substituent disclosed herein.
[0075] "Heterocyclylalkenyl" refers to a group of the formula -R b -R e A group in which R b is alkenylene as defined herein and R e is a heterocyclyl group as defined herein. Unless otherwise specified, a heterocyclylalkenyl group may be unsubstituted or substituted with substituents disclosed herein.
[0076] "Heterocyclylalkynyl" refers to a group of the formula -R b -R e A group in which R b is alkynylene as defined herein and R e is a heterocyclyl group as defined herein. Unless otherwise specified, a heterocyclylalkynyl group may be unsubstituted or substituted with substituents disclosed herein.
[0077] "N-heterocyclyl" refers to a heterocyclyl as defined herein, which includes at least one nitrogen and wherein the point of attachment of the heterocyclyl to the atoms of the compounds of the invention is through the nitrogen atom in the heterocyclyl. Unless otherwise specified, the N-heterocyclyl may be unsubstituted or substituted with substituents disclosed herein.
[0078] "Heteroaryl" refers to a 5- to 20-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six nitrogen, oxygen or sulfur heteroatoms and at least one aromatic ring. The heteroaryl group may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl group may be optionally oxidized; the nitrogen atom may be optionally quaternized. Examples of heteroaryl groups include, but are not limited to, azepine, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyrone, benzofuranyl, benzofuranone, benzothiophenyl (benzothiophene), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl , dibenzothiophene, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolyl, isoquinolinyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-pyridinyl oxide, 1-pyrimidinyl oxide, 1-pyrazinyl oxide, 1-pyridazinyl oxide, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl and thienyl). Unless otherwise specified, a heteroaryl group may be unsubstituted or substituted.
[0079] "N-heteroaryl" refers to a heteroaryl group as defined herein having at least one nitrogen atom and wherein the point of attachment of the heteroaryl group to the atoms of the compounds of the invention is through the nitrogen atom in the heteroaryl group. Unless otherwise specified, an N-heteroaryl group may be unsubstituted or substituted with substituents disclosed herein.
[0080] "Heteroarylalkyl" refers to a group of the formula -R b -R f A group in which R b is an alkylene chain as defined herein and R fis a heteroaryl group as defined herein. Unless otherwise specified, a heteroarylalkyl group may be unsubstituted or substituted with a substituent disclosed herein.
[0081] "Heteroarylalkenyl" refers to a group of the formula -R b -R f A group in which R b is an alkenylene chain as defined herein and R f is a heteroaryl group as defined herein. Unless otherwise specified, a heteroarylalkenyl group may be unsubstituted or substituted with substituents disclosed herein.
[0082] "Heteroarylalkynyl" refers to a group of the formula -R b -R f A group in which R b is an alkynylene chain as defined herein and R f is a heteroaryl group as defined herein. Unless otherwise specified, a heteroarylalkynyl group may be unsubstituted or substituted with substituents disclosed herein.
[0083] "Cycle" refers to a cyclic group, which may be saturated or include one or more double or triple bonds. The ring may be monocyclic, bicyclic, tricyclic or tetracyclic. Unless otherwise indicated, the ring may be unsubstituted or substituted with substituents disclosed herein.
[0084] "Thioalkyl" refers to a group of the formula -SR a A group in which R a is alkyl, alkenyl or alkynyl as defined herein. Unless otherwise specified, a thioalkyl group may be unsubstituted or substituted with a substituent disclosed herein.
[0085] The groups or radicals disclosed herein may be substituted with one or more of the following substituents: halogen atoms such as F, Cl, Br and I; hydroxyl, alkoxy or ester; thiol, thioalkyl, sulfone, sulfone or sulfoxide; amine, amide, alkylamine, dialkylamine, arylamine, alkylarylamine, diarylamine, N-oxide, imide and enamine; trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl and triarylsilyl; and other groups, optionally including one or more heteroatoms.
[0086] The groups or radicals disclosed herein may alternatively or additionally be substituted with one or more of the following substituents: oxo, carbonyl, carboxyl, or ester; or imine, oxime, hydrazone, and nitrile.
[0087] Examples of other substituents include, but are not limited to:
[0088] amino, cyano, hydroxy, imino, nitro, oxo, thio, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and heteroarylalkyl, -NR g R h 、-NR g C(=O)R h 、-NR g C(=O)NR g R h 、-NR g C(=O)OR h 、-NR g S02R h 、-OC(=O)NR g R h 、-OR g 、-SR g 、-SOR g 、-SO2R g 、-OSO2R g 、-SO2OR g , =NSO2R g 、-SO2NR g R h 、-C(=O)R g 、-C(=O)OR g 、-C(=O)NR g R h 、-CH2SO2R g and -CH2SO2NR g R h , where R g and R h are the same or different and are independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, arylalkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl or heteroarylalkyl, wherein each of the foregoing substituents is unsubstituted or substituted with one or more substituents disclosed herein.
[0089] As used herein, the symbol ("point of attachment bond") refers to a bond at the point of attachment between two chemical entities, one of which is described as being attached to the point of attachment bond and the other is not described as being attached to the point of attachment bond. For example, Indicates that the chemical entity "XY" is bonded to another chemical entity via a connection point bond.
[0090] Compounds of the present invention
[0091] Compound of formula (IA)
[0092] In some embodiments, the compound of the present invention is a compound of formula (IA):
[0093]
[0094] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0095] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0096] Z 1 and Z 2 are independently -C(R 1A )(R 2A )-(CH2) d -X A or -W-(CH2) d -C(R 3 )(R 4 )-Y;
[0097] Each d is independently 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;
[0098] Each R 1A and R 2A are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1A and R 2A Together they independently form -C3-C7 cycloalkyl;
[0099] Each R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0100] Each X A are independently H, OH, -SO3H,
[0101]
[0102]
[0103] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0104] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0105] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2- or -Se-;
[0106] Each Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0107]
[0108] and
[0109] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0110] In some embodiments of the compound of Formula (IA), Z 1 and Z 2 are independently -C(R 1A )(R 2A )-(CH2)dX A .
[0111] In some embodiments of the compound of Formula (IA), each R 1A and R 2A Independently -C 1- C6 alkyl, -C2- C6 alkenyl or -C 2- C6 alkynyl. In some embodiments, each R 1A and R 2A Independently -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl. In some embodiments, each R 1A and R 2A are independently H or -C 1- C6 alkyl. In some embodiments, R 1A and R 2A It is methyl.
[0112] In some embodiments of the compound of Formula (IA), each p is 2, 3, 4 or 5.
[0113] In some embodiments of compounds of Formula (IA), each d is 0, 1, 2, or 3. In some embodiments, d is 0 or 1.
[0114] In some embodiments, the compound of the present invention is a compound of formula (IA):
[0115]
[0116] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0117] Each p is independently 4, 5, 6 or 7;
[0118] Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y;
[0119] Each c is independently 0, 1, 2 or 3;
[0120] Each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0121] Each R 3 and R4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0122] Each X and Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0123]
[0124] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0125] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0126] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; and
[0127] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0128] In some embodiments, the compound of Formula (IA) has any one of the structures shown in Table A-1, or a pharmaceutically acceptable salt or solvate thereof.
[0129] Table A-1
[0130]
[0131]
[0132] Compound of formula (IB)
[0133] In some embodiments, the compound of the present invention is a compound of formula (IB):
[0134]
[0135] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0136] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0137] Each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y;
[0138] Each c is independently 0, 1, 2 or 3;
[0139] Each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0140] Each R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0141] Each X and Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0142]
[0143] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0144] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0145] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; and
[0146] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0147] In some embodiments, the compound of Formula (IB) has any one of the structures shown in Table A-2, or a pharmaceutically acceptable salt or solvate thereof.
[0148] Table A-2
[0149]
[0150]
[0151] Compound of formula (IC)
[0152] In some embodiments, the compound of the present invention is a compound of formula (IC):
[0153]
[0154] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0155] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0156] Each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y;
[0157] Each c is independently 0, 1, 2 or 3;
[0158] Each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0159] Each R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0160] Each X and Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0161]
[0162]
[0163] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0164] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0165] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; and
[0166] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0167] In some embodiments of the compound of Formula (IA), (IB) or (IC), Z 1 and Z 2 Each is independently -C(R 1 )(R 2 )-(CH2) c -X. In some embodiments, Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y.
[0168] In some embodiments of the compounds of Formula (IA), (IB) or (IC), X is -COOH or -COOR 5 .
[0169] In some embodiments of compounds of Formula (IA), (IB) or (IC), each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl. In some embodiments, each R 1 and R 2 Independently -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl. In some embodiments, R 1 and R 2 It is methyl.
[0170] In some embodiments of the compound of Formula (IA), (IB) or (IC), Z 1 and Z 2 Each is independently -C(R 1 )(R 2 )-(CH2) c -X, X is -COOH or -COOR 5 , and R 1 and R 2 It is methyl.
[0171] In some embodiments of compounds of Formula (IA), (IB) or (IC), c is 0 or 1.
[0172] In some embodiments of the compound of Formula (IA), (IB) or (IC), Z 1 and Z 2 Each is -C(R 1 )(R 2 )-(CH2) c -X. In some embodiments, Z 1 and Z 2 Each is -C(R 1 )(R 2 )-(CH2) c -X, and each X is -COOH.
[0173] In some embodiments of the compounds of Formula (IA), (IB) or (IC), each carbon atom and the R attached to said carbon atom are 1 and R 2 Together, they independently form a -C3-C7 cycloalkyl. In some embodiments, each carbon atom and the R 1 and R 2 Together they independently form a cyclopropyl ring.
[0174] In some embodiments of the compound of Formula (IA), (IB) or (IC), Z 1 and Z 2 Each is -C(R 1 )(R 2 )-(CH2) c -X, and at least one R 1 and an R 2 Together with the carbon atoms to which they are attached, they form -C3-C7 cycloalkyl. 1 and Z 2 Each is -C(R 1 )(R 2 )-(CH2) c -X, and at least one R 1 and an R2 Together with the carbon atom to which they are attached they form a cyclopropyl ring.
[0175] In some embodiments of compounds of Formula (IA), (IB) or (IC), R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl.
[0176] In some embodiments of the compounds of Formula (IA), (IB) or (IC), Y is -COOH or -COOR 5 .
[0177] In some embodiments of compounds of Formula (IA), (IB) or (IC), R 5 For -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl. In some embodiments, R 5 For -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl.
[0178] In some embodiments of compounds of Formula (IA), (IB), or (IC), p is 3, 4, 5, 6, or 7. In some embodiments, p is 4, 5, 6, or 7.
[0179] In some embodiments of the compound of Formula (IA), (IB) or (IC), Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y, and R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl. In some embodiments, Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y, and Y is -COOH or -COOR 5 In some embodiments, Z 1 and Z 2 One or both of them are -W-(CH2)c -C(R 3 )(R 4 )-Y, Y is -COOH or -COOR 5 , and R 5 For -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl. In some embodiments, Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y, Y is -COOH or -COOR 5 , and R 5 For -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl.
[0180] In some embodiments, the compound of Formula (IC) has any one of the structures shown in Table A-3, or a pharmaceutically acceptable salt or solvate thereof.
[0181] Table A-3
[0182]
[0183]
[0184]
[0185]
[0186]
[0187] Compound of formula (ID)
[0188] In some embodiments, the compound of the present invention is a compound of formula (ID):
[0189]
[0190] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0191] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0192] Z 1 and Z 2 are independently -C(R 1A )(R 2A )-(CH2) d -X Aor -W-(CH2) d -C(R 3 )(R 4 )-Y;
[0193] Each d is independently 0, 1, 2, 3, 4, 5, 6, 7, 8 or 9;
[0194] Each R 1A and R 2A are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1A and R 2A Together they independently form -C3-C7 cycloalkyl;
[0195] Each R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0196] Q 1 and Q 2 are independently H, OH, -C 1- C6 alkyl, -O(C 1- C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A 、-NR 1A R 2A ,F,Cl,Br,I,-CF3,-COR 1A , heteroaryl, heterocyclic or -V-OH, or each carbon atom and a Q connected to the carbon atom 1 and Q 2 together independently form a heterocyclyl or a carbocyclyl;
[0197] V is (CH2) t or arylene;
[0198] t is 0, 1, 2, 3, or 4;
[0199] Each X A are independently H, -OH, -SO3H,
[0200]
[0201]
[0202] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0203] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0204] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2- or -Se-;
[0205] Each Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0206]
[0207] and
[0208] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0209] In some embodiments of the compound of Formula (ID), Z 1 and Z 2 are independently -C(R 1A )(R 2A )-(CH2)dX A .
[0210] In some embodiments of the compound of Formula (ID), each R 1A and R 2A Independently -C 1-C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl. In some embodiments, each R 1A and R 2A Independently -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl. In some embodiments, each R 1A and R 2A are independently H or -C 1- C6 alkyl. In some embodiments, R 1A and R 2A It is methyl.
[0211] In some embodiments of the compound of Formula (ID), each p is 2, 3, 4 or 5.
[0212] In some embodiments of compounds of Formula (ID), each d is 0, 1, 2, or 3. In some embodiments, d is 0 or 1.
[0213] In some embodiments, the compound of the present invention is a compound of formula (ID):
[0214]
[0215] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0216] Each p is independently 4, 5, 6 or 7;
[0217] Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y;
[0218] Each c is independently 0, 1, 2 or 3;
[0219] Each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0220] Each R 3 and R4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0221] Q 1 and Q 2 are independently H, OH, -C 1- C6 alkyl, -O(C 1- C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A 、-NR 1A R 2A ,F,Cl,Br,I,-CF3,-COR 1A , heteroaryl, heterocyclic or -V-OH, or each carbon atom and a Q connected to the carbon atom 1 and Q 2 together independently form a heterocyclyl or a carbocyclyl;
[0222] Each R 1A and R 2A are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl;
[0223] V is (CH2) t or arylene;
[0224] t is 0, 1, 2, 3, or 4;
[0225] Each X and Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0226]
[0227] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1-C6 alkyl) or phenyl;
[0228] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0229] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; and
[0230] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0231] In some embodiments, the compound of formula (ID) has the structure shown in Table A-1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (ID) has the structure shown in Table A-5, which is mono- or di-substituted by -OH or methyl on the phenyl group, or a pharmaceutically acceptable salt or solvate thereof.
[0232] Compound of formula (IG)
[0233] In some embodiments, the compound of the present invention is a compound of formula (IG):
[0234]
[0235] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0236] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0237] Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y;
[0238] Each c is independently 0, 1, 2 or 3;
[0239] Each R 1 and R 2 Independently -C1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0240] Each R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0241] Q 1 and Q 2 are independently H, OH, -C 1- C6 alkyl, -O(C 1- C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A 、-NR 1A R 2A ,F,Cl,Br,I,-CF3,-COR 1A , heteroaryl, heterocyclic or -V-OH, or each carbon atom and a Q connected to the carbon atom 1 and Q 2 together independently form a heterocyclyl or a carbocyclyl;
[0242] Each R 1A and R 2A are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl;
[0243] V is (CH2) t or arylene;
[0244] t is 0, 1, 2, 3, or 4;
[0245] Each X and Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0246]
[0247]
[0248] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0249] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0250] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; and
[0251] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0252] In some embodiments, the compound of formula (IG), Q 1 and Q 2 Each is H.
[0253] In some embodiments, for compounds of formula (IG), p is 2, 3, 4, 5, 6, or 7. In some embodiments, for compounds of formula (IG), p is 2.
[0254] In some embodiments, the compound of formula (IG) has any one of the structures shown in Table A-4, or a pharmaceutically acceptable salt or solvate thereof.
[0255] Table A-4
[0256]
[0257] Compound of formula (IE)
[0258] In some embodiments, the compound of the present invention is a compound of formula (IE):
[0259]
[0260] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0261] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0262] Each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y;
[0263] Each c is independently 0, 1, 2 or 3;
[0264] Each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0265] Each R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0266] Q 1 and Q 2 are independently H, OH, -C 1- C6 alkyl, -O(C 1- C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A 、-NR 1A R 2A ,F,Cl,Br,I,-CF3,-COR 1A , heteroaryl, heterocyclic or -V-OH, or each carbon atom and a Q connected to the carbon atom 1 and Q 2together independently form a heterocyclyl or a carbocyclyl;
[0267] Each R 1A and R 2A are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl;
[0268] V is (CH2) t or arylene;
[0269] t is 0, 1, 2, 3, or 4;
[0270] Each X and Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0271]
[0272]
[0273] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0274] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0275] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; and
[0276] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0277] In some embodiments, the compound of formula (IE) has the structure shown in Table A-2, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IE) has the structure shown in Table A-6, which is mono- or di-substituted with -OH or methyl on the phenyl group, or a pharmaceutically acceptable salt or solvate thereof.
[0278] Compound of formula (IF)
[0279] In some embodiments, the compound of the present invention is a compound of formula (IF):
[0280]
[0281] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0282] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0283] Each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y;
[0284] Each c is independently 0, 1, 2 or 3;
[0285] Each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0286] Each R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0287] Q1 and Q 2 are independently H, OH, -C 1- C6 alkyl, -O(C 1- C6 alkyl), phenoxy, aryloxy, benzyl, -S-aryl, -SR 1A 、-NR 1A R 2A ,F,Cl,Br,I,-CF3,-COR 1A , heteroaryl, heterocyclic or -V-OH, or each carbon atom and a Q connected to the carbon atom 1 and Q 2 together independently form a heterocyclyl or a carbocyclyl;
[0288] Each R 1A and R 2A are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl;
[0289] V is (CH2) t or arylene;
[0290] t is 0, 1, 2, 3, or 4;
[0291] Each X and Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0292]
[0293] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0294] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0295] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; and
[0296] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0297] In some embodiments, the compound of formula (IF) has the structure shown in Table A-3, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the compound of formula (IE) has the structure shown in Table A-7, which is mono- or di-substituted by -OH or methyl on the phenyl group, or a pharmaceutically acceptable salt or solvate thereof.
[0298] Compounds of formula (IH) and (IJ)-(IL)
[0299] In some embodiments, the compound of the present invention is a compound of formula (IH):
[0300]
[0301] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0302] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0303] Each Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -X or -W-(CH2) c -C(R 3 )(R 4 )-Y;
[0304] Each c is independently 0, 1, 2 or 3;
[0305] Each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0306] Each R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2-C6 alkenyl, -C 2- C6 alkynyl, -O(C 1- C6 alkyl), phenyl, benzyl, Cl, Br, CN, NO2 or CF3, or each carbon atom and R attached to the carbon atom 3 and R 4 Together they independently form -C3-C7 cycloalkyl;
[0307] Q is independently -OH, methyl or methoxy;
[0308] t is 1, 2, 3, or 4;
[0309] Each X and Y is independently -OH, -COOH, -COOR 5 、-SO3H、
[0310]
[0311]
[0312] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl;
[0313] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl;
[0314] Each W is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2-, or -Se-; and
[0315] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl.
[0316] In some embodiments, the compound of Formula (IH) has the structure of Formula (IJ), (IK) or (IL) or a pharmaceutically acceptable salt thereof:
[0317]
[0318] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL),
[0320] Z 1 and Z 2 Each is independently -C(R 1 )(R 2 )-(CH2) c -X. In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y.
[0321] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), X is -COOH or -COOR 5 .
[0322] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- In some embodiments of compounds of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK) or (IL), each R 1 and R 2 Independently -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK) or (IL), R 1 and R 2 It is methyl.
[0323] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 Each is independently -C(R 1 )(R 2 )-(CH2) c -X, X is -COOH or -COOR 5 , and R 1 and R 2 It is methyl.
[0324] In some embodiments of a compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), c is 0 or 1.
[0325] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 Each is -C(R 1 )(R 2 )-(CH2) c -X. In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 Each is -C(R 1 )(R 2 )-(CH2) c -X, and each X is -COOH.
[0326] In some embodiments of the compounds of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), each carbon atom and the R attached to the carbon atom are 1 and R 2 In some embodiments of the compounds of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK) or (IL), each carbon atom and the R attached to the carbon atom are independently -C3-C7 cycloalkyl. 1 and R 2 Together they independently form a cyclopropyl ring.
[0327] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 Each is -C(R 1 )(R 2)-(CH2) c -X, and at least one R 1 and an R 2 Together with the carbon atom to which they are attached, they form a -C3-C7 cycloalkyl group. In some embodiments of the compounds of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK) or (IL), Z 1 and Z 2 Each is -C(R 1 )(R 2 )-(CH2) c -X, and at least one R 1 and an R 2 Together with the carbon atom to which they are attached they form a cyclopropyl ring.
[0328] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl.
[0329] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Y is -COOH or -COOR 5 .
[0330] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), R 5 For -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK) or (IL), R 5 For -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl.
[0331] In some embodiments of compounds of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), p is 3, 4, 5, 6, or 7. In some embodiments, p is 4, 5, 6, or 7.
[0332] In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK), or (IL), Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y, and R 3 and R 4 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- In some embodiments of the compounds of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK) or (IL), Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y, and Y is -COOH or -COOR 5 In some embodiments of the compound of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK) or (IL), Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y, Y is -COOH or -COOR 5 , and R 5 For -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- In some embodiments of the compounds of Formula (ID), (IE), (IF), (IG), (IH), (IJ), (IK) or (IL), Z 1 and Z 2 One or both of them are -W-(CH2) c -C(R 3 )(R 4 )-Y, Y is -COOH or -COOR 5 , and R 5 For -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl.
[0333] In some embodiments of compounds of Formula (IH), (IJ), (IK), or (IL), Q is independently methyl or -OH.
[0334] In some embodiments of compounds of Formula (IH), (IJ), (IK), or (IL), t is 1. In some embodiments, t is 2. In some embodiments, t is 3.
[0335] In some embodiments, the compound of Formula (IH), (IJ), (IK) or (IL) has any one of the structures shown in Table A-5, Table A-6 or Table A-7, or a pharmaceutically acceptable salt or solvate thereof.
[0336] Table A-5.
[0337]
[0338]
[0339]
[0340]
[0341]
[0342] Table A-6
[0343]
[0344]
[0345]
[0346]
[0347]
[0348]
[0349]
[0350]
[0351]
[0352]
[0353]
[0354]
[0355]
[0356] Table A-7
[0357]
[0358]
[0359]
[0360]
[0361]
[0362]
[0363]
[0364]
[0365]
[0366]
[0367]
[0368]
[0369]
[0370]
[0371]
[0372]
[0373]
[0374]
[0375]
[0376]
[0377]
[0378]
[0379]
[0380]
[0381]
[0382]
[0383]
[0384]
[0385]
[0386]
[0387]
[0388]
[0389]
[0390]
[0391]
[0392]
[0393]
[0394]
[0395]
[0396] Compound of formula (II)
[0397] In some embodiments, the compound of the present invention is a compound of formula (II):
[0398]
[0399] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0400] Each R 1 and R 2 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0401] Each n is independently 0, 1, 2 or 3;
[0402] Each m is independently 1, 2, 3, 4, 5, 6, 7, 8 or 9;
[0403] X is -C(=O)-, -CHR3 -、-CH-CH2(OR 3 )-, -O-, -S-, -S(=O)-, -S(O)2-, -NR 3 -, -N(OH)-, -N(→O)-, or -Se-;
[0404] R 3 H, -OH, -O(C 1- C6 alkyl), -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -C3-C7 cycloalkyl, C4-C7 cycloalkenyl, C5-C8 cycloalkynyl, phenyl or benzyl, each -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, -C3-C7 cycloalkyl, C4-C7 cycloalkenyl, C5-C8 cycloalkynyl, phenyl and benzyl are unsubstituted or substituted by one or more halogen, -CN, -NO2 or -CF3 groups;
[0405] Each Y is independently -O-, -NH-, -N(OH)-, -N(→O)-, -S-, -S(=O)-, -S(O)2- or -Se-;
[0406] Each Z is independently -OH, -COOH, -COOR 5 、-SO3H、-SO3R 5 ,
[0407]
[0408]
[0409] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl;
[0410] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C1- C6 alkyl) or phenyl; and
[0411] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl.
[0412] In some embodiments of the compound of formula (II), X is -C(=O)-, -CHR 3 In some embodiments, X is -C(=O)-, -CH(OH)-, -O-, -S-, -S(=O)-, or Se.
[0413] In some embodiments of the compound of Formula (II), R 3 It is H, -OH, -O(C1-C3 alkyl) or -C1-C3 alkyl.
[0414] In some embodiments of the compound of Formula (II), each Y is independently -O- or -S-.
[0415] In some embodiments of the compound of formula (II), each R 1 and R 2 are independently H, -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl. In some embodiments, each R 1 and R 2 are independently H or methyl.
[0416] In some embodiments of the compound of formula (II), each Z is independently -COOH or -COOR 5 In some embodiments, each Z is -COOH.
[0417] In some embodiments of the compound of formula (II), each R 5 Independently -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl.
[0418] In some embodiments of the compound of Formula (II), each n is independently 0, 1, or 2. In some embodiments, n is 1.
[0419] In some embodiments of compounds of Formula (II), each m is independently 3, 4, 5, or 6. In some embodiments, each m is independently 4 or 5.
[0420] In some embodiments, the compound of formula (II) has any one of the structures shown in Table B1, or a pharmaceutically acceptable salt or solvate thereof.
[0421] Table B1
[0422]
[0423]
[0424]
[0425] Compounds of formula (III), (IIIA) and (IIIB)
[0426] In some embodiments, the compound of the present invention is a compound of formula (III):
[0427]
[0428] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0429] R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or R 1 and R 2 The connected carbon atoms together form a -C3-C7 cycloalkyl group;
[0430] Each m is independently 3, 4, 5, 6 or 7;
[0431] Each n is independently 0, 1, 2, 3, 4 or 5;
[0432] Each q is 0, 1, 2, 3 or 4;
[0433] X is -O-, -S-, -S(=O)-, -S(O)2-, -NH-, -N(OH)-, -N(→O)-,
[0434] N(alkyl)- or -N(aryl)-;
[0435] Z1 and Z2 are independently -C 1- C6 alkyl, -OH, -COOH, -COOR 5 、-SO3H、-SO3R 5 ,
[0436]
[0437]
[0438] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl;
[0439] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl; and
[0440] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl.
[0441] In some embodiments, the compound of the present invention is a compound of formula (IIIA):
[0442]
[0443] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0444] R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or R 1 and R 2 Together with the carbon atom to which it is attached, it forms a -C3-C7 cycloalkyl group;
[0445] Each m is independently 2, 3, 4, 5, 6 or 7;
[0446] Each n is independently 0, 1, 2, 3, 4 or 5;
[0447] Each q is 0, 1, 2, 3 or 4;
[0448] X is -O-, -S-, -S(=O)-, -S(O)2-, -NH-, -N(OH)-, -N(→O)-,
[0449] N(alkyl)- or -N(aryl)-;
[0450] Z1 and Z2 are -C 1- C6 alkyl, -COOH, -COOR 5 、-SO3R 5 ,
[0451]
[0452] Where Z1 and Z2 are the same;
[0453] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl;
[0454] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl; and
[0455] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl.
[0456] In some embodiments, the compound of the present invention is a compound of formula (IIIB):
[0457]
[0458] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0459] R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or R 1 and R 2 Together with the carbon atom to which it is attached, it forms a -C3-C7 cycloalkyl group;
[0460] Each m is independently 2, 3, 4, 5, 6 or 7;
[0461] Each n is independently 0, 1, 2, 3, 4 or 5;
[0462] Each q is 0, 1, 2, 3 or 4;
[0463] X is -S-, -S(=O)-, -S(O)2-, -NH-, -N(OH)-, -N(→O)-, N(alkyl)-
[0464] or -N(aryl)-;
[0465] Z1 and Z2 are independently -C 1- C6 alkyl, -OH, -COOH, -COOR 5 、-SO3H、-SO3R 5 ,
[0466]
[0467] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl;
[0468] Each R 6 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl, wherein the -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl is unsubstituted or substituted by one or two halogens, -OH, -O(C 1- C6 alkyl) or phenyl; and
[0469] Each R 7 are independently H, -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl.
[0470] In some embodiments of compounds of Formula (III) and (IIIB), each Z 1 and Z 2 are independently -OH, -COOH or -COOR 5 In some embodiments, each Z1 and Z 2 Independently -C 1- C6 alkyl.
[0471] In some embodiments of the compounds of Formula (III), (IIIA) and (IIIB), Z 1 and Z 2 The same group: -OH, -COOH or -COOR 5 In some embodiments, Z 1 and Z 2 Both are -C 1- C6 alkyl.
[0472] In some embodiments of the compound of formula (III), X is -S-, -S(=O)-, -S(O)2-, -NH-, -N(OH)-, -N(→O)-, N(alkyl)-, or -N(aryl)-.
[0473] In some embodiments of the compound of formula (III) and (IIIA), X is O. In some embodiments of the compound of formula (III), when X is O, m is 2, 3, 5, 6 or 7.
[0474] In some embodiments of compounds of Formula (III), (IIIA), and (IIIB), each n is independently 0 or 1. In some embodiments, n is 0. In some embodiments, n is 1.
[0475] In some embodiments of compounds of Formula (III), (IIIA), and (IIIB), each m is independently 4, 5, or 6. In some embodiments, m is 5 or 6. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 2 or 3.
[0476] In some embodiments of compounds of Formula (III), (IIIA), and (IIIB), R 1 and R 2 Together with the attached carbon atom, it forms a -C3-C7 cycloalkyl group.
[0477] In some embodiments, the compound of formula (III) or (IIIA) has any one of the structures shown in Table B2, or a pharmaceutically acceptable salt or solvate thereof.
[0478] Table B2
[0479]
[0480]
[0481] Composition of the present invention
[0482] In some embodiments, the compositions of the invention comprise (i) an effective amount of a compound of the invention and (ii) a pharmaceutically acceptable carrier or vehicle.
[0483] In some embodiments, the compositions of the present invention comprise (i) an effective amount of a compound of formula (IA):
[0484]
[0485] or a pharmaceutically acceptable salt or solvate thereof, wherein:
[0486] Each p is independently 1, 2, 3, 4, 5, 6 or 7;
[0487] Z 1 and Z 2 are independently -C(R 1 )(R 2 )-(CH2) c -COOH or -C(R 1 )(R 2 )-(CH2) c -COOR 5 ;
[0488] Each c is independently 0, 1, 2 or 3;
[0489] Each R 1 and R 2 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, or each carbon atom and R attached to the carbon atom 1 and R 2 Together they independently form -C3-C7 cycloalkyl;
[0490] Each R 5 Independently -C 1- C6 alkyl, -C 2- C6 alkenyl, -C 2- C6 alkynyl, phenyl or benzyl, each unsubstituted or substituted by one or more halogen, -OH, -O(C 1- C6 alkyl) or phenyl; and
[0491] (ii) a pharmaceutically acceptable carrier or vehicle.
[0492] In some embodiments of the composition comprising a compound of Formula (IA), each R 1 and R 2 Independently -C 1- C6 alkyl, -C2- C6 alkenyl or -C 2- C6 alkynyl. In some embodiments, each R 1 and R 2 Independently -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl. In some embodiments, R 1 and R 2 It is methyl.
[0493] In some embodiments of the composition comprising a compound of Formula (IA), c is 0 or 1.
[0494] In some embodiments of the composition comprising a compound of Formula (IA), R 5 For -C 1- C6 alkyl, -C 2- C6 alkenyl or -C 2- C6 alkynyl. In some embodiments, R 5 For -C 1- C3 alkyl, -C 2- C3 alkenyl or -C 2- C3 alkynyl.
[0495] In some embodiments of the composition comprising a compound of formula (IA), the compound is compound I-1, I-2, I-3, I-4, I-5, I-6, I-7, I-8, I-9 or I-10 or a pharmaceutically acceptable salt or solvate thereof or having structure or a pharmaceutically acceptable salt or solvate thereof.
[0496] In some embodiments, the composition of the present invention comprises an effective amount of a compound having a structure as described in Table A-1, A-2, A-3 or A-4, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the composition of the present invention comprises an effective amount of a compound having a structure as described in Table B1, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the composition of the present invention comprises an effective amount of a compound having a structure as described in Table B2, or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, the composition of the present invention comprises an effective amount of a compound having a structure as described in Table C, or a pharmaceutically acceptable salt or solvate thereof.
[0497] Table C
[0498]
[0499] In some embodiments, the compositions of the invention further comprise another pharmaceutically active agent.
[0500] In some embodiments, the other pharmaceutically active agent is a statin, a thiazolidinedione or a fibrate, a bile-acid-binding-resin, niacin, an anti-obesity agent, a hormone, tyrophostine, a sulfonylurea-based drug, a biguanide, an alpha-glucosidase inhibitor, an apolipoprotein AI agonist, an apolipoprotein E agonist, a phosphodiesterase type 5 inhibitor, a cardiovascular drug, an HDL-raising drug, an HDL enhancer, an agonist of the apolipoprotein AI gene or protein, an agonist of the apolipoprotein A-IV gene or protein, an agonist of an apolipoprotein gene, an ATP citrate lyase modulator, an ATP citrate lyase allosteric inhibitor, an acetyl-CoA carboxylase modulator, or an acetyl-CoA carboxylase allosteric inhibitor.
[0501] In some embodiments, the other pharmaceutically active agent is an antagonist or inhibitor of a pro-inflammatory gene or protein or an agonist of an anti-inflammatory gene or protein. In some embodiments, the other pharmaceutically active agent inhibits or reduces pro-inflammatory function or increases the anti-inflammatory function of IL-6, CRP, TNF-α, MCP-1, MIP-1β, CCR5, CCR2, NF-κB or TGF-β1.
[0502] In some embodiments, the other pharmaceutically active agent affects the expression or function of a fibrotic gene or protein or a mitogenic gene or protein. In some embodiments, the other pharmaceutically active agent modulates the expression or function of FGF-21, MMP-2, TIMP-1, ASK1, or type 3 collagen.
[0503] In some embodiments, the other pharmaceutically active agent is a modulator of a gene involved in lipid metabolism or transport, a modulator of a PPAR-α target gene, such as but not limited to HD (ECHS1), PDK4 and Cyp7A 1, SGLT 1, SGL2, ApoC-III, Sulf-2, ANGPTL3, ANGPTL4 and LPL genes.
[0504] In some embodiments, the other pharmaceutically active agent is a statin. In some embodiments, the statin is atorvastatin, simvastatin, pravastatin, rosuvastatin, fluvastatin, lovastatin, pitavastatin, mevastatin, dalvastatin, dihydrocompactin or cerivastatin or a pharmaceutically acceptable salt thereof. The statin is lovastatin.
[0505] In some embodiments, the other pharmaceutically active agent is a fibrate. In some embodiments, the fibrate is fenofibrate, gemfibrozil, or fenofibric acid.
[0506] In some embodiments, the other pharmaceutically active agent is sorafenib. In yet other embodiments, the other pharmaceutically active agent is taxol. In yet other embodiments, the other pharmaceutically active agent is carotuximab. In yet other embodiments, the other pharmaceutically active agent is pembrolizumab. In yet other embodiments, the other pharmaceutically active agent is lenvatinib. In yet other embodiments, the other pharmaceutically active agent is avelumab. In some embodiments, the other pharmaceutically active agent is durvalumab. In yet other embodiments, the other pharmaceutically active agent is tremelimumab. In yet other embodiments, the other pharmaceutically active agent is nivolumab. In yet other embodiments, the other pharmaceutically active agent is tazemetostat, cemiplimab, ABX196, T cell receptor (TCR) immune cell therapy agents, such as LioCyx TM , TBI-302, namodenoson, MM-310, tumor-injected oncolytic virus or genetically modified oncolytic virus, such as but not limited to telomelysin and imlygic; or immunomodulatory gene therapy agents such as MDA-7 / IL-24, GLIPR1 / RTVP-1 and REIC / Dkk-3.
[0507] In yet other embodiments, the other pharmaceutically active agent is cenicriviroc, elafibranor, eicosapentaenoic acid, galunisertib, LY2109761, LDE225, nivolumub, firsocostat, apararenone, metformin, a leucine-metformin-sildenafil combination, IMM-124E, RG-125, vitamin E, cysteamine, selonsertib, losartan, RO5093151, pradigastat, sitagliptin, vildagliptin, NGM282, pegbelfermin, PF-05231023, obeticholic acid, acid), cilofexo, tropifexor, EDP-305, INT-767, arabinogalactan-rhamnogalacturonate, liraglutide, semaglutide, exenatide, ND-L02-s0201 / BMS-986263, volixibat, amlexanox, PF-06835919, leptin, metreleptin, simtuzumab b), tipelukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elareno, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanibibranor, aramchol, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, or nalmafene. In some embodiments, the other pharmaceutically active agent is pentamidine, berberine, L-carnitine, EYP001a. silymarin, miricorilant, ursodeoxycholic acid acid), metadoxine, ezetimibe, cystadane, L-alanine, saroglitazar magnesium, worixib, ficostat, herofloxol, elarenol, nalmefene, solithromycin, 99mtechnetium-methylbromphenin, tripifluxol, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, seladelpar, fisogatinib, doxorubicin, cabozantinib, deferoxamine, itacitinib, chiauranib, SF 1126, anlotinib, P1101, varlitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapanisertib, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolin Temsirolimus, epacadostat, RO7119929, guadecitabine, linrodostat, copanlisib, MIV-818, vorolanib, RO7070179, axitinib, sunitinib, zotiraciclib citrate, sintilimab tilimab), camrelizumab, spartalizumab, toripalimab, bispecific antibody XmAb20717, mapatumumab, tremelimumab, carlotuximab, tocilizumab, ipilimumab, atezolizumab, bevacizumab, ramucirumab ramucirumab, IBI305, ascrinvacumab, sitravatinib, cytokine-based biologics IRX-2, bempegaldesleukin, DKN-01, PTX-9908, AK104, PT-112, SRF388, ET1402L1-CART, T cells expressing glypican 3-specific chimeric antigen receptor (CAR-T cells), CAR-T cells targeting CD 147, NKG2D-based CAR T cells, neoantigen-reactive T cells, Pexastimogene Devacirepvec, Talimogene Laherparepvec, GNOS-PV02, INO-9012, ABBV-176, NCI-4650, DNAJB1-PRKACA fusion kinase peptide vaccine or IMA970A, novantrone, prednisone, pixantrone, losoxantrone, cytidine-phosphate-guanosine (CpG) DNA, paclitaxel, oraxol, MTL-CEBPA, ribavirin, elbasvir, grazoprevir, lipotecan, ZSP1241, U3-1784, avadomide, INCAGN01949, or CMP-001.
[0508] In some embodiments, the other pharmaceutically active agent is an anticancer agent. In some embodiments, the anticancer agent is sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, narmodison, MM-310, senevirol, elareno, eicosapentaenoic acid, ganiserti, LY2109761, LDE225, ficostat, aparetone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, seronserti, losartan, RO5093151 puglipitin, sitagliptin, vildagliptin, NGM282, pebbefumin, PF-05231023 , obeticholic acid, heroflumilast, tripifluxol, EDP-305, INT-767, arabinogalactan-rhamnogalacturonate, liraglutide, semaglutide, exenatide, worixib, amlexanox, PF-06835919, leptin, metreleptin, sintuzumab, talukastat, oltipraz, MSDC-0602K, ASP9831, roflumilast, elareno, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanileno, alatraquin, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmefene, pentamidine, berberine, L-carnitine, EYP001a, silymarin, melicoran, ursodeoxycholic acid, metadoxine, ezetimibe, cistatin, L-alanine, saroglitazar magnesium, vorixib, elareno, nalmefene, solithromycin, 99m-technetium-methylbrompheniramine, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, celadepa, fexotinib, doxorubicin, cabozantinib, deferoxamine, itatinib, sioronib, SF 1126, anlotinib, P 1101, valitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapacerti, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, edostat, RO7119929, guacitabine, linrodostat, copanis, MIV-818, vololanib, RO7070179, axitinib, sunitinib, or zotilin citrate.
[0509] In some embodiments, the compositions of the invention further comprise an anti-cancer agent.
[0510] In some embodiments, the other pharmaceutically active agent is an immunotherapeutic agent. In some embodiments, the immunotherapeutic agent is pembrolizumab, avelumab, durvalumab, nivolumab, cemiplimab, ABX 196, sintilimab, carrelizumab, spartalizumab, toripalimab, bispecific antibody XmAb20717, mapatumumab, tremelimumab, carlotuximab, tocilizumab, ipilimumab, atezolizumab, bevacizumab, ramucirumab, IBI305, avastinib, TCR T-cell therapeutic, cetirizumab, cytokine-based biologics IRX-2, bepealdoleukin, DKN-01, PTX-9908, AK104, PT-112, SRF388, ET 1402L 1-CART, T cells expressing glypican 3-specific chimeric antigen receptor (CAR-T cells), targeted CD 147-based CAR-T cells, NKG2D-based CAR T cells, or neoantigen-reactive T cells.
[0511] In some embodiments, the compositions of the invention further comprise an immunotherapeutic agent.
[0512] In some embodiments, the other pharmaceutically active agent is an oncologic virus. In some embodiments, the oncogenic virus is di-pesatimogin or la-tarimotogen. In some embodiments, the composition of the present invention further comprises an oncogenic virus.
[0513] In some embodiments, the other pharmaceutically active agent is a vaccine. In some embodiments, the vaccine is GNOS-PV02, INO-9012, ABBV-176, NCI-4650, DNAJB 1-PRKACA fusion kinase peptide vaccine or IMA970A. In some embodiments, the composition of the present invention further comprises a vaccine.
[0514] In some embodiments, the other pharmaceutically active agent is Noantol, prednisone, pyrantrone, losoxantrone, cytidine-phosphate-guanosine (CpG) DNA, paclitaxel, olazosor, MTL-CEBPA, ribavirin, elbasvir, grazoprevir, liponotecan, ZSP 1241, U3-1784, avadomide, INCAGN01949, or CMP-001.
[0515] In some embodiments, the compositions of the present invention further comprise two or more other pharmaceutically active agents. In some embodiments, the two or more other pharmaceutically active agents are oncolytic agents, such as but not limited to nanatinostat and valganciclovir.
[0516] In some embodiments, the composition of the present invention further comprises a pharmaceutically active agent: sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, narmodison, MM-310, senevirol, elareno, eicosapentaenoic acid, ganiserti, LY2109761, LDE225, ficostat, aparetone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, seronserti, losartan, RO5093151 puglipitin, sitagliptin, vildagliptin, NGM282, pebbefumin, PF-05 231023, obeticholic acid, heroflumizone, tripifluxol, EDP-305, INT-767, arabinogalactan-rhamnogalacturonate, liraglutide, semaglutide, exenatide, worixib, amlexanox, PF-06835919, leptin, metreleptin, sintuzumab, talukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elareno, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanileno, alatraquin, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmefene, pentamidine, berberine, L-carnitine, EYP001 a, silymarin, melicoran, ursodeoxycholic acid, metadoxine, ezetimibe, cistat, etc., L-alanine, saroglitazar magnesium, vorixib, elareno, nalmefene, solithromycin, 99m-technetium-methylbrompheniramine, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, celadepa, fexotinib, doxorubicin, cabozantinib, deferoxamine, itatinib, sioronib, SF 1126, anlotinib, P 1101, valitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapacerti, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, edostat, RO7119929, guacitabine, linrodostat, copanis, MIV-818, vololanib, RO7070179, axitinib, sunitinib, or zotilin citrate.In some embodiments of the composition of the present invention, the composition comprises (a) Compound I-1, Compound I-32, Compound I-61 or Compound III-1 or a pharmaceutically acceptable salt or solvate thereof and (b) a pharmaceutically active agent: sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, namodison, MM-310, senevirol, elareno, eicosapentaenoic acid, ganiserti, LY2109761, LDE225, ficostat, aparetone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, seronseti, losartan, RO5093151 pugasistat , sitagliptin, vildagliptin, NGM282, pebofurmin, PF-05231023, obeticholic acid, herofluxol, tripifluxol, EDP-305, INT-767, arabinogalactan-rhamnogalacturonate, liraglutide, semaglutide, exenatide, worixib, amlexanox, PF-06835919, leptin, metreleptin, sintuzumab, talukastat, oltipraz, MSDC-0602K, ASP9831, roflumilast, elareno, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanileno, alatraquin, ipraglixin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmefene, pentamidine, berberine, L-carnitine, EYP001a, silymarin, melicoran, ursodeoxycholic acid, metadoxine, ezetimibe, cisstat, L-alanine, saroglitazar magnesium, vorixib, elareno, nalmefene, solithromycin, 99m-technetium-methylbrompheniramine, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, celadepa, fesotinib, doxorubicin, cabozantinib, deferrin amine, itatinib, sioroni, SF1126, anlotinib, P1101, valitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapacerti, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, edostat, RO7119929, guacitabine, linrodostat, copanitinib, MIV-818, vololanib, RO7070179, axitinib, sunitinib, or zoticollis citrate.
[0517] In some embodiments of the compositions of the invention, the composition comprises a compound of the invention and a pharmaceutically active agent: sorafenib, taxol, carlotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX 196, T cell receptor (TCR) immune cell therapy, TBI-302, namodixon, MM-310, tumor injected oncolytic virus or gene-modified oncolytic virus or immunomodulatory gene therapy. In some embodiments, the composition comprises (a) Compound I-1, Compound I-32, Compound I-61 or Compound III-1 or a pharmaceutically acceptable salt or solvate thereof and (b) the pharmaceutically active agent is sorafenib, taxol, carlotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX196, T cell receptor (TCR) immune cell therapy, TBI-302, namodixon, MM-310, tumor-injected oncolytic virus or genetically modified oncolytic virus or immunomodulatory gene therapy.
[0518] In some embodiments of the composition of the present invention, the composition comprises a compound of the present invention and sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-1, compound I-32, compound I-61 or compound III-1 or a pharmaceutically acceptable salt or solvate thereof and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-1 or a pharmaceutically acceptable salt or solvate thereof and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-32 or a pharmaceutically acceptable salt or solvate thereof and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-32 or a pharmaceutically acceptable salt or solvate thereof and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) compound I-32 or a pharmaceutically acceptable salt or solvate thereof and (b) sorafenib. In some embodiments, the composition comprises (a) compound I-32 or a pharmaceutically acceptable salt or solvate thereof and (b) lenvatinib. In some embodiments, the composition comprises (a) Compound I-61 or a pharmaceutically acceptable salt or solvate thereof and (b) sorafenib or lenvatinib. In some embodiments, the composition comprises (a) Compound I-61 or a pharmaceutically acceptable salt or solvate thereof and (b) sorafenib. In some embodiments, the composition comprises (a) Compound I-61 or a pharmaceutically acceptable salt or solvate thereof and (b) lenvatinib. In some embodiments, the composition comprises (a) Compound III-1 or a pharmaceutically acceptable salt or solvate thereof and (b) sorafenib or lenvatinib.
[0519] Table D describes embodiments A1-A4, B 1-B4, C 1-C4, D 1-D4, E 1-E4, F 1-F4, G 1-G4, H1-H4, I1-I4, J1-J4, K1-K4, L 1-L4, M1-M4, N 1-N4, O 1-O4, P 1-P4, Q 1-Q4, R1-R4, and S1-S4. Each embodiment of Table D refers to a specific compound of the present invention and another pharmaceutically active agent. For example, embodiment A1 refers to compound I-1 (or a pharmaceutically acceptable salt or solvate thereof) and sorafenib; embodiment A2 refers to compound I-32 (or a pharmaceutically acceptable salt or solvate thereof) and sorafenib; and so on. In some embodiments, the composition of the present invention comprises an effective amount of a compound of the present invention described in the embodiments of Table D and another pharmaceutically active agent.
[0520] Table D. Implementation Scheme
[0521]
[0522] In some embodiments, pharmaceutically acceptable carriers or vehicles include, but are not limited to, binders, fillers, diluents, disintegrants, wetting agents, lubricants, glidants, colorants, dye migration inhibitors, sweeteners, or flavoring agents.
[0523] Binders or granulating agents give the tablet cohesion to ensure that the tablet remains intact after compression. Suitable binders or granulating agents include, but are not limited to, starches such as corn starch, potato starch, and pregelatinized starch (e.g., STARCH 1500); gelatin; sugars such as sucrose, glucose, dextrose, molasses, and lactose; natural and synthetic gums such as acacia, alginic acid, alginates, Irish moss extract, Panwar gum, ghatti gum, esparto husk mucilage, carboxymethyl cellulose, methyl cellulose, polyvinyl pyrrolidone (PVP), magnesium aluminum silicate (Veegum), larch arabinogalactan, powdered tragacanth gum, and guar gum; celluloses such as ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose, methyl cellulose, hydroxyethyl cellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC); microcrystalline cellulose such as AVICEL-PH-101, AVICEL-PH-103, AVICEL RC-581, AVICEL-PH-105 (FMC Corp., Marcus Hook, PA); and mixtures thereof.
[0524] Suitable fillers include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pregelatinized starch, and mixtures thereof. In some embodiments, the binder is hydroxypropyl cellulose.
[0525] Adhesive or filler can exist with about 2 % by weight of the present composition provided herein to about 49 % by weight or any scope in these values.In some embodiments, adhesive or filler is present in the present composition with about 5 % by weight to about 15 % by weight.In some embodiments, adhesive or filler is present in the present composition with about 5 % by weight, 6 % by weight, 7 % by weight, 8 % by weight, 9 % by weight, 8 % by weight, 10 % by weight, 11 % by weight, 12 % by weight, 13 % by weight, 14 % by weight or 15 % by weight or any scope in these values.
[0526] Suitable diluents include, but are not limited to, dicalcium phosphate, calcium sulfate, lactose, sorbitol, sucrose, inositol, cellulose, kaolin, mannitol, sodium chloride, dry starch, and powdered sugar. Certain diluents (such as mannitol, lactose, sorbitol, sucrose, and inositol) when present in sufficient amounts can impart properties to some compressed tablets that allow disintegration in the oral cavity by chewing. Such compressed tablets can be used as chewable tablets. In some embodiments, the diluent is lactose monohydrate. In some embodiments, the diluent is lactose monohydrate Fast-Flo 316NF.
[0527] The present composition may include a diluent, such as about 5% to about 49% by weight of the composition or any range between any of these values. In some embodiments, the diluent is present in the present composition with about 15% to about 30% by weight. In some embodiments, the diluent is present in the present composition with about 15%, 16%, 17%, 18%, 19%, 18%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30% by weight or any range within any of these values.
[0528] Suitable disintegrants include, but are not limited to, agar; bentonite; celluloses such as methylcellulose and carboxymethylcellulose; wood products; natural sponges; cation exchange resins; alginic acid; gums such as guar gum and magnesium aluminum silicate HV; citrus pulp; cross-linked celluloses such as cross-linked carboxymethylcellulose (croscarmellose); cross-linked polymers such as crospovidone; cross-linked starch; calcium carbonate; microcrystalline cellulose such as sodium starch glycolate; polacrilin potassium; starches such as corn starch, potato starch, tapioca starch, and pregelatinized starch; clays; aligns; and mixtures thereof. The amount of disintegrant in the compositions of the present invention may vary. In some embodiments, the disintegrant is cross-linked carboxymethylcellulose sodium. In some embodiments, the disintegrant is cross-linked carboxymethylcellulose sodium NF (Ac-Di-Sol).
[0529] The compositions of the present invention may include a disintegrant, such as from about 0.5% to about 15% by weight or from about 1% to about 10% by weight of a disintegrant. In some embodiments, the compositions of the present invention include a disintegrant in an amount of about 5%, 6%, 7%, 8%, 9%, 8%, 10%, 11%, 12%, 13%, 14%, or 15% by weight of the composition, or any range of disintegrants within any of these values.
[0530] Suitable lubricants include, but are not limited to, calcium stearate; magnesium stearate; mineral oil; light mineral oil; glycerin; sorbitol; mannitol; glycols, such as glyceryl behenate and polyethylene glycol (PEG); stearic acid; sodium lauryl sulfate; talc; hydrogenated vegetable oils, including peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil; zinc stearate; ethyl oleate; ethyl laurate; agar; starch; lycopodium; silicon dioxide or silica gel, such as 200 (WR Grace Co., Baltimore, MD) and (Cabot Co. of Boston, MA); and mixtures thereof. In some embodiments, the lubricant is magnesium stearate.
[0531] The present composition may include a lubricant, such as from about 0.1% to about 5% by weight of a lubricant. In some embodiments, the present composition includes an amount of about 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 0.8%, 1.0%, 1.1%, 1.2%, 1.3%, 1.4%, 1.5%, 1.6%, 1.7%, 1.8%, 1.9%, 2.0%, 2.1%, 2.2%, 2.3%, 2.4%, 2.5%, 2.6%, 2.7%, 2.8%, 2.9%, or 3.0% by weight of the composition, or any range of lubricants within any of these values.
[0532] Suitable glidants include colloidal silicon dioxide, (Cabot Co. of Boston, MA) and talc, including asbestos-free talc.
[0533] Colorants include approved certified water-soluble FD&C dyes and water-insoluble FD&C dyes suspended on alumina hydrate and lakes and mixtures thereof.
[0534] Flavoring agents include natural flavors extracted from plants, such as fruits, and synthetic blends of compounds that provide a pleasant taste, such as peppermint and methyl salicylate.
[0535] Sweeteners include sucrose, lactose, mannitol, syrups, glycerin, sucralose, and artificial sweeteners such as saccharin and aspartame.
[0536] Suitable emulsifiers include gelatin, gum arabic, gum tragacanth, bentonite, and surfactants such as polyoxyethylene sorbitan monooleate. Polyoxyethylene sorbitan monooleate 80 and triethanolamine oleate. Suspending and dispersing agents include sodium carboxymethylcellulose, pectin, tragacanth, magnesium aluminum silicate (Veegum), gum arabic, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, and polyvinyl pyrrolidone. Preservatives include glycerin, methyl and propyl parabens, benzoic acid, sodium benzoate, and alcohol. Wetting agents include propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate, and polyoxyethylene lauryl ether.
[0537] Suitable solvents include glycerol, sorbitol, ethanol and syrups.
[0538] Examples of non-aqueous liquids for emulsions include mineral oil and cottonseed oil. Organic acids include citric acid and tartaric acid. Sources of carbon dioxide include sodium bicarbonate and sodium carbonate.
[0539] The compounds of the invention and compositions of the invention can be formulated for administration in various ways, including oral, parenteral, by inhalation spray, topical or rectal administration with formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular and intraarterial injections with various infusion techniques. Intraarterial and intravenous injections as used herein include administration by catheter.
[0540] The compounds of the present invention and the compositions of the present invention can be formulated according to routine procedures suitable for the desired route of administration. Therefore, the compositions of the present invention may be in the form of suspensions, solutions or emulsions such as in oily or aqueous vehicles, and may contain preparatons such as suspending agents, stabilizers and / or dispersants. The compounds of the present invention and the compositions of the present invention may be formulated into preparations suitable for implantation or injection. Therefore, for example, the compositions of the present invention may be formulated into slightly soluble derivatives (for example, slightly soluble salts) suitable for polymeric or hydrophobic materials (for example, in an emulsion in an acceptable oil) or ion exchange resins. The compounds of the present invention and the compositions of the present invention may be in the form of powders reconstituted with a suitable vehicle (for example, sterile pyrogen-free water) before use. Suitable preparations for each of these methods of administration can be found in, for example, Remington: The Science and Practice of Pharmacy, A. Gennaro, ed., 20th edition, Lippincott, Williams & Wilkins, Philadelphia, PA.
[0541] In some embodiments, the compositions of the present invention are suitable for oral administration. These compositions may include solid, semisolid, gel matrix or liquid dosage forms suitable for oral administration. As used herein, oral administration includes buccal, tongue and sublingual administration. Suitable oral dosage forms include but are not limited to tablets, capsules, pills, lozenges, pastilles, pastilles, cachets, pellets, medicated chewing gum, granules, bulk powders, effervescent or non-effervescent powders or granules, solutions, emulsions, suspensions, solutions, wafers, sprays, elixirs, syrups or any combination thereof. In some embodiments, the compositions of the present invention suitable for oral administration are in the form of tablets or capsules. In some embodiments, the compositions of the present invention are in the form of tablets. In some embodiments, the compositions of the present invention are in the form of capsules. In some embodiments, the compounds of the present invention are contained in capsules.
[0542] In some embodiments, the capsule is an immediate release capsule. Non-limiting examples of capsules are Hard gelatin capsule.
[0543] The composition of the present invention can be in the form of compressed tablets, tablets, chewable lozenges, fast dissolving tablets, multiple compressed tablets or enteric coated tablets, sugar-coated tablets or film-coated tablets. Enteric coated tablets are compressed tablets coated with a substance that resists the action of gastric acid but dissolves or disintegrates in the intestine, thereby protecting the active ingredient from the acidic environment of the stomach. Enteric coatings include but are not limited to fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac and cellulose acetate phthalate. Sugar-coated tablets are compressed tablets surrounded by sugar coatings, which may be useful in covering up unpleasant tastes or odors and protecting tablets from oxidation. Film-coated tablets are compressed tablets covered with a thin layer or film of a water-soluble material. Film coatings include but are not limited to hydroxyethylcellulose, sodium carboxymethylcellulose, polyethylene glycol 4000 and cellulose acetate phthalate. Film coatings can impart the same general characteristics as sugar coatings. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered tablets, compression coatings or dry coated tablets.
[0544] In some embodiments, the coating is a film coating.In some embodiments, the film coating comprises Opadry white and simethicone emulsion 30% USP.
[0545] In some embodiments, the compounds of the invention are contained within a tablet. In some embodiments, the compounds of the invention are contained within a compressed tablet. In some embodiments, the compounds of the invention are contained within a film-coated compressed tablet. In some embodiments, the compositions of the invention are in the form of a film-coated compressed tablet.
[0546] In some embodiments, the compositions of the present invention are prepared by fluid bed granulation of the compounds of the present invention and one or more pharmaceutically acceptable carriers, vehicles or excipients. In some embodiments, the compositions of the present invention prepared by the fluid bed granulation method can provide tablet formulations with good flowability, good compressibility, rapid dissolution, good stability and / or minimal to no cracking. In some embodiments, the fluid bed granulation method allows the preparation of formulations with high drug loading (such as more than 70% or more than 75% of the compounds of the present invention).
[0547] The composition of the present invention can be in the form of a soft or hard capsule, which can be made of gelatin, methylcellulose, starch or calcium alginate. Hard gelatin capsules (also known as dry filled capsules (DFC)) can be composed of two parts, one part is sleeved on the other part, so that the active ingredient is completely encapsulated. Soft elastic capsules (SEC) are soft spherical shells, such as gelatin shells, which are plasticized by adding glycerol, sorbitol or similar polyols. The soft gelatin shell can contain a preservative to prevent microbial growth. Suitable preservatives are those as described herein, including methylparaben and propylparaben and sorbic acid. Liquid, semisolid and solid dosage forms provided herein can be encapsulated in capsules. Suitable liquid and semisolid dosage forms include solutions and suspensions in propylene carbonate, vegetable oils or triglycerides. Capsules containing such solutions can be prepared as described in U.S. Patent Nos. 4,328,245; 4,409,239 and 4,410,545. The capsules may also be coated as known to those skilled in the art to improve or sustain dissolution of the active ingredient.
[0548] The compositions of the present invention may be in liquid and semisolid dosage forms (including emulsions, solutions, suspensions, elixirs and syrups). Emulsions may be two-phase systems in which one liquid is dispersed throughout another liquid in the form of small spheres, which may be oil-in-water or water-in-oil. Emulsions may include pharmaceutically acceptable non-aqueous liquids or solvents, emulsifiers and preservatives. Suspensions may include pharmaceutically acceptable suspending agents and preservatives. Alcoholic aqueous solutions may include pharmaceutically acceptable acetals, such as di(low alkyl) acetals of low alkyl aldehydes (the term "low" means an alkyl group having between 1 and 6 carbon atoms), for example acetaldehyde diethyl acetal; and water-miscible solvents having one or more hydroxyl groups, such as propylene glycol and ethanol. Elixirs may be transparent, sweetened and water-alcoholic solutions. Syrups may be concentrated aqueous solutions of sugars (e.g., sucrose) and may contain preservatives. In the case of liquid dosage forms, for example, a solution in polyethylene glycol may be diluted with a sufficient amount of a pharmaceutically acceptable liquid carrier (eg, water) to allow for convenient measured administration.
[0549] The compositions of the invention for oral administration may also be provided in the form of liposomes, micelles, microspheres or nanosystems. Micellar dosage forms may be prepared as described in US Pat. No. 6,350,458.
[0550] The composition of the present invention can be provided as non-effervescent or effervescent granules and powders to be reconstituted into liquid dosage forms. Pharmaceutically acceptable carriers and excipients for non-effervescent granules or powders may include diluents, sweeteners and wetting agents. Pharmaceutically acceptable carriers and excipients for effervescent granules or powders may include organic acids and sources of carbon dioxide.
[0551] Coloring and flavoring agents can be used in all of the above dosage forms. Also, flavoring and sweetening agents are particularly useful in the formation of chewable tablets and lozenges.
[0552] The compositions of the present invention may be formulated to be immediate or modified release, including delayed, extended, pulsed, controlled, targeted and programmed release.
[0553] In some embodiments, the compositions of the invention comprise a film coating.
[0554] The composition of the present invention may contain another active ingredient that does not confer therapeutic or prophylactic efficacy on the composition or may contain a substance that expands or supplements the efficacy of the composition.
[0555] Tablet dosage forms may contain a compound of the invention in powdered, crystalline or granular form, and may further contain a carrier or vehicle as described herein, including a binder, a disintegrant, a controlled release polymer, a lubricant, a diluent or a colorant.
[0556] In some embodiments, the composition of the present invention may also include an excipient, such as a diluent, a disintegrant, a wetting agent, a binder, a glidant, a lubricant, or any combination thereof. In some embodiments, the tablet comprises a binder. Also, in some embodiments, the binder comprises microcrystalline cellulose, calcium hydrogen phosphate, sucrose, corn starch, polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxymethyl cellulose, or any combination thereof. In other embodiments, the tablet comprises a disintegrant. In other embodiments, the disintegrant comprises cross-linked sodium carboxymethyl cellulose, sodium starch glycolate, or any combination thereof. In other embodiments, the tablet comprises a lubricant. Also, in some embodiments, the lubricant comprises magnesium stearate, stearic acid, hydrogenated oil, sodium stearyl fumarate, or any combination thereof.
[0557] In some embodiments, the compositions of the invention are in the form of a tablet comprising a binder, such as any binder described herein.
[0558] In some embodiments, the compositions of the invention are in the form of a tablet comprising a disintegrant, such as any disintegrant described herein.
[0559] In some embodiments, the compositions of the invention are in the form of a tablet comprising a lubricant, such as any lubricant described herein.
[0560] In some embodiments, the compositions of the present invention may be in a modified release or controlled release dosage form. In some embodiments, the compositions of the present invention may include particles that exhibit specific release characteristics. For example, the compositions of the present invention may include a compound of the present invention in an immediate release form and also include a statin or a pharmaceutically acceptable salt thereof in a modified release form, both compressed into a single tablet. As will be appreciated by those skilled in the art, other combinations and modifications of release characteristics may be achieved. Examples of modified release dosage forms suitable for the pharmaceutical compositions of the present invention are described without limitation in U.S. Patent Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,639,480; 5,733,566; 5,73 9,108; 5,891,474; 5,922,356; 5,972,891; 5,980,945; 5,993,855; 6,045,830; 6,087,324; 6,113,943; 6,1 97,350; 6,248,363; 6,264,970; 6,267,981; 6,376,461; 6,419,961; 6,589,548; 6,613,358; and 6,699,500.
[0561] In some embodiments, the present composition is a matrix controlled release dosage form. For example, the present composition may include about 300 mg to about 600 mg of the compound of the present invention provided in a matrix controlled release form. In some embodiments, the matrix controlled release form may also include another pharmaceutically active agent. In some embodiments, the release characteristics of the compounds of the present invention and other pharmaceutically active agents are the same or different. Suitable matrix controlled release dosage forms are described in, for example, "Encyclopedia of Controlled Drug Delivery," Vol. 2, Mathiowitz, ed., Wiley, 1999 by Takada et al.
[0562] In some embodiments, the compositions of the present invention comprise from about 10 mg to about 400 mg of another pharmaceutically active agent and from about 300 mg to about 600 mg of the compounds of the present invention. In some embodiments, the compositions of the present invention comprise from about 10 mg to about 400 mg of an anticancer agent and from about 300 mg to about 600 mg of the compounds of the present invention. In some embodiments, the compositions are in a matrix-controlled modified release dosage form.
[0563] In some embodiments, the compositions of the invention comprise about 10 mg to about 40 mg of a statin and about 300 mg to about 600 mg of a compound of the invention, wherein the composition is in a matrix controlled modified release dosage form.
[0564] In some embodiments, matrix controlled release forms comprise an erodible matrix comprising water-swellable, erodible, or soluble polymers, including synthetic polymers and naturally occurring polymers and derivatives, such as polysaccharides and proteins.
[0565] In some embodiments, the erodible matrix of the matrix controlled release form comprises chitin, chitosan, dextran or pullulan; agar, gum arabic, gum karaya, locust bean gum, gum tragacanth, carrageenan, gum ghatti, guar gum, xanthan gum, scleroglucan; starches such as dextrin or maltodextrin; hydrophilic colloids such as pectin; phospholipids such as lecithin; alginates; propylene glycol alginate; gelatin; collagen; cellulosics such as ethylcellulose (EC), methylethylcellulose (MEC), carboxymethylcellulose (CMC), carboxymethylethylcellulose (CMEC), hydroxyethylcellulose Cellulose acetate (HEC), hydroxypropyl cellulose (HPC), cellulose acetate (CA), cellulose propionate (CP), cellulose butyrate (CB), cellulose acetate butyrate (CAB), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose (HPMC), HPMCP, HPMCAS, hydroxypropyl methylcellulose trimellitate acetate (HPMCAT) or ethyl hydroxyethyl cellulose (EHEC); polyvinyl pyrrolidone; polyvinyl alcohol; polyvinyl acetate; glycerol fatty acid esters; polyacrylamide; polyacrylic acid; copolymers of ethyl acrylic acid or methacrylic acid ( Rohm America, Inc., Piscataway, NJ); poly(2-hydroxyethyl-methacrylate); polylactide; copolymers of L-glutamic acid and ethyl-L-glutamate; degradable lactic acid-glycolic acid copolymers; poly-D-(-)-3-hydroxybutyric acid; or other acrylic acid derivatives, such as homopolymers and copolymers of butyl methacrylate, methyl methacrylate, ethyl methacrylate, ethyl acrylate, (2-dimethylaminoethyl) methacrylate, or (trimethylaminoethyl) methacrylate chloride; or any combination thereof.
[0566] In other embodiments, the compositions of the invention are in a matrix-controlled modified release form comprising a non-erodible matrix. In some embodiments, the statin, compound of the invention is dissolved or dispersed in an inert matrix and upon administration is released primarily by diffusion through the inert matrix. In some embodiments, the non-erodible matrix of the matrix controlled-release form comprises an insoluble polymer such as polyethylene, polypropylene, polyisoprene, polyisobutylene, polybutadiene, polymethyl methacrylate, polybutyl methacrylate, chlorinated polyethylene, polyvinyl chloride, methyl acrylate-methyl methacrylate copolymer, ethylene-vinyl acetate copolymer, ethylene / propylene copolymer, ethylene / ethyl acrylate copolymer, vinyl chloride copolymer with vinyl acetate, vinylidene chloride, ethylene or propylene, ionomer polyethylene terephthalate, butyl rubber, epichlorohydrin rubber, ethylene / vinyl alcohol copolymer, ethylene / vinyl acetate / vinyl alcohol terpolymer, ethylene / vinyloxyethanol copolymer, polyvinyl chloride, plasticized nylon, plasticized polyethylene terephthalate, natural rubber, silicone rubber, polydimethylsiloxane, silicone carbonate copolymer, or a hydrophilic polymer such as ethylcellulose, cellulose acetate, crospovidone, or cross-linked partially hydrolyzed polyvinyl acetate; a fatty compound such as carnauba wax, microcrystalline wax, or a triglyceride; or any combination thereof.
[0567] The compositions of the present invention in modified release dosage form can be prepared by methods known to those skilled in the art including direct compression, dry or wet granulation followed by compression, melt granulation followed by compression.
[0568] In some embodiments, the composition of the present invention comprises a capsule-tablet system that can be a multifunctional and multi-unit system, which comprises a variety of mini-tablets (mini-tablets) in a hard gelatin capsule. The mini-tablets can be fast-release, extended-release, pulsed, delayed-start extended-release mini-tablets, or any combination thereof. In some embodiments, a combination of mini-tablets comprising a variety of active agents or a combination of mini-tablets and mini-beads can each have a specific lag time for a pulsed drug delivery system (DDS) with multiplied release, site-specific DDS, slow-fast DDS, fast / slow DDS, and zero-order DDS.
[0569] In some embodiments, the compositions of the present invention are in an osmotic controlled release dosage form.
[0570] In some embodiments, the osmotic controlled release device comprises a single chamber system, a dual chamber system, an asymmetric membrane technology (AMT), an extruded core system (ECS), or any combination thereof. In some embodiments, such devices comprise at least two components: (a) a core containing an active agent and (b) a semipermeable membrane having at least one delivery port encapsulating the core. The semipermeable membrane controls the flow of water from the aqueous environment of use into the core to release the drug through the delivery port by extrusion.
[0571] In some embodiments, the core of the osmotic device optionally comprises an osmotic agent that creates a driving force for transport of water from the environment of use into the core of the device. One class of osmoagents useful in the compositions of the present invention comprises water-swellable hydrophilic polymers, also referred to as "osmopolymers" or "hydrogels", which include, but are not limited to, hydrophilic vinyl and acrylic polymers, polysaccharides such as calcium alginate, polyethylene oxide (PEO), polyethylene glycol (PEG), polypropylene glycol (PPG), poly(2-hydroxyethyl methacrylate), poly(acrylic) acid, poly(methacrylic) acid, polyvinyl pyrrolidone (PVP), cross-linked PVP, polyvinyl alcohol (PVA), PVA / PVP copolymers, PVA / PVP copolymers with hydrophobic monomers such as methyl methacrylate and vinyl acetate, hydrophilic polyurethanes containing large PEO blocks, cross-linked sodium carboxymethylcellulose, carrageenan, hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), carboxymethylcellulose (CMC) and carboxyethylcellulose (CEC), sodium alginate, polycarbophil, gelatin, xanthan gum, and sodium starch glycolate.
[0572] Another class of osmogens useful in the compositions of the present invention comprises osmogens, which are capable of absorbing water to affect an osmotic pressure gradient across the barrier of the surrounding coating. Suitable osmogens include, but are not limited to, inorganic salts such as magnesium sulfate, magnesium chloride, calcium chloride, sodium chloride, lithium chloride, potassium sulfate, potassium phosphate, sodium carbonate, sodium sulfite, lithium sulfate, potassium chloride, and sodium sulfate; sugars such as dextrose, fructose, glucose, inositol, lactose, maltose, mannitol, raffinose, sorbitol, sucrose, trehalose, and xylitol; organic acids such as ascorbic acid, benzoic acid, fumaric acid, citric acid, maleic acid, sebacic acid, sorbic acid, adipic acid, edetic acid, glutamic acid, p-toluenesulfonic acid, succinic acid, and tartaric acid; urea; and mixtures thereof.
[0573] Osmotic agents with different dissolution rates can be used to affect how quickly the compounds of the invention dissolve after administration. For example, amorphous sugars (such as Mannogeme EZ (SPIPharma, Lewes, DE)) can be included to provide faster delivery within the first few hours (e.g., about 1 to about 5 hours) to quickly produce preventive or therapeutic effects, and gradually and continuously release the remaining amount over an extended period of time to maintain the desired level of therapeutic or preventive effect. In some embodiments, the compounds of the invention are released from the compositions of the invention at a rate that replaces the amount of the compounds of the invention metabolized or secreted by the subject.
[0574] The core may also include a wide variety of other excipients and carriers as described herein to enhance the performance of the dosage form or to facilitate stability or processing.
[0575] Materials useful for forming the semipermeable membrane include various grades of acrylic resins, vinyls, ethers, polyamides, polyesters, and cellulosic derivatives that are water permeable and water-insoluble at physiologically relevant pH, or susceptible to chemical changes (such as cross-linking) to become water-insoluble. Examples of suitable polymers useful for forming the coating include plasticized, non-plasticized and reinforced cellulose acetate (CA), cellulose diacetate, cellulose triacetate, CA propionate, cellulose nitrate, cellulose acetate butyrate (CAB), CA ethyl carbamate, CAP, CA methyl carbamate, CA succinate, cellulose acetate trimellitate (CAT), CA dimethylaminoacetate, CA ethyl carbonate, CA chloroacetate, CA ethyl oxalate, CA methyl sulfonate, CA butyl sulfonate, p-toluenesulfonic acid CA, agar acetate, amylose triacetate, β-glucan acetate, β-Glucan triacetate, dimethyl acetaldehyde acetate, triacetate of locust bean gum, hydroxylated ethylene vinyl acetate, EC, PEG, PPG, PEG / PPG copolymers, PVP, HEC, HPC, CMC, CMEC, HPMC, HPMCP, HPMCAS, HPMCAT, poly(acrylic acid) and esters and poly(methacrylic acid) and esters and copolymers thereof, starch, dextran, dextrin, chitosan, collagen, gelatin, polyolefins, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinyl esters and ethers, natural waxes and synthetic waxes.
[0576] The semipermeable membrane may also be a hydrophobic microporous membrane in which the pores are substantially filled with gas and are not wetted by aqueous media, but are permeable to water vapor, as disclosed in U.S. Pat. No. 5,798, 119. The hydrophobic but water vapor permeable membrane is typically composed of a hydrophobic polymer such as polyolefins, polyethylene, polypropylene, polytetrafluoroethylene, polyacrylic acid derivatives, polyethers, polysulfones, polyethersulfones, polystyrenes, polyvinyl halides, polyvinylidene fluoride, polyvinyl esters and ethers, natural waxes, and synthetic waxes.
[0577] Delivery ports on the semipermeable membrane can be formed after coating by mechanical or laser drilling. Delivery ports can also be formed in situ by etching a plug of water-soluble material or by rupturing a thinner membrane portion over a depression in the core. In addition, delivery ports can be formed during the coating process, as in the case of asymmetric membrane coatings of the type disclosed in U.S. Patent Nos. 5,612,059 and 5,698,220.
[0578] The total amount of the compounds of the invention released and the rate of release can be substantially controlled via the thickness and porosity of the semipermeable membrane, the composition of the core and the number, size and location of the delivery ports.
[0579] In some embodiments, the pharmaceutical composition in an osmotic controlled release dosage form may further comprise additional conventional excipients as described herein to facilitate the performance or processing of the formulation.
[0580] Osmotic controlled release dosage forms can be prepared according to conventional methods and techniques known to those skilled in the art (see Remington: The Science and Practice of Pharmacy, supra; Santus and Baker, J. Controlled Release 1995, 35, 1-21; Verma et al., Drug Development and Industrial Pharmacy 2000, 26, 695-708; Verma et al., J. Controlled Release 2002, 79, 7-27.
[0581] In some embodiments, the pharmaceutical composition provided herein is formulated into asymmetric membrane technology (AMT) controlled release dosage form, which comprises an asymmetric permeable membrane coated core, and the core comprises active ingredients and other pharmaceutically acceptable excipients. Referring to U.S. Patent No. 5,612,059 and WO 2002 / 17918. AMT controlled release dosage form can be prepared according to conventional methods and techniques known to those skilled in the art, including direct compression, dry granulation, wet granulation and dip coating methods.
[0582] In some embodiments, the pharmaceutical compositions provided herein are formulated as ESC controlled release dosage forms comprising a permeable membrane coating a core comprising a compound of the invention, hydroxyethylcellulose and other pharmaceutically acceptable excipients.
[0583] In some embodiments, the composition of the present invention is a modified release dosage form manufactured as a multiparticulate controlled release dosage form comprising a plurality of particles, granules or pellets, microparticles, beads, microcapsules and microtablets having a diameter ranging from about 10 μm to about 3 mm, about 50 μm to about 2.5 mm, or about 100 μm to 1 mm.
[0584] Multiparticulate controlled release dosage forms can provide extended release dosage forms with improved bioavailability. Suitable carriers for maintaining the release rate of the compounds of the invention include, but are not limited to, ethylcellulose, HPMC, HPMC-phthalate, colloidal silicon dioxide, and Eudragit-RSPM.
[0585] The composition of the invention in the form of pellets comprises 50 to 80% (w / w) drug and 20 to 50% (w / w) microcrystalline cellulose or other polymers. Suitable polymers include, but are not limited to, microcrystalline wax, pregelatinized starch and maltodextrin.
[0586] Beads in capsule and tablet dosage forms can be prepared. Beads in tablet dosage form can show a slower dissolution profile than microparticles in capsule form. Microparticle fillers suitable for the compositions and treatment or prevention methods of the present invention include, but are not limited to, sorbitan monooleate (Span 80), HPMC, or any combination thereof. Suitable dispersants for controlled release latex include, for example, ethyl-acrylate and methyl-acrylate.
[0587] In some embodiments, the composition of the present invention is in the form of microcapsules and / or microtablets. In some embodiments, microcapsules include extended release polymer microcapsules, which contain statins and the compounds of the present invention with various solubility characteristics. Extended release polymer microcapsules can be prepared by colloidal polymer dispersions in aqueous environments. In other embodiments, microcapsules suitable for the compositions and methods provided herein can be prepared using conventional microencapsulation technology (Bodmeier & Wang, 1993).
[0588] Such multiparticulates can be prepared by methods known to those skilled in the art, including wet and dry granulation, extrusion / spheronization, roller compaction, melt congealing, and by spray coating of seed cores. See, for example, Multiparticulate Oral Drug Delivery; Marcel Dekker: 1994; and Pharmaceutical Pelletization Technology; Marcel Dekker: 1989. Excipients for such techniques are commercially available and described in the U.S. Pharmacopoeia.
[0589] Other excipients as described herein may be blended with the compositions of the present invention to aid in processing and forming multiparticulates. The resulting particles themselves may constitute a multiparticulate dosage form or may be coated with various film-forming materials such as enteric polymers, water-swellable or water-soluble polymers. The multiparticulates may be further processed into capsules or tablets.
[0590] In other embodiments, the composition of the present invention is in a dosage form having an immediate release component and at least one delayed release component and is capable of producing discontinuous release of the compound in the form of at least two continuous pulses separated in time from 0.1 hour to 24 hours.
[0591] In some embodiments, the compositions of the present invention include about 1 mg to about 1000 mg of the compounds of this invention or any amount from these values and to these values. In some embodiments, the compositions of the present invention include about 1 mg to about 500 mg of the compounds of this invention or any amount from these values and to these values. In some embodiments, the compositions of the present invention include about 1 mg to about 400 mg of the compounds of this invention or any amount from these values and to these values.
[0592] In other embodiments, the compositions of the present invention include compounds of the present invention in an amount equivalent to a molar equivalent of about 1 mg to about 1000 mg of the compounds of the present invention or any amount from these values and to these values. In other embodiments, the compositions of the present invention include compounds of the present invention in an amount equivalent to a molar equivalent of about 1 mg to about 500 mg of the compounds of the present invention or any amount from these values and to these values. In other embodiments, the compositions of the present invention include compounds of the present invention in an amount equivalent to a molar equivalent of about 1 mg to about 400 mg of the compounds of the present invention or any amount from these values and to these values.
[0593] In some embodiments, the compositions of the present invention comprise a compound of the present invention in an amount of about 10 wt % to about 99 wt % of the total weight of the composition of the present invention.
[0594] Method of the present invention
[0595] The present invention provides a method for treating or preventing a disease, the method comprising administering an effective amount of a compound of the present invention or a composition of the present invention to a subject in need thereof, wherein the disease is a liver disease or abnormal liver condition; cancer (such as hepatocellular carcinoma or cholangiocarcinoma); malignant or benign tumors of the lung, liver, gallbladder, bile duct or digestive tract; intrahepatic or extrahepatic bile duct disease; lipoprotein disorders; lipid and metabolic disorders; cirrhosis; fibrosis; glucose metabolism disorders; cardiovascular or related vascular disorders; diseases caused by steatosis, fibrosis or cirrhosis; diseases associated with increased inflammation (such as liver inflammation or lung inflammation); hepatocyte ballooning; peroxisome proliferator-activated receptor-related disorders; ATP-citrate lyase disorders; acetyl-CoA carboxylase disorders; obesity; pancreatitis; or kidney disease.
[0596] The present invention provides a method for treating or preventing a disease, the method comprising administering an effective amount of a compound of the present invention or a composition of the present invention to a subject in need thereof, wherein the disease is cancer, lipid and metabolic disorders, liver disorders, cirrhosis, fibrosis, glucose metabolism disorders, peroxisome proliferator-activated receptor-related disorders, malignant or benign tumors of the lung, liver, gallbladder and digestive tract, ATP-citrate lyase disorders, acetyl-CoA carboxylase disorders, obesity, pancreatitis, kidney disease, hepatocyte ballooning, liver inflammation or lung inflammation.
[0597] In some embodiments of the methods as disclosed herein, the disease is cancer. In some embodiments, the cancer is hepatocellular carcinoma (HCC), HCC with concurrent cirrhosis, HCC without concurrent cirrhosis, bile duct cancer, colorectal cancer, biliary tract cancer, or lung cancer. In some embodiments, the cancer is fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendothelial sarcoma, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, colon cancer, colorectal cancer, kidney cancer, pancreatic cancer, bone cancer, breast cancer, ovarian cancer, prostate cancer, esophageal cancer, stomach cancer, oral cancer, nasal cancer, laryngeal cancer, squamous cell carcinoma, basal cell carcinoma adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchial carcinoma, renal cell carcinoma, liver cancer, bile duct cancer, carcinoma), choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, uterine cancer, testicular cancer, small cell lung cancer, bladder cancer, lung cancer, epithelial cancer, glioma, glioblastoma multiforme, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, skin cancer, melanoma, neuroblastoma, retinoblastoma, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia (AML), acute promyelocytic leukemia (APL), acute monocytic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocytic leukemia (nonlymphocytic leukemia), acute undifferentiated leukemia, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), hairy cell leukemia, multiple myeloma, lymphoblastic leukemia, myeloid leukemia, lymphocytic leukemia, myeloid leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia ( macroglobulinemia, heavy chain disease, gastrointestinal cancer, head-and-neck cancer, hematopoietic cancer, or polycythemia vera.
[0598] In some embodiments, the gastrointestinal (digestive system) cancer is gastrointestinal stromal tumor (GIST), esophageal cancer, gallbladder cancer, gastrointestinal carcinoid tumor, bile duct cancer, duodenal cancer, gastroesophageal (GE) junction cancer, islet cell carcinoma, pancreatic cancer, gastric cancer, colon cancer, rectal cancer, colorectal cancer, anal cancer, liver cancer, biliary cancer, bile duct cancer, small intestine cancer, seudomyxoma peritonei, small intestine cancer, or cancer of unknown primary site.
[0599] In some embodiments, the hematopoietic cancer is non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's lymphoma (HL), or chronic myeloid leukemia (CML).
[0600] In some embodiments of the methods as disclosed herein, the cancer is at any stage. In some embodiments, the cancer may be at stage 0, stage I, stage II, stage III, or stage IV. In some embodiments of the methods as disclosed herein, the disease is a tumor and the tumor may be at any stage. In some embodiments, the tumor is grade 1, grade 2, grade 3, or grade 4.
[0601] In some embodiments of the methods as disclosed herein, the disease is a lipid and metabolic disorder. In some embodiments, the lipid and metabolic disorder is characterized by high C-reactive protein (CRP), high serum amyloid A (SAA), high alanine aminotransferase (ALT), high aspartate aminotransferase (AST), high alkaline phosphatase (ALP), high gamma-glutamyl transferase (CGT), high low-density lipoprotein (LDL), high very low-density lipoprotein (VLDL), high apolipoprotein B (ApoB) and ApoB / Lp (a) (lipoprotein (a)) ratio, high total cholesterol, low high-density lipoprotein (HDL) or high non-HDL-cholesterol in the plasma or serum of the subject; or characterized by high glucose and insulin resistance in subjects with diabetes. In some embodiments, the lipid and metabolic disorder is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) or alcoholic steatohepatitis (ASH).
[0602] In some embodiments of the methods as disclosed herein, the disease is a glucose metabolism disorder. In some embodiments, the glucose metabolism disorder is type I diabetes or type II diabetes.
[0603] In some embodiments of the methods as disclosed herein, the disease is a disease caused by steatosis, fibrosis, and cirrhosis. In some embodiments, the disease caused by steatosis is inflammation. In some embodiments, the disease caused by steatosis is NAFLD, NASH, or ASH. In some embodiments, the disease caused by fibrosis is cirrhosis or liver failure. In some embodiments, the disease caused by cirrhosis is hepatocellular carcinoma, liver damage, or hepatic encephalopathy.
[0604] The present invention provides a method for reducing the C-reactive protein (CRP) concentration, serum amyloid A (SAA) concentration, alanine aminotransferase (ALT) concentration, aspartate aminotransferase (AST) concentration, alkaline phosphatase (ALP) concentration, γ-glutamyl transferase (GGT) concentration, serum creatinine concentration, 7α-hydroxy-4-cholesten-3-one (C4) concentration, protein: creatinine ratio, creatine kinase concentration, angiopoietin-like protein 3 concentration, angiopoietin-like protein 4 concentration, angiopoietin-like protein 8 concentration, fibrinogen concentration, total cholesterol concentration, low-density lipoprotein cholesterol concentration, low-density lipoprotein concentration, very low-density lipoprotein cholesterol concentration, very low-density lipoprotein concentration, non-HDL cholesterol concentration, non-HDL concentration, apolipoprotein B concentration, lipoprotein (a) concentration or serum triglyceride concentration of the subject in the plasma or serum of the subject, the method comprising administering an effective amount of a compound of the present invention or a composition of the present invention to a subject in need thereof.
[0605] The present invention provides a method for reducing triglyceride concentration in the liver of a subject, the method comprising administering an effective amount of a compound of the present invention or a composition of the present invention to a subject in need thereof.
[0606] The present invention provides a method for increasing the concentration of high-density lipoprotein cholesterol or high-density lipoprotein in the plasma or serum of a subject, the method comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0607] The present invention provides a method for increasing the functionalization of high-density lipoprotein cholesterol without increasing its concentration in the plasma or serum of a subject, the method comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof, wherein the excretion amount or excretion rate of triglycerides is increased.
[0608] The present invention provides a method for treating a disease, comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof, wherein the disease is a gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) or an autoimmune disease.
[0609] In some embodiments of the methods as disclosed herein, the disease is inflammatory bowel disease. In some embodiments, the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
[0610] In some embodiments of the methods as disclosed herein, the disease is an autoimmune disease. In some embodiments, the autoimmune disease is systemic lupus erythematosus.
[0611] The present invention provides a method for regressing, reducing the progression rate or inhibiting the progression of fibrosis, hepatocyte ballooning or liver inflammation, which comprises administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0612] The present invention provides a method for inhibiting, reducing or delaying the development of lipid synthesis, hepatic steatosis, hepatocyte ballooning or inflammation, liver fibrosis, pulmonary fibrosis or cirrhosis in a subject, the method comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0613] The present invention provides a method for reducing the risk of a subject developing or suffering from atherosclerosis, coronary heart disease, peripheral vascular disease, stroke or restenosis, the method comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0614] The present invention provides a method for increasing the HDL concentration in the serum or plasma of a subject, the method comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0615] The present invention provides a method for inhibiting NF-kB or stellate cell activation, comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0616] The present invention provides a method for activating PPAR (peroxisome proliferator-activated receptor) in a subject, the method comprising administering an effective amount of a compound of the present invention or a composition of the present invention to a subject in need thereof.
[0617] The present invention provides a method for down-regulation of CCR2 / CCR5 genes, comprising administering an effective amount of a compound of the present invention to a subject in need thereof.
[0618] The present invention provides a method for inhibiting one or more of NF-kB activation, CCR2 activation, CCR5 activation and stellate cell activation, comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0619] The present invention provides a method for inhibiting the activation or concentration of interleukins, the method comprising administering an effective amount of a compound of the present invention or a composition of the present invention to a subject in need thereof. In some embodiments, the interleukin (IL) is IL-2, IL-6, IL-17 or IL-18.
[0620] The present invention provides a method for inhibiting fibrin / fibrinogen, gastrin, lactate dehydrogenase, prostatic acid phosphatase (PAP), thyroglobulin, urinary catecholamines, urinary vanillylmandelic acid (VMA) or urinary homovanillic acid (HVA), which comprises administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0621] The present invention provides a method for inhibiting β-human chorionic gonadotropin (β-hCG), β-2-microglobulin (B2M), and B-cell immunoglobulin, which comprises administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0622] The present invention provides a method for inhibiting alpha-fetoprotein (AFP), comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0623] The present invention also provides a method for inhibiting hepatic fatty acid or sterol synthesis, which comprises administering an effective amount of the compound or composition of the present invention to a subject in need thereof.
[0624] The present invention also provides a method for treating or preventing a disease or condition that can be treated or prevented by increasing HDL levels, the method comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0625] The present invention also provides a method for treating or preventing a disease or condition that can be treated or prevented by lowering LDL levels, the method comprising administering an effective amount of a compound or composition of the present invention to a subject in need thereof.
[0626] Without being limited by theory, it is believed that the compounds of the invention advantageously alter lipid metabolism by enhancing the oxidation of fatty acids, at least in part, through the ACC / malonyl-CoA / CPT-I regulatory axis. Thus, the present invention also provides a method for treating or preventing metabolic syndrome conditions, the method comprising administering an effective amount of a compound of the invention or a composition of the invention to a subject in need thereof.
[0627] The present invention further provides a method for modulating, directly inhibiting or allosterically inhibiting ATP citrate lyase in a subject, the method comprising administering to the subject an effective amount of a compound of the present invention or a composition of the present invention.
[0628] The present invention further provides a method for modulating, directly inhibiting or allosterically inhibiting acetyl-CoA carboxylase 1 (ACC 1) or acetyl-CoA carboxylase 2 (ACC2) in a subject, the method comprising administering an effective amount of a compound or composition of the present invention to the subject.
[0629] The present invention further provides a method for reducing the fat or cholesterol content of livestock meat or poultry eggs, which comprises administering an effective amount of the compound or composition of the present invention to the livestock or poultry.
[0630] In some embodiments of the methods as disclosed herein, the compounds of the invention are administered to a subject in need thereof in a range of about 1 mg to about 1000 mg or any amount from these values and to these values. In some embodiments, the compounds of the invention are administered to a subject in need thereof in a range of about 1 mg to about 900 mg, about 1 mg to about 800 mg, about 1 mg to about 700 mg, about 1 mg to about 600 mg, about 1 mg to about 500 mg, about 1 mg to about 400 mg, or about 1 mg to about 300 mg.
[0631] In some embodiments of the methods as disclosed herein, the compounds of the present invention are administered to a subject in need thereof at a daily dose ranging from about 1 mg to about 1000 mg or any amount ranging from these values and to these values. In some embodiments, the compounds of the present invention are administered to a subject in need thereof at a daily dose of about 1000 mg, about 950 mg, about 900 mg, about 850 mg, about 800 mg, about 750 mg, about 700 mg, about 650 mg, about 600 mg, about 550 mg, about 500 mg, about 450 mg, about 400 mg, about 350 mg, about 300 mg, about 250 mg, about 200 mg, about 150 mg, about 100 mg, about 80 mg, about 60 mg, about 40 mg, about 20 mg, about 10 mg, about 5 mg or about 1 mg.
[0632] In some embodiments of the methods as disclosed herein, a compound of the invention is administered to a subject in need thereof once a day at a dosage of about 1 mg to about 1000 mg, or any amount ranging from and to these values.
[0633] In some embodiments of the methods as disclosed herein, the compounds of the present invention are administered twice a day to a subject in need thereof, each dose comprising about 1 mg to about 500 mg or any amount of the compounds of the present invention ranging from these values and to these values. In some embodiments, the compounds of the present invention are administered twice a day to a subject in need thereof, each dose comprising about 500 mg, about 450 mg, about 400 mg, about 350 mg, about 300 mg, about 250 mg, about 200 mg, about 150 mg, about 100 mg, about 80 mg, about 60 mg, about 40 mg, about 20 mg, about 10 mg, about 5 mg or about 1 mg of the compounds of the present invention.
[0634] In some embodiments of the methods as disclosed herein, the compounds of the present invention are administered to subjects in need three times a day, each dose comprising about 1 mg to about 400 mg or any amount of the compounds of the present invention ranging from these values and to these values. In some embodiments, the compounds of the present invention are administered to subjects in need three times a day, each dose comprising about 400 mg, about 350 mg, about 300 mg, about 250 mg, about 200 mg, about 150 mg, about 100 mg, about 80 mg, about 60 mg, about 40 mg, about 20 mg, about 10 mg, about 5 mg or about 1 mg of the compounds of the present invention.
[0635] In some embodiments of the method as disclosed herein, the method further comprises administering an effective amount of another pharmaceutically active agent. In some embodiments, other pharmaceutically active agents are administered simultaneously or sequentially (before or after) with the administration of the compounds of the present invention or the compositions of the present invention. In some embodiments, other pharmaceutically active agents are statins, thiazolidinediones or fibrates, bile acid binding resins, niacin, anti-obesity drugs, hormones, tylosin, sulfonylurea-based drugs, biguanides, α-glucosidase inhibitors, apolipoprotein AI agonists, apolipoprotein E agonists; phosphodiesterase type 5 inhibitors, cardiovascular drugs, HDL-raising drugs, HDL enhancers, regulators of apolipoprotein AI genes, regulators of apolipoprotein A-IV genes, regulators of apolipoprotein genes, ATP citrate lyase regulators, ATP citrate lyase allosteric inhibitors, acetyl-CoA carboxylase regulators, or acetyl-CoA carboxylase allosteric inhibitors. In some embodiments, other pharmaceutically active agents are lovastatin. In some embodiments, the other pharmaceutically active agent is sorafenib; taxol; caprolactam; pembrolizumab; lenvatinib; avelumab; durvalumab; tremelimumab; nivolumab; tazemestat; cemiplimab; ABX 196; T cell receptor (TCR) immune cell therapy; TBI-302; namodixon; MM-310; tumor-injected oncolytic viruses or genetically modified oncolytic viruses such as, but not limited to, tromecin and ilige; or immunomodulatory gene therapy agents such as MDA-7 / IL-24, GLIPR1 / RTVP-1, and REIC / Dkk-3.
[0636] In some embodiments of the methods as disclosed herein, the method further comprises administering two or more other pharmaceutically active agents. In some embodiments, the methods of the present invention comprise administering two or more other pharmaceutically active agents, optionally in combination. In some embodiments, two or more other pharmaceutically active agents are oncolytic agents, such as but not limited to nanasta and valganciclovir. In other embodiments, the methods of the present invention comprise oral administration of the compounds of the present invention and further comprise administering tumor injection oncolytic therapy. In some embodiments, the combination is oral administration.
[0637] In some embodiments, the other pharmaceutically active agent is senevirorc, elareno, eicosapentaenoic acid, ganisertib, LY2109761, LDE225, nivolumab, ficostat, apalizumab, metformin, leucine-metformin-sildenafil combination (NS-0200), IMM-124E, RG-125, vitamin E, cysteamine, seronsertib, losartan, RO5093151, pugalistat, sitagliptin, vildagliptin, NGM282, pebbefumin, PF-05231023, obeticholic acid, herofloxacin, tripipric Flusor, EDP-305, INT-767, arabinogalactan-rhamnogalacturonate, liraglutide, semaglutide, exenatide, ND-L02-s0201 / BMS-986263, worixib, amlexanox, PF-06835919, leptin, metreleptin, sintuzumab, talukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elareno, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanileno, alatraquin, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmafen, pentamidine, berberine, L-carnitine, EYP001 a, silymarin, melikran, ursodeoxycholic acid, metadoxine, ezetimibe, cistatin, L-alanine, saroglitazar magnesium, worixib, solithromycin, 99m-technetium-methylbrompheniramine, tripifoxol, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, or serradepa.
[0638] In some embodiments of the methods as disclosed herein, the method for treating or preventing a disease comprises administering Compound I-1, Compound I-32, Compound I-61, or Compound III-1, or a pharmaceutically acceptable salt or solvate thereof.
[0639] In some embodiments of the methods disclosed herein, the method for treating or preventing a disease comprises administering an effective amount of (a) a compound of the invention and (b) another pharmaceutically active agent, which is sorafenib, taxol, lenvatinib, tazemetostat, TBI-302, narmodison, MM-310, senevirol, elareno, eicosapentaenoic acid, ganiserti, LY2109761, LDE225, ficostat, aparetone, metformin, leucine-metformin-sildenafil combination, vitamin E, cysteamine, seronserti, losartan, RO5093151 pugalistat, sitagliptin, vildagliptin, NGM282, pebbefumin, PF-05231023, obeticholic acid, xi Roflumilast, tripifluxol, EDP-305, INT-767, arabinogalactan-rhamnogalacturonate, liraglutide, semaglutide, exenatide, worixib, amlexanox, PF-06835919, leptin, metreleptin, sintuzumab, talukast, oltipraz, MSDC-0602K, ASP9831, roflumilast, elareno, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanileno, alaqu, ipraglixin, dapagliflozin, empagliflozin, BI1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmafin, pentamidine, berberine, L-carnitine, EYP001 a, silymarin, melicoran, ursodeoxycholic acid, metadoxine, ezetimibe, cistatin, etc., L-alanine, saloglitazar magnesium, worixib, elareno, nalmefene, solithromycin, 99m technetium-methylbrompheniramine, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, celadepa, fexotinib, doxorubicin, cabozantinib, deferoxamine, itatinib, sioronib, SF 1126, anlotinib, P 1101, valitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapacerti, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, edostat, RO7119929, guacitabine, linrodostat, copanis, MIV-818, vololanib, RO7070179, axitinib, sunitinib, or zotilin citrate.In some embodiments of the methods disclosed herein, the method for treating or preventing a disease comprises administering an effective amount of (a) Compound I-1, Compound I-32, Compound I-61 or Compound III-1 or a pharmaceutically acceptable salt or solvate thereof and (b) another pharmaceutically active agent, which is sorafenib, Taxol, Lenvatinib, Tazerestat, TBI-302, Namodisone, MM-310, Cenivelo, Elareno, Eicosapentaenoic acid, Ganiserti, LY2109761, LDE225, Ficostat, Apaline, Metformin, Leucine-Metformin-Sildenafil Combination, Vitamin E, Cysteamine, Seronserti, Losartan, RO 5093151 Prugastat, sitagliptin, vildagliptin, NGM282, pebofurmin, PF-05231023, obeticholic acid, herofloxacin, tripifluxol, EDP-305, INT-767, arabinogalactan-rhamnogalacturonate, liraglutide, semaglutide, exenatide, worixib, amlexanox, PF-06835919, leptin, metreleptin, sintuzumab, talukastat, oltipraz, MSDC-0602K, ASP9831, roflumilast, elareno, pioglitazone, rosiglitazone, fenofibrate, saroglitazar, lanileno, alatraquin, ipragliflozin, dapagliflozin, empagliflozin, BI 1467335, rosuvastatin, atorvastatin, pitavastatin, VK2809, MGL-3196, nalmefene, pentamidine, berberine, L-carnitine, EYP001 a, silymarin, melicoran, ursodeoxycholic acid, metadoxine, ezetimibe, cistat, etc., L-alanine, saroglitazar magnesium, vorixib, elareno, nalmefene, solithromycin, 99m-technetium-methylbrompheniramine, S-adenosylmethionine, pentoxifylline, olesoxime, AKR-001, celadepa, fexotinib, doxorubicin, cabozantinib, deferoxamine, itatinib, sioronib, SF 1126, anlotinib, P 1101, valitinib, SHR-1210, SHR6390, capmatinib, dabrafenib, trametinib, sapacerti, meclizine, enzalutamide, H3B-6527, OBI-3424, brivanib, tepotinib, temsirolimus, edostat, RO7119929, guacitabine, linrodostat, copanis, MIV-818, vololanib, RO7070179, axitinib, sunitinib, or zotilin citrate.
[0640] In some embodiments of the methods as disclosed herein, the method for treating or preventing a disease comprises administering an effective amount of (a) a compound of the invention and (b) another pharmaceutically active agent, which is sorafenib, taxol, camotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX 196, T cell receptor (TCR) immune cell therapy, TBI-302, namodixon, MM-310, tumor-injected oncolytic virus, gene-modified oncolytic virus, or immunomodulatory gene therapy. In some embodiments of the methods disclosed herein, the method for treating or preventing a disease comprises administering an effective amount of (a) Compound I-1, Compound I-32, Compound I-61 or Compound III-1 or a pharmaceutically acceptable salt or solvate thereof and (b) another pharmaceutically active agent, which is sorafenib, taxol, carlotuximab, pembrolizumab, lenvatinib, avelumab, durvalumab, tremelimumab, nivolumab, tazemetostat, cemiplimab, ABX196, T cell receptor (TCR) immune cell therapy, TBI-302, namodixon, MM-310, tumor-injected oncolytic virus, genetically modified oncolytic virus or immunomodulatory gene therapy.
[0641] In some embodiments, the methods of the present invention comprise administering to a subject in need thereof an effective amount of a compound of the present invention and another pharmaceutically active agent as described in the embodiments of Table D. In some embodiments, the other pharmaceutically active agent is administered simultaneously with, before, or after administration of a compound of the present invention or a composition of the present invention.
[0642] In some embodiments of the methods as disclosed herein, the method further comprises administering radiation therapy to the subject. In some embodiments, the radiation therapy is gamma ray radiation therapy or x-ray radiation therapy. In some embodiments, the radiation therapy is administered via a gamma ray or x-ray radiation device.
[0643] In some embodiments, radiation therapy is administered simultaneously with, before, or after administration of a compound or composition of the invention. In some embodiments, radiation therapy is administered before or after administration of a compound or composition of the invention.
[0644] Process for preparing the compounds of the present invention
[0645] Synthesis and general procedures
[0646] Compounds of Formula (IA), (IB), (IC), (ID), (IE), (IF), (IG), (IH), (IJ), (IK) and (IL) (collectively referred to as "Formula (I)") can be prepared via the synthetic methods illustrated in Schemes 1 to 7. Starting materials that can be used to prepare the compounds of the present invention and their intermediates are commercially available or can be prepared from commercially available materials using known synthetic methods and reagents.
[0647] Scheme 1: General synthesis of formula (I)
[0648]
[0649] In Scheme 1, A may be a halogen, such as Cl, Br, or I. In some embodiments, A is Br. In Scheme 1, B may be a carbanion of an ester of a carboxylic acid or a malonate. In Scheme 1, Q 1 and Q 2 can be independently -O-alkyl, -S-alkyl, -S-aryl, -NR 1A R 2A 、NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl or heterocyclic group, or each carbon atom and Q connected to the carbon atom 1 and Q 2 Together, R independently forms a heterocyclic group or a carbocyclic group. 1A and R 2A As defined herein for formula (I).
[0650] Scheme 2: General synthesis of formula (I)
[0651]
[0652] In Scheme 2, Q 1 and Q 2 can be independently -O-alkyl, -S-alkyl,
[0654] -S-aryl, -NR 1A R 2A 、NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl or heterocyclic group, or each carbon atom and Q connected to the carbon atom 1 and Q 2 Together, R independently forms a heterocyclic group or a carbocyclic group. 1A and R 2A As defined herein for formula (I).
[0655] Scheme 3: General synthesis of formula (I) wherein Z is -C(R 1 )(R 2 )-(CH2) c -X, where X is COOR 5 Or COOH, and c is 0.
[0656]
[0657] In Scheme 3, Q 1 and Q 2 can be independently -O-alkyl, -S-alkyl, -S-aryl, -NR 1A R 2A 、NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl or heterocyclic group, or each carbon atom and Q connected to the carbon atom 1 and Q 2 Together, R independently forms a heterocyclic group or a carbocyclic group. 1A , R 2A As defined herein for formula (I).
[0658] Scheme 3 illustrates the ortho-, meta- or para-ω-haloalkyl-substituted aromatic hydrocarbons of Formula 5 (wherein p is an integer in the range of 2 to 5 and Hal is Cl, Br or I) to dicarboxylic acids of Formula 7 (wherein R 1 and R 2 The transformation can be accomplished by two different but related approaches. According to the first approach, the formula R 1 R 2 CHCO2R 5 Esters (where R 1 and R 2 is an alkyl and / or aryl moiety or is connected in a three- to seven-membered ring and R 5The 2-hydroxy-1-(2-hydroxy-2-yl)-1-yl group (usually ethyl or methyl) is deprotonated with a strong base (preferably but not limited to butyl lithium or lithium diisopropylamide) and then reacted with a dihalide of Formula 5 to provide the corresponding diester of Formula 6. Typically, the reaction is carried out at a temperature of about -78°C to about 25°C and the reaction solvent is preferably THF or diethyl ether (for a discussion of the scope of this method, see Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2nd Edition; Wiley-VCH, New York, 1999, pp. 1725-1726. For specific examples of this method, see Dasseux et al., US Pat. No. 6,646,170 and US Pat. No. 6,410,802; Oniciu et al. US Pat. No. 10,227,285 and Ackerley et al., J. Med. Chem. 1995, 38, 1608-1628). In the second step, the diester of formula 6 is saponified (for overview, see Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2nd edition; Wiley-VCH, New York, 1999, pages 1959-1968 and Smith, MB; March, J. March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure, 5th edition; John Wiley and Sons, New York, 2001, pages 469-474) to the diacid of formula 7. Alternatively, when the formula R 1 R 2 The carboxylic acid of CHCO2H (where R 1 and R 2 is alkyl and / or aryl) in a similar manner to the above R 1 R 2 CHCO2R 5The conversion of the dihalide of Formula 5 to the diacid of Formula 7 can also be achieved in one step when the alkylation conditions of 5 are deprotonated twice and then reacted with the dibromide 5 (for discussion, see Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2nd edition; Wiley-VCH, New York, 1999, pages 1717-1718). For example, reacting the compound of Formula 5 (ortho position, p = 3, Hal = Br) with lithio ethyl isobutyrate (prepared from ethyl isobutyrate and lithium diisopropylamide) at a temperature ranging from about -78°C to room temperature in a mixture solvent of THF and DMPU provides the corresponding diester of Formula 7 (ortho position, p = 3). This diester is then hydrolyzed under standard conditions (aqueous ethanol, potassium hydroxide, reflux temperature) to provide, after re-acidification with dilute aqueous hydrochloric acid, a dicarboxylic acid of Formula 7 having an ortho substitution pattern, R 1 =R 2 = methyl and p = 3. In another method (described in Gleiter et al., J. Org. Chem. 1992, 57, 252-258), isobutyric acid is first deprotonated twice with n-butyl lithium and diisopropylamine in THF solution, first at about -20°C and then at about 50°C. After cooling to about -20°C, the compound of formula 5 (ortho, R 1 =R 2 = methyl, p = 3, Hal = Br) in THF while keeping the temperature below 10° C. The mixture is then stirred first at room temperature and then at about 40° C. and worked up in a typical manner to provide the corresponding diacid 7. Type 5 halide derivatives can be obtained by several methods, for example as described in Gleiter et al., J. Org. Chem. 1992, 57, 252-258.
[0659] Scheme 4: General synthesis of compound 5-Br (compound 5, wherein Hal = Br)
[0660]
[0661] In Scheme 4, Q 1 and Q 2 can be independently -O-alkyl, -S-alkyl, -S-aryl, -NR 1A R 2A 、NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A, heteroaryl or heterocyclic group, or each carbon atom and Q connected to the carbon atom 1 and Q 2 Together, R independently forms a heterocyclic group or a carbocyclic group. 1A and R 2A As defined herein for formula (I).
[0662] Scheme 4 illustrates the synthesis of para-, meta- and ortho-di-bromoalkyl substituted aromatic compounds 5-Br from parent dicarboxylic acids 10, wherein (p-1) is an integer ranging from 1 to 2. Scheme 4 first summarizes the esterification of compounds of formula 10 to diesters of formula 20, wherein R is an alkyl moiety such as, but not limited to, methyl, ethyl or isopropyl, using the general procedures cited in Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2nd ed.; Wiley-VCH, New York, 1999, pp. 1932-1941 and Smith, MB; March, J. March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure, 5th ed.; John Wiley and Sons, New York, 2001, pp. 484-486. Diol 30 can be prepared from diester 20 by well-known synthetic methods (for a discussion of suitable reduction methods, see, for example, Hudlicky, M. Reductions in Organic Chemistry, 2nd Edition; ACS Monograph 188, Washington, DC, 1996, pages 212-216). In the next step, the alcohol functionality in 30 can be converted to the bromine moiety in compound 5-Br by a variety of standard methods cited in Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2nd Edition; Wiley-VCH, New York, 1999, pages 693-695. For example, a compound of formula 10 having a para-substitution pattern and (p-1) = 1 (available from Aldrich Chemical Co., Milwaukee, Wisconsin) is treated with excess methanol and concentrated sulfuric acid at reflux temperature to produce the corresponding dimethyl ester of formula 2. The procedures that can be used for this transformation are, for example, Schimelpfenig, CWJ Org. Chem. 1975, 40, 1493-1494 (incorporated herein by reference). In addition, the compound of formula 20 (para position, (p-1) = 1) can be converted to the corresponding compound of formula 30 by reaction with a complex metal hydride (preferably but not limited to lithium aluminum hydride) in an aprotic organic solvent (such as THF or diethyl ether), as cited in US Pat. No. 2,789,970, Application No. 397,037, filed by Reynolds et al. on Dec. 8, 1953.Alternatively, the diol of formula 30 (para, p=1) can be converted to the bromide of formula 5-Br (para, p=1) by treatment with sodium bromide and concentrated sulfuric acid at elevated temperature. A useful solvent for this conversion is water, as described in Schimelpfenig, CWJ Org. Chem. 1975, 40, 1493-1494.
[0663] Scheme 5: General synthesis of compound 5A-Br
[0664]
[0665] In Scheme 5, Q 1 and Q 2 can be independently -O-alkyl, -S-alkyl, -S-aryl, -NR 1A R 2A 、NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl or heterocyclic group, or each carbon atom and Q connected to the carbon atom 1 and Q 2 Together, R independently forms a heterocyclic group or a carbocyclic group. 1A and R 2A As defined herein for formula (I).
[0666] Scheme 5 illustrates the preparation of ortho-, meta- and para-substituted aromatic compounds of formula 5A-Br having two 3-bromopropyl substituents. Specific examples of the synthesis of meta- and para-substituted compounds 5A-Br are given in Schimelpfenig, CWJ Org. Chem. 1975, 40, 1493-1494 and Gleiter et al., J. Org. Chem. 1992, 57, 252-258, respectively. For example, the compound of formula 50 is treated with malonic acid and piperidine in a pyridine solution at about 90° C. to 110° C. to produce an α,β-unsaturated carboxylic acid of formula 60. The endpoint of this transformation is usually indicated by the cessation of CO2 bubbling. This procedure is known as the Knoevenagel-Doebner reaction and a useful reaction procedure for this transformation is given in Organikum, Organisch-Chemisches Grundpraktikum, VEB Verlag Deutscher Wissenschaften, Berlin 1984, pp. 572-574. Reduction of compounds of formula 60 to compounds of formula 70 can be accomplished using catalytic hydrogenation over colloidal palladium, Raney nickel or copper chromite as described in Hudlicky, M. Reductions in Organic Chemistry, 2nd ed.; ACS Monograph 188, Washington, DC, 1996, pp. 196-197. Schimelpfenig, CWJ Org. Chem. 1975, 40, 1493-1494 (the entire contents of which are incorporated herein by reference) reported that compounds of formula 60 having meta-substitution were converted to the corresponding compounds 70 by treatment with hydrogen gas over a palladium carbon catalyst in aqueous sodium hydroxide solution at a pressure of about 20-60 psi. Further conversion of compounds of formula 70 to compounds of formula 5A-Br can then be accomplished according to the method described in Scheme 4.
[0667] Scheme 6: General synthesis of compound 5-Br via chain extension
[0668]
[0669] In Scheme 6, Q 1 and Q 2 can be independently -O-alkyl, -S-alkyl, -S-aryl, -NR 1A R 2A 、NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl or heterocyclic group, or each carbon atom and Q connected to the carbon atom 1 and Q2 Together, R independently forms a heterocyclic group or a carbocyclic group. 1A and R 2A As defined herein for formula (I).
[0670] Scheme 6 illustrates a general method for chain extension of a bromide of formula 90 having an alkyl chain consisting of (p-2)methylene groups to a bromide of formula 5-Br having an alkyl chain consisting of (p)methylene groups. The sequence of transformations from alkyl halides such as 90 to carboxylic acids such as 120 can be accomplished using the malonate syntheses cited in Smith, MB; March, J. March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure, 5th ed.; John Wiley and Sons, New York, 2001, p. 549 and Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2nd ed.; Wiley-VCH, New York, 1999, p. 1765. Typically, monoalkylation of the malonate (R is typically ethyl or methyl) uses a base-solvent combination of sodium ethoxide in ethanol, which can suppress the formation of dialkylated byproducts (Organic Reactions, Volume IX, Editor: R. Adams; Robert E. Krieger Publishing Company, Malabar, Florida, 1957, p. 132) to produce a compound of Formula 100. The compound of Formula 100 is then saponified to produce a compound of Formula 110, which can be dealkoxycarbonylated to a compound of Formula 120 by heating it above its melting point. Conversion from the dicarboxylic acid 120 to the chain-extended dibromide 5-Br via the diester 20 is then carried out according to the method described in Scheme 4. Alternatively, direct dealkoxycarbonylation of the geminal diester 100 to the compound of Formula 20 can be achieved by treatment with water and DMSO in the presence or absence of added salt. However, adding salts such as KCN, NaCl or LiCl to the water / DMSO solvent can increase the dealkoxycarbonylation rate of these reactants (Fakhri, SA; Yousefi, BH Tetrahedron 2000, 56, 8301-8308). For example, ethyl malonate is reacted with a solution of sodium metal and a compound of formula 90 having (p-2) = 2 in ethanol, and ethyl malonate is added to produce the corresponding compound of formula 100. This tetraester is then saponified using, for example, ethanol and aqueous potassium hydroxide to produce the corresponding tetraacid of formula 110. The tetraacid is then decarboxylated to the diacid of formula 120 at a temperature of about 200°C. Esterification to diester 20 is performed with methanol and concentrated sulfuric acid (see Scheme 4).Useful methods for converting tetraesters of formula 100 (ortho, (p-2) = 1, R = ethyl) to diesters of formula 20 are described in Fakhri, SA; Yousefi, BH Tetrahedron 2000, 56, 8301-8308 (the entire contents of which are incorporated herein by reference).
[0671] Scheme 7: General synthesis for compounds of formula 7
[0672]
[0673] In Scheme 7, Q 1 and Q 2 can be independently -O-alkyl, -S-alkyl, -S-aryl, -NR 1A R 2A , NHR 1A , phenoxy, aryloxy, benzyl, aryl, cycloalkyl, F, Cl, Br, I, -CF3, -COR 1A , heteroaryl or heterocyclic group, or each carbon atom and Q connected to the carbon atom 1 and Q 2 Together, R independently forms a heterocyclic group or a carbocyclic group. 1A and R 2A As defined herein for formula (I).
[0674] Scheme 7 illustrates the synthesis of ortho-, meta- and para-substituted aromatic compounds of Formula 7 having ω-carboxyalkyl substitutions, wherein (p-1) is an integer ranging from 2 to 12 and R 1 and R 2 The synthesis begins with double deprotonation of ortho-, meta- or para-xylene 3 with a strong base (such as, but not limited to, a combination of n-butyllithium and potassium tert-butoxide) in an aprotic solvent (such as, but not limited to, hexane) and the resulting dianion of 3 reacts with an appropriate electrophile A-(CH2) p-1 -CR 1 R 2 -CH2O-PG, where (p-1), R 1 and R 2As defined above and A is Cl, Br or I. "PG" is a hydroxy protecting group. Examples of hydroxy protecting groups are described in Greene, TW; Wuts, PGM Protective groups in organic synthesis, 3rd edition, John Wiley and Sons, New York, 1999, pages 17-245, which are incorporated herein by reference in their entirety. Methyl aromatics can be alkylated by deprotonation using a lithium base according to Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2nd edition; Wiley-VCH, New York, 1999, page 88, followed by alkylation with an appropriate electrophilic agent. For examples of preparing xylene dianions, see Bates et al., J. Am. Chem. Soc. 1981, 103, 5052-5058. In the next step, the protecting group of 190 is removed to release the terminal hydroxymethyl moiety in 200, which is oxidized using a suitable oxidant (Larock, RC Comprehensive Organic Transformations. A Guide to Functional Group Preparations, 2nd edition; Wiley-VCH, New York, 1999, pages 1646-1648 and Smith, MB; March, J. March's Advanced Organic Chemistry. Reactions, Mechanisms, and Structure, 5th edition; John Wiley and Sons, New York, 2001, page 1537) to produce the dicarboxylic acid of formula 7. For example, meta-xylene (meta-3) is first reacted with n-butyl lithium and potassium tert-butoxide in hexane at room temperature and then at reflux temperature. After cooling to 0°C, a compound of formula 180 (A = Br, (p-1) = 3, R 1 =R 2 = methyl, PG = tetrahydropyranyl, prepared according to Dasseux et al., US 6,646,170 and US 6,410,802) and continued at reflux temperature to provide the corresponding compound of formula 190 after the usual work-up and purification by column chromatography. 190 is then deprotected to 200 (R 1 , R 2= methyl, p = 3) by heating in methanol and concentrated aqueous hydrochloric acid (Vogel, A.I. Vogel's textbook of practical organic chemistry, 5th edition, Longman Scientific and Technical, 1989, p. 552). Compound 200 is then treated with pyridinium dichromate in N,N'-dimethylformamide according to Vedejs, E.; Dent, WH, III; Gapinski, DM; McClure, CKJ Am. Chem. Soc. 1987, 109, 5437-5446 to produce the dicarboxylic acid of formula 7 (meta, p = 3; R 1 , R 2 = methyl).
[0675] Scheme 8 shows an alternative synthesis of illustrative compounds 1-1 and 1-32. Commercially available phthalaldehyde (Sigma-Aldrich, AK Scientific, etc.) is reacted with (5-ethoxy-4,4-dimethyl-5-oxopentyl)triphenylphosphonium bromide (220) (prepared as described in Oniciu, D, C., et al., WO2012 / 054535 and US 8,349,833 B2) in the presence of a base (including but not limited to sodium or potassium hydroxide, potassium or sodium tert-butoxide, potassium or sodium carbonate, and sodium hydride) in the manner described in Le Bigot Y. et al., 1988, Tetrahedron 44 (4), pp. 1057-1072, as a mixture of cis and trans isomers. The mixture of cis and trans isomers of formula (230) or (240) can be catalytically reduced by methods known in the art for hydrogenation of olefins such as H.-U. Blaser, F. Spindler, M. Thommen, The Handbook of Homogeneous Hydrogenation, JG De Vries, CJ Elsevier, ed. (Wiley-VCH, 2008), Chapter 37; Scharnagl, FK et al., Sci. Adv. 2018; 4:eaau1248, Sept. 21, 2018; and methods described in references cited herein. After the hydrogenation reaction is deemed substantially complete using appropriate analytical methods, the ester thus obtained is hydrolyzed. The reaction mixture containing the compound of formula (250) or (260) is hydrolyzed in the presence of an alkaline earth metal salt or base or an oxide or an alkali metal salt or base in refluxing alcohol for 2 to 96 hours. Typical examples include, but are not limited to, hydrolysis with K2CO3 in a refluxing mixture of DMSO and water. Other suitable procedures are cited in Houben-Weyl, Methoden der Organische Chemie, Georg Thieme Verlag Stuttgart 1964, Volume XII / 2, pages 143-210 and 872-879, or Anderson, NG, Practical Process Research & Development, Academic Press, London, 2000, pages 93-94 and 181-182.
[0676] Scheme 8. Illustrative syntheses of compounds 1-1 and 1-32.
[0677]
[0678]
[0679] Scheme 9. General synthesis of compounds of formula (III) or (IIIA) wherein X = O, Z 1 , Z 2 =COOH, q = 0, and R 1 and R 2 Together they form a cyclopropyl ring
[0680]
[0681] Compounds of formula (III) or (IIIA) wherein X=O can be prepared by the Williamson synthesis by reacting an alcohol with a derivative containing a leaving group such as a halide, tosylate or mesylate. See Scheme 9.
[0682] Synthesis Example
[0683] Example 1: Synthesis of (9-carboxymethylsulfanyl-5-oxo-nonylsulfanyl)-acetic acid (Compound II-3)
[0684]
[0685] The reaction of ethyl 5-bromovalerate with lithium diisopropylamide in THF at room temperature produces ketoester 1-1 (see, e.g., Cooke, MPJ Org. Chem. 1993, 58, 2910-2912; Stetter, H.; Rauhut, H. Chem. Ber. 1958, 91). Decarboxylation of 1-1 by refluxing in HCl / ethanol (Cooke, MPJ Org. Chem. 1993, 58, 2910-2912) produces crude product 1-2, which can be purified by column chromatography using a system such as silica gel and a mixture of ethyl acetate / hexane in a ratio of from 1 / 20 to 1 / 8. Thioglycolic acid dissolved in a mixture of ethanol and water is treated with a solution of sodium hydroxide in water to prepare sodium thioglycolate and used to treat 1-2 in a solvent such as ethanol, as described in Agnus, A., Louis, Gissebrecht, JP, Weiss, R., J. Am. Chem. Soc., 1984, 106, 93 or Riesen, PC; Kaden, TA Helv. Chim. Acta. 1995, 78, 1325-1333, to provide crude compound II-3. Crude compound II-3 can be purified by recrystallization from a solvent or a mixture of solvents such as MTBE and heptane.
[0686] Example 2: Synthesis of (9-carboxymethylsulfanyl-5-hydroxy-nonylsulfanyl)-acetic acid (Compound II-1)
[0687]
[0688] The reduction of the ketodiacid compound II-3 from Example 1 is achieved with sodium borohydride after salt formation with NaOH to produce compound II-1 (see U.S. Patent No. 7,119,221 for appropriate reaction conditions). Compound II-3 (Example 1) is dissolved in NaOH solution (2 to 7 equivalents) to form the intermediate disodium salt in water. Isopropanol is then added, followed by sodium borohydride (1.05 equivalents) in batches. The reaction mixture is heated to about 45 ° C for several hours to produce compound II-1. The product can be purified by recrystallization from MTBE, heptane or a mixture.
[0689] Example 3: Synthesis of [5-(5-carboxymethoxy-pentyloxy)-pentyloxy]-acetic acid (Compound II-12)
[0690]
[0691] Compound II-12 is prepared starting from 3-1 and 3-2 (prepared as described in Dasseux et al. US6,459,003) via Williamson ether synthesis. The resulting 3-3 is deprotected in methanol in the presence of a catalytic amount of p-toluenesulfonic acid monohydrate to produce diol 3-4. This diol is then coupled with tert-butyl bromoacetate in a two-phase system of aqueous NaOH solution and toluene in the presence of tetrabutylammonium bromide as a PTC catalyst as described in U.S. Pat. No. 10,227,285. Finally, this tert-butyl ester is cleaved under acidic conditions to provide compound II-12.
[0692] Example 4: Synthesis of [5-(5-carboxymethoxy-pentylsulfanyl)-pentyloxy]-acetic acid (Compound II-20)
[0693]
[0694] Compound 3-1 (prepared as described in U.S. Pat. No. 6,790,953) is treated with sodium sulfide analogously to the method of Edwards, D.; Stenlake, JBJ Pharmacy Pharmacol. 1955, 7, 852-860 to form thioether 4-1, which is deprotected in the presence of a catalytic amount of pyridinium p-toluenesulfonate (PPTS) in methanol as described in Miyashita, N.; Yoshikoshi, A.; Grieco, P.A. J Org. Chem. 1977, 42 (23), 3772-73. The diol 4-2 thus obtained is reacted with tert-butyl bromoacetate under phase transfer catalysis using (Bu4N)(HSO4) as a catalyst, following the method of Nagatsugi, F.; Sasaki, S.; Maeda, MJ Fluorine Chem. 1992, 56, 373-383 to obtain its tert-butyl ester 4-3. Subsequent cleavage of the tert-butyl ester with trifluoroacetic acid (TFA) analogous to the procedure in Nagatsugi, F.; Sasaki, S.; Maeda, MJ Fluorine Chem. 1992, 56, 373-383 provided the free acid compound II-20 in 90% yield.
[0695] Example 5: Synthesis of [5-(5-carboxymethoxy-pentane-1-sulfinyl)-pentyloxy]-acetic acid (Compound II-24)
[0696]
[0697] Compound II-24 was prepared starting from Compound II-12 (Example 4) using hydrogen peroxide as the oxidant similar to the procedure described in US Pat. No. 6,673,780.
[0698] Example 6: Synthesis of [5-(5-carboxymethylsulfanyl-pentyloxy)-pentylsulfanyl]-acetic acid (Compound II-6)
[0699]
[0700] Compounds 6-1 and 6-2 were obtained according to the methods described in Harrison, GC; Diehl, H. Organic Synthesis 1955 Coll. Vol. 3, 370 and Francis, GW; Berg, JF Acta Chem. Scand. B 1977, 31, 721-722, respectively. 5-Chloro-pentan-1-ol is commercially available and 3-4 was prepared as described in Example 3 as follows: Thioglycolic acid (8.1 g, 87.9 mmol) was dissolved in deionized water / ethanol solution (50 mL / 40 mL). A solution of sodium hydroxide (7.0 g, 175.5 mmol) in water (50 mL) was added under stirring. Bis(4-chlorobutyl ether) (7.0 g, 35.1 mmol) in ethanol (20 mL) was added dropwise to this mixture over 30 minutes. This mixture was heated to reflux for 20 hours, followed by evaporation of ethanol. The residue was diluted with water (20 mL). The aqueous layer was extracted with MTBE (4 x 20 mL) and the organic layer was discarded. The aqueous layer was acidified to pH 2 (about 12 mL) with concentrated HCl and extracted with MTBE (4 x 30 mL). The combined organic layers were checked for the presence of starting thioglycolic acid by TLC (silica, CH2Cl2: MeOH = 9: 1) (RF = 0.7; bright blue spot, using phosphomolybdic acid (Phosphomolybdic acid) / EtOH). The organic layer was washed with water until the starting acid disappeared completely (about 700 mL batches). The solvent was removed under reduced pressure to produce a colorless oil (7.7 g), which solidified at room temperature. This solid was recrystallized from heptane / MTBE (50 / 60 mL) to produce fine white crystals (6.2 g, yield 57%; purity 99%-RI, 91%-UV, mp 43°C-44°C). An additional amount of product (0.87 g, mp 38°C-40°C) was obtained from the mother liquor.
[0701] Example 7: Synthesis of (11-carboxymethylsulfanyl-6-oxo-undecylsulfanyl)-acetic acid (Compound II-4) and (11-carboxymethylsulfanyl-6-hydroxy-undecylsulfanyl)-acetic acid (Compound II-2)
[0702]
[0703] The synthesis of compounds II-4 and II-2 begins with 1,11-dibromondecane-6-one (7-4) (prepared as shown above, starting from commercially available 6-bromohexanol). Protection of the hydroxyl group of 6-bromohexanol with dihydropyran as described in U.S. Pat. Nos. 6,646,170 and 6,410,802 provides intermediate 7-1. The reaction of 7-1 with TosMIC in dimethylacetamide (DMAc) in the presence of sodium amyloxide (NaOAm-t) leads to the formation of intermediate 7-2, which is converted to diol 7-3. In about 12 to 24 hours, in a mixture of solvents such as dichloromethane, methanol, in the presence of aqueous HCl, removal of the THP protecting group and conversion of the isocyano-tolyl-fragment to a keto group are carried out simultaneously. Diol 7-3 can be purified by column chromatography on silica gel and a mixture of solvents such as ethyl acetate and dichloromethane. Compound 7-3 thus obtained is subjected to Mitsunobu reaction to provide bromide 7-4, which is subsequently treated with sodium salt of thioglycolic acid in alcohol or mixture of alcohols (ethanol, isopropanol) to provide diacid compound II-4. Compound II-4 is reduced with sodium borohydride to provide compound II-2 (see Example 2).
[0704] Example 8: Synthesis of [4-(4-carboxymethoxy-butoxy)-butoxy]-acetic acid (Compound II-11)
[0705]
[0706] Commercially available bis(4-chlorobutyl ether) is converted to diol 8-2 via diacetate 8-1 [Kliem, A., Schniepp, LEJ Am. Chem. Soc, 1948, 70, 1839], which is further reacted with ethyl bromoacetate to provide 8-3. Compound 8-3 is hydrolyzed to provide II-11. Alternatively, bis(4-chlorobutyl ether) is treated with the dianion of glycolic acid via autoclave or high temperature to provide compound II-11.
[0707] Specifically, similar to the method described in Kliem, A., Schniepp, LEJ Am. Chem. Soc, 1948, 70, 1839, diacetate 8-1 is treated with potassium carbonate in methanol, and crude compound 8-2 is optionally purified by column chromatography. Diol 8-2 is reacted with sodium hydride (95% or 60% in mineral oil) in THF and deprotonated for about 2 hours to about 4 hours and then reacted with ethyl bromoacetate to produce diester 8-3. The last step, the hydrolysis of 8-3, is carried out in ethanol with KOH for about 2 to about 8 hours. The product is then post-treated, including acidification with HCl aqueous solution, followed by extraction with dichloromethane, to provide crude compound II-11. Compound II-11 is optionally purified by gradient column chromatography on silica gel using solvents such as EtOAc and hexane and mixtures thereof.
[0708] Example 9: Synthesis of 5,5'-(1,4-phenylene)bis(2,2-dimethylpentanoic acid) (Compound I-78)
[0709]
[0710] (4-Methoxycarbonylmethylphenyl)-acetic acid methyl ester (A2)
[0711] Concentrated sulfuric acid (40 mL) was added to phenylenediacetic acid (A1) (25.0 g, 0.129 mol) in MeOH (300 mL). The reaction mixture was heated to reflux overnight. Most of the MeOH was evaporated in vacuo. The residue was diluted with EtOAc (300 mL) and water (300 mL). The aqueous solution was separated and extracted with EtOAc (2×100 mL). The combined organic solution was diluted with water (100 mL), saturated NaHCO3 solution (2×100 mL) and brine (100 mL) and dried over MgSO4. The solvent was evaporated to produce (4-methoxycarbonylmethylphenyl)-acetic acid methyl ester (27.1 g, 95%, 92.3% by HPLC) as a white solid. Mp 59°C-60°C (51°C-54°C, Dynamit Nobel, British Patent 1495472, Application No. 9008 / 75, filed on March 4, 1975). 1 H NMR (CDCl3): δ = 7.25 (s, 4H), 3.70 (s, 6H), 3.60 (s, 4H). 13 C NMR (CDCl3): δ=174.0, 132.5, 129.0, 52.0, 40.5.
[0712] 2-[4-(2-Hydroxyethyl)-phenyl]-ethanol (A3)
[0713] (4-Methoxycarbonylmethylphenyl)-acetic acid methyl ester (A2) (26.5 g, 0.12 mol) in THF (100 mL) was added to a solution of LiAlH4 (11.0 g, 0.29 mol) in THF (300 mL) at room temperature and stirred. The reaction mixture was heated to reflux for 2 hours. Water (100 mL) was carefully added followed by dilute aqueous HCl (75 mL concentrated HCl in 100 mL water). The aqueous phase was extracted with EtOAc (2×100 mL). The combined organic solution was washed with water (100 mL), saturated NaHCO3 solution (150 mL) and brine (100 mL) and dried over MgSO4. The solvent was evaporated to produce 2-[4-(2-hydroxyethyl)-phenyl]-ethanol (18.68 g, 94%, 93.5% pure by HPLC) as a white solid. Mp 89°C-90°C (87°C-88°C, Reynolds et al. US 2,789,970, application number 397,037, filed on December 8, 1953). 1 H NMR (CDCl3): δ = 7.17 (s, 4H), 3.78 (t, J = 6.6Hz, 4H), 2.81 (t, J = 6.6Hz, 4H), 2.30 (br s, 2H). 13 C NMR (CDCl3): δ=136.9, 129.4, 63.8, 39.0.
[0714] 1,4-Bis-(2-bromoethyl)-benzene(A4)
[0715] Concentrated sulfuric acid (30.0 g) was added dropwise to a boiling mixture of 2-[4-(2-hydroxyethyl)-phenyl]-ethanol (A3) (18.29 g, 0.11 mol), NaBr (40.0 g, 0.39 mol) and water (50 mL) over 1 hour. The reaction mixture was heated to reflux for 1 hour. Sulfuric acid (10 mL) and NaBr (16.0 g, 0.16 mol) of other parts were added and continued to heat for 1.5 hours under reflux. Water (100 mL) was added to the cooling mixture and the product was extracted with dichloromethane (3 × 100 mL). The combined organic solution was washed with water (100 mL) and brine (100 mL), and dried over MgSO4. The solvent was evaporated and the residue was purified by column chromatography (silica gel, EtOAc: hexane, 1: 1). The solid product was recrystallized from hexanes to yield 1,4-bis-(2-bromoethyl)-benzene (22.27 g, 69%, 99.8% pure by HPLC) as a white solid. Mp 71-72°C (70-71°C, Longone, DT; Kusefoglu, SH; Gladysz, JAJ Org. Chem. 1977, 42, 2787-2788. 1 H NMR (CDCl3): δ = 7.18 (s, 4H), 3.57 (t, J = 2.2 Hz, 4H), 3.16 (t, J = 7.8 Hz, 4H). 13 C NMR (CDCl3): δ=138.6, 130.0, 40.1, 34.0.
[0716] 4-[4-(3-Carboxy-3-methylbutyl)-phenyl]-2,2-dimethylbutanoic acid
[0717] A solution of lithium diisopropylamide (89 mL, 0.16 mol, 1.8 M in heptane / THF / EtPh) was added dropwise to a solution of ethyl isobutyrate (18.0 g, 155 mmol) in THF (100 mL) at -78 °C. The reaction mixture was stirred for 1 hour and a solution of 1,4-bis-(2-bromoethyl)-benzene (A4) (20.0 g, 68.5 mmol) in THF (50 mL) was slowly added, followed by DMPU (10 mL). The reaction mixture was heated to room temperature over 2 hours and stirred at 40 °C-50 °C for 1 hour. Water (200 mL) was added, the aqueous solution was separated, and extracted with EtOAc (3 × 80 mL). The combined organic solution was washed with water (100 mL) and brine (100 mL). After concentration under reduced pressure, the residue was purified by column chromatography (silica gel, EtOAc: heptane, 1: 10) to produce 4-[4-(3-ethoxycarbonyl-3-methylbutyl)-phenyl]-2,2-dimethylbutyric acid ethyl ester (24.0 g). This intermediate (24.0 g, 66.2 mmol) was dissolved in EtOH (300 mL) and water (50 mL), KOH (85%, 15.0 g, 227 mmol) was added, and the reaction mixture was refluxed for 3 hours. The solvent was evaporated, the residue was dissolved in water (150 mL) and extracted with MTBE (2×30 mL). The aqueous solution was acidified to pH 1-2 with aqueous HCl. The precipitate was filtered, recrystallized from CHCl3 / EtOH (1:1), and dried in vacuo to give 4-[4-(3-carboxy-3-methylbutyl)-phenyl]-2,2-dimethylbutanoic acid (13.6 g, 64%, 94.8% pure by HPLC) (Compound I-78) as white crystals. Mp 214°C-215°C. Elemental analysis (C 18 H 26 O4): calculated value C, 70.56; H, 8.55, found value: C, 70.78; H, 8.64. 1 H NMR (CD3OD): δ = 7.06 (s, 4H), 4.90 (s, 2H), 2.54-2.48 (m, 4H), 1.80-1.74 (m, 4H), 1.22 (m, 12H). 13 C NMR (CD3OD): δ = 181.5, 140.9, 129.2, 44.3, 43.2, 32.3, 25.8. C 18 H 26 HRMS calculated value of O4 (M + ): 306.1831, measured value: 306.1831.
[0718] Example 10: Synthesis of 6,6'-(1,4-phenylene)bis(2,2-dimethylhexanoic acid) (Compound I-1)
[0719]
[0720] 4-[4-(3-Methoxycarbonylpropyl)-phenyl]-butyric acid methyl ester (B1)
[0721] The compounds were prepared by a modification of the method reported in Cram, DJ; Allinger, NL; Steinberg, HJ Amer. Chem. Soc. 1954, 76, 6132.
[0722] Under N2 atmosphere, sodium (3.5g, 0.152mol) is dissolved in EtOH (200mL) and ethyl malonate (50.0g, 0.31mol) is added to the warm solution. The reaction mixture is heated to reflux for 5 minutes and a solution of 1,4-bis-(2-bromoethyl)-benzene (A4) (22.02g, 75.4mmol) in ethyl malonate (50mL) is added dropwise at room temperature for 5 minutes. The reaction mixture is heated to reflux for 0.5 hours. After adding water (150mL) and EtOAc (200mL), the solvent is evaporated and the residue is dissolved in EtOAc (200mL). The solution is washed with water (100mL) and brine (100mL), dried over MgSO4, and concentrated in a vacuum. The residue is dried in a high vacuum at 80°C-100°C (oil bath). The obtained crude 2-{2-[4-(3,3-bis-ethoxycarbonylpropyl)-phenyl]-ethyl}malonic acid diethyl ester was dissolved in EtOH aqueous solution (80%, 200 mL) and KOH (85%, 35.0 g, 0.53 mol) was added. The reaction mixture was heated to reflux for 2 hours. The solvent was partially evaporated and EtOAc (150 mL) was added. The aqueous layer was separated and extracted with EtOAc (2×100 mL). The combined organic solution was washed with brine (100 mL), dried over MgSO4, and concentrated. The crude 2-{2-[4-(3,3-bis-carboxypropyl)-phenyl]-ethyl}malonic acid (28.0 g) was heated on an oil bath at 200°C-210°C for 1.5 hours. The obtained crude 4-[4-(3-carboxypropyl)-phenyl]-butyric acid (16.3 g) was dissolved in MeOH (100 mL) and concentrated sulfuric acid (40 mL) was added. The reaction mixture was refluxed for 5 hours and then stirred at room temperature overnight. The MeOH was partially evaporated, and the residue was dissolved in EtOAc (150 mL), washed with water (150 mL) and brine (150 mL), and dried over MgSO4. The solvent was evaporated to produce crude 4-[4-(3-methoxycarbonylpropyl)-phenyl]-butyric acid methyl ester (B1) (17.9 g, 85%) as a yellow oil, which was used in the next step without purification. 1H NMR (CDCl3): δ = 7.10 (s, 4H), 3.67 (s, 6H), 2.59 (t, J = 7.4Hz, 4H), 2.33 (t, J = 7.4Hz, 4H), 1.95-1.90 (m, 4H). 13 C NMR (CDCl3): δ=174.0, 138.9, 128.4, 51.5, 34.6, 33.3, 26.5.
[0723] 4-[4-(4-Hydroxybutyl)-phenyl]-butan-1-ol (B2)
[0724] Compounds were prepared according to Cram, DJ; Allinger, NL; Steinberg, HJ Am. Chem. Soc. 1954, 76, 6132-6141. A solution of 4-[4-(3-methoxycarbonylpropyl)-phenyl]-butyric acid methyl ester (17.7 g, 63.6 mmol) in THF (50 mL) was added to a suspension of LiAlH4 (7.2 g, 0.19 mol) in THF (300 mL) at 0°C and stirred. The reaction mixture was heated to reflux for 1 hour. Water (100 mL) and aqueous HCl (10%, 200 mL) were added. The aqueous layer was separated and extracted with EtOAc (2×50 mL). The combined organic solution was washed with brine, dried over MgSO4, and concentrated. The residue was purified by column chromatography (silica gel, ETOAc: hexane, 1: 1) to give 4-[4-(4-hydroxybutyl)-phenyl]-butan-1-ol (7.5 g, 53%, 96.2% pure by HPLC) as white crystals. Mp 60°C-62°C (60.5°C-62.4°C, Cram, DJ; Allinger, NL; Steinberg, HJ Am. Chem. Soc. 1954, 76, 6132-6141). 1 H NMR (CDCl3): δ = 7.10 (s, 4H), 3.63 (t, J = 6.4Hz, 4H), 2.61 (t, J = 7.1Hz, 4H), 2.12 (br s, 2H), 1.71-1.57 (m, 8H). 13 C NMR (CDCl3): δ=140.7, 129.4, 63.8, 36.3, 33.4, 28.67.
[0725] 1,4-Bis-(4-bromobutyl)-benzene(B3)
[0726] Concentrated sulfuric acid (30 mL) was added dropwise to a boiling mixture of 4-[4-(4-hydroxybutyl)-phenyl]-butan-1-ol (9.4 g, 42.3 mmol), NaBr (17.4 g, 0.169 mol) and water (50 mL) over 1 hour. The reaction mixture was refluxed for 1 hour. Additional concentrated sulfuric acid (10 mL) was added over 20 minutes and refluxed for 1.5 hours. After adding water (300 mL) and dichloromethane (500 mL), the aqueous solution was separated and extracted with dichloromethane (2×50 mL). The combined organic solution was washed with water (200 mL) and brine (150 mL) and dried over MgSO4. The solvent was evaporated and the residue was purified by column chromatography (silica gel, EtOAc: hexane, 1:20) to produce 1,4-bis-(4-bromobutyl)-benzene (11.8 g, 80%, 96.1% pure by HPLC) as an oil. 1 H NMR (CDCl3): δ = 7.14 (s, 4H), 3.46 (t, J = 6.6Hz, 4H), 2.65 (t, J = 7.5Hz, 4H), 1.96-1.89 (m, 4H), 1.83-1.75 (m, 4H). 13 C NMR (CDCl3): δ = 139.5, 128.6, 34.7, 34.0, 32.5, 30.1. This procedure was modified from the method described by Cram, DJ; Allinger, NL; Steinberg, HJ Am. Chem. Soc. 1954, 76, 6132-6141.
[0727] 6-[4-(5-Carboxy-5-methylhexyl)-phenyl]-2,2-dimethylhexanoic acid
[0728] A solution of lithium diisopropylamide (90mmol, 1.8M in heptane / THF / EtPh, 50mL) was added dropwise to a solution of ethyl isobutyrate (8.97g, 77.2mmol) in THF (200mL) at -78°C. The reaction mixture was stirred for 1 hour, after which a solution of 1,4-bis-(4-bromobutyl)-benzene (11.2g, 32.2mmol) in THF (50mL) was slowly added, followed by DMPU (10mL). The reaction mixture was heated to room temperature over 2 hours and stirred at 40°C-50°C for 1 hour. Water (200mL) was added, the aqueous solution was separated, and extracted with EtOAc (3×80mL). The combined organic solution was washed with water (100mL) and brine (100mL). The solvent was evaporated, and the residue was dissolved in EtOH (100mL). Water (50mL) and KOH (85%, 15.0g, 227mmol) are added and the reaction mixture is heated to reflux for 3 hours. After adding water (200mL) and cooling to room temperature, the reaction mixture is acidified to pH 1 with concentrated HCl and stirred for 1 hour. The precipitate is filtered, washed with water and dissolved in dichloromethane (400mL). The solution is dried with MgSO4 and evaporated in a vacuum. The residue is dissolved in EtOAc: hexane (1:30, 200mL) under heating and cooled in a freezer. The solution is poured out from the oil and evaporated to a volume of 60mL. The mixture is stirred overnight, the precipitate is filtered, washed with hexane, and dried in a vacuum to produce 6- [4- (5- carboxyl -5- methylhexyl) -phenyl] -2,2- dimethylhexanoic acid (8.02g, 69%, 96.4% pure by HPLC) (Compound I-1) as a white solid. Mp129 ° C -131 ° C. Elemental analysis (C 22 H 34 O4): Calculated value C, 72.89; H, 9.45. Found: C, 72.90; H, 9.49. 1 HNMR (CDCl3): δ = 7.05 (s, 4H), 2.66-2.62 (m, 4H), 1.68-1.56 (m, 4H), 1.53-1.47 (m, 4H), 1.17 (s, 12H), 1.08-0.98 (m, 4H). 13 C NMR (CDCl3): δ = 185.3, 138.6, 128.5, 42.3, 41.5, 34.5, 30.6, 25.0, 23.2. C 22 H 34 HRMS calculated value of O4 (M + ): 362.2457, measured value: 362.2453.
[0729] Example 11: Synthesis of 1,4-bis(4-carboxy-4-methylpentyl)benzene (Compound III-1)
[0730]
[0731] 1,4-Bis(2-methoxycarbonylethyl)benzene(C2)
[0732] Under Ar atmosphere, a solution of 1,4-bis(2-carboxyethyl)benzene (C1) (10.0 g, 45.0 mmol) in anhydrous methanol (75 mL) and concentrated sulfuric acid (5.0 g) was added and heated to reflux for 5 hours. The reaction mixture was cooled to room temperature, the crystals were filtered, washed with MeOH (30 mL), and dried in vacuo to give 1,4-bis(2-methoxycarbonylethyl)-benzene (11.0 g, 99%) as white crystals. Mp 116°C-117°C (116°C-118°C, Matsuoka, T.; Negi, T.; Otsubo, T.; Sakata, Y.; Misumi, S. Bull. Chem. Soc. Japan 1972, 45, 1825-1833). 1 H NMR (CDCl3): δ = 7.11 (s, 4H), 3.69 (s, 6H), 2.94 (t, J = 8.1 Hz, 4H), 2.62 (t, J = 8.2 Hz, 4H). 13 C NMR (CDCl3): δ = 173.3, 138.4, 128.4, 51.6, 35.6, 30.5. This known compound was prepared by a method different from that described in Matsuoka, T.; Negi, T.; Otsubo, T.; Sakata, Y.; Misumi, S. Bull. Chem. Soc. Japan 1972, 45, 1825-1833.
[0733] 1,4-Bis(3-hydroxypropyl)benzene(C3)
[0734] C3 was prepared according to Matsuoka, T.; Negi, T.; Otsubo, T.; Sakata, Y.; Misumi, S. Bull. Chem. Soc. Japan 1972, 45, 1825-1833. Lithium aluminum hydride (5.2 g, 13.7 mmol) was added to anhydrous THF (300 mL) in batches under an Ar atmosphere. A solution of 1,4-bis(2-methoxycarbonylethyl)benzene (11.5 g, 45.9 mmol) in THF (50 mL) was added dropwise over 1 hour, resulting in an exothermic reaction. The reaction mixture was refluxed for 5 minutes and stirred at room temperature for 3 hours. It was then hydrolyzed with a 10% aqueous solution of water (100 mL) and NH4Cl (50 mL). The organic layer was separated and the aqueous solution was extracted with EtOAc (100 mL). The organic phases were combined, washed with brine (50 mL), dried over MgSO 4 , and concentrated to provide 1,4-bis(3-hydroxypropyl)benzene (9.0 g, quantitative) as an oil, which was used in the next step without further purification. 1 HNMR (DMSO-d6): δ = 7.10 (s, 4H), 4.43 (br s, 2H), 3.41 (t, J = 8.1Hz, 4H), 2.59 (t, J = 8.2Hz, 4H), 1.71 (m, 2H). 13 C NMR (DMSO-d6): δ=139.0, 127.0, 60.0, 34.5, 31.2.
[0735] 1,4-Bis(3-bromopropyl)benzene(C4)
[0736] An emulsion of 1,4-bis(3-hydroxypropyl)benzene (9.0 g, 46.3 mmol) and sodium bromide (24.0 g, 0.23 mol) in deionized water (25 mL) was heated to reflux while concentrated sulfuric acid (17 mL) was added dropwise over 1 hour. After addition, heating was continued at reflux for 3.5 hours. The solution was cooled to room temperature, diluted with water (40 mL), and extracted with CH2Cl2 (2×150 mL). The combined organic layers were washed with a saturated solution of NaHCO3 (100 mL), a saturated NaCl solution (100 mL), and dried over MgSO4. The solvent was evaporated and the residue was purified by column chromatography (silica gel, EtOAc: hexane, 1:40) to give 1,4-bis(3-bromopropyl)benzene (11.6 g, 78%) as a colorless oil. 1 H NMR (CDCl3): δ = 7.15 (s, 4H), 3.41 (t, J = 6.6 Hz, 4H), 2.77 (t, J = 7.1 Hz, 4H), 2.18 (m, 4H). 13C NMR (CDCl3): δ = 138.3, 128.7, 34.2, 33.4, 33.3. This known compound was prepared by a method different from the method described in Matsuoka, T., Negi, T., Otsubo, T., Sakata, Y., Misumi, S. Bull. Chem. Soc., Japan, 1972, 45, 1825-1833 and Ruzicka, L.; Buijs, JB; Stoll, M. Helv. Chim. Acta 1932, 15, 1220.
[0737] 1,4-Bis(4-ethoxycarboxy-4-methylpentyl)benzene(C5)
[0738] Under N2-atmosphere, lithium diisopropylamide (1.8M solution in heptane / THF / EtPh, 46.7 mL, 84.0 mmol) was added dropwise to a solution of ethyl isobutyrate (9.0 g, 77.5 mmol) in anhydrous THF (300 mL) at -78 °C. After 1 hour, a solution of 1,4-bis(3-bromopropyl)benzene (11.6 g, 36.3 mmol) in anhydrous THF (70 mL) was added dropwise, followed by DMPU (20 mL). The reaction mixture was heated to room temperature overnight, then cooled with an ice bath, and hydrolyzed with saturated NH4Cl solution (100 mL). Water (100 mL) was added and the layers were separated. The aqueous layer was extracted with ethyl acetate (2×50 mL). The combined organic layers were diluted with saturated NaCl solution (100 mL), dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography on silica gel (EtOAc:hexanes, 1:10) to give 1,4-bis(4-ethoxycarboxy-4-methylpentyl)benzene (13.3 g, 94%) as a colorless oil. 1 H NMR (CDCl3): δ=7.09 (s, 4H), 4.11 (q, J=7.1Hz, 4H), 2.57 (m, 4H), 1.57 (m, 8H), 1.24 (t, J=7.1Hz, 6H), 1.47 (s, 12H). 13 C NMR (CDCl3): δ=177.9, 139.6, 128.2, 60.1, 42.0, 40.2, 35.8, 26.8, 25.1, 14.2. C 24 H 39 Calculated value of O4 (MH + ): 391.2838, measured value: 391.2836.
[0739] 1,4-Bis(4-carboxy-4-methylpentyl)benzene
[0740] A solution of 1,4-bis(4-ethoxycarboxyl-4-methylpentyl)benzene (13.0 g, 33.3 mmol) and potassium hydroxide (85%, 7.0 g, 106 mmol) in ethanol (25 mL) and water (15 mL) was heated to reflux for 3.5 hours. The reaction mixture was cooled to room temperature, diluted with water (100 mL) and acidified to pH 1 with HCl (2M solution in water). A precipitate was formed immediately. The mixture was stirred for 1 hour, the precipitate was filtered and washed with water (2×50 mL). The crude precipitate was dissolved in dichloromethane (700 mL) and the solution was dried overnight over MgSO4. The solvent was evaporated and the residue was recrystallized (dichloromethane: hexane, 1: 1) to produce 1,4-bis(4-carboxyl-4-methylpentyl)benzene (9.5 g, 85%, 100% pure by HPLC) (Compound III-1) as white crystals. Mp 131℃(125℃-126℃, Gleiter, R.; R.; Irngart inger, H.; Bissinger, C. Synthesis and Properties of 4,4,9,9-Tetramet hyl
[12] paracyclophane-5,6,7,8-tetrone. J. Org. Chem. 1992, 57, 252-258). Elemental Analysis (C 20 H 30 O4): calculated value C, 71.82; H, 9.04; found value: C, 71.10; H, 9.00. 1 H NMR (CDCl3): δ = 7.07 (br s, 4H), 2.55 (m, 4H), 1.59 (m, 8H), 1.18 (s, 12H). 13 C NMR (CDCl3): δ = 184.9, 139.6, 128.1, 42.1, 40.3, 35.8, 26.8, 24.9. This known compound was modified by Gleiter, R.; R.; Irngartinger, H.; Bissinger, C. Synthesis and Properties of 4,4,9,9-Tetramethyl
[12] paracyclophane-5,6,7,8-tetrone. Prepared by the method described in J.Org.Chem.1992,57,252-258.
[0741] Example 12: Synthesis of 5,5'-(1,3-phenylene)bis(2,2-dimethylpentanoic acid) (Compound I-31)
[0742]
[0743] m-Benzene-bis(2,2-dimethyl)valerate dimethyl ester (D2)
[0744] Under Ar atmosphere, lithium diisopropylamide (2.0 M in heptane / THF / ethylbenzene, 91.5 mL, 183 mmol) was added dropwise to a solution of ethyl isobutyrate (21.2 g, 24.4 mL, 183 mmol) in anhydrous THF (200 mL) at -78 ° C. After 1 hour, a solution of m-bis(3-bromopropyl)benzene (D1) (prepared according to Schimelpfenig, CWJ Org. Chem. 1975, 40, 1493–1494 and Effenberger, F.; Kurtz, W. Chem. Ber. 1973, 106, 511–524; 26.6 g, 83.1 mmol) in anhydrous THF (50 mL) was added dropwise, followed by DMPU (25 mL). The reaction mixture was heated to room temperature overnight, then cooled with an ice bath, and hydrolyzed with saturated NH4Cl solution (100 mL). Deionized water (100 mL) was added and the layers were separated. The aqueous layer was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with saturated NaCl solution (100 mL), 1N hydrochloric acid (2×100 mL), saturated NaHCO3 solution (100 mL) and saturated NaCl solution (100 mL). The combined organic phases were dried over MgSO4, concentrated in vacuo, and dried in high vacuum. The residue was purified by flash chromatography on silica (hexane / ethyl acetate=95 / 5) to produce 5,5'-(1,3-phenylene)bis(2,2-dimethylpentanoic acid) diethyl ester (15.7 g, 48%) as a light yellow oil. 1 H NMR (CDCl3): δ = 7.17 (t, 1H, J = 7.0Hz), 6.97 (m, 3H), 4.09 (q, 4H, J = 7.3Hz), 2.55 (m, 4H), 1.56 (m, 8H), 1.22 (t, 6H, J = 7.3Hz), 1.15 (s, 12H). 13 C NMR (CDCl3): δ = 178.02, 142.37, 128.58, 128.32, 125.86, 60.31, 42.25, 40.52, 36.48, 27.03, 25.30, 14.39.
[0745] 5,5'-(1,3-phenylene)bis(2,2-dimethylvaleric acid)
[0746] A solution of 5,5'-(1,3-phenylene)bis(2,2-dimethylpentanoic acid) diethyl ester (D2) (10.6 g, 27.14 mmol) and potassium hydroxide (85%, 6.3 g, 95.00 mmol) in ethanol (20 mL) and water (10 mL) was heated to reflux for 4 hours. The reaction mixture was cooled to room temperature, diluted with water (50 mL), and ethanol was removed under reduced pressure. The remaining aqueous solution was extracted with dichloromethane (2×50 mL). The aqueous layer was acidified to pH 1 with concentrated hydrochloric acid (10 mL) and extracted with dichloromethane (3×50 mL). The combined organic layers were washed with saturated NaCl solution (50 mL), dried over MgSO4, concentrated in vacuo, and dried in high vacuum to produce a viscous oil (9.3 g). This oil was crystallized from pentane / dichloromethane (75 mL / 5 mL) at -5 °C to provide 5,5'-(1,3-phenylene)bis(2,2-dimethylpentanoic acid) (4.78 g, 49%, 93.2% pure by HPLC) (Compound I-31) as a white powder. Mp 79 °C. Elemental analysis (C 20 H 30 O4): calculated value C, 71.82; H, 9.04; found value: C, 71.71; H, 9.22. 1 H NMR (DMSO-d6): δ = 12.2-11.7 (m br, 2H), 7.17 (m, 1H), 6.98 (m, 3H), 2.52 (m, 4H), 1.49 (m, 8H), 1.07 (s, 12H). 13 C NMR (DMSO-d6): δ = 178.86, 141.96, 128.26, 125.69, 41.21, 39.91, 35.68, 26.62, 25.06. C 30 H 31 HRMS calculated value of O3 (MH + ): 335.2222, measured value: 335.2232.
[0747] Example 13: Synthesis of 6-[3-(5-carboxy-5-methylhexyl)-phenyl]-2,2-dimethylhexanoic acid (Compound I-32)
[0748]
[0749] [1,3-Bis(5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-phenylene(E2)
[0750] At room temperature, a solution of n-butyl lithium (38.8 mL, 2.5 M in hexane / THF / EtPh, 96.9 mmol) is added to a mixture of m-xylene (E1) (5.0 g, 47.1 mmol) and potassium tert-butoxide (5.4 g, 48.1 mmol) in hexane (100 mL). The reaction mixture is heated to reflux for 1 hour. A yellow precipitate is formed. The reaction mixture is cooled to 0 ° C and 2- (5- bromo-2,2-dimethylpentyloxy) -tetrahydropyran (prepared according to Dasseux et al., US6646170 and US6410802, 30.0 g, 107.5 mmol) is added dropwise. The reaction mixture is heated to reflux for 20 hours. Water (150 mL) is added and the organic phase is separated. The aqueous solution is extracted with EtOAc (2 × 100 mL). The organic phases are combined, washed with brine (50 mL), and dried over MgSO4. The solvent was evaporated and the residue was purified by column chromatography (silica gel, EtOAc:hexanes, 1:30) to give [1,3-bis(5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-phenylene as an oil (14.8 g, 62%, 96.1% pure by HPLC). 1 H NMR (CDCl3): δ=7.17-7.14(m,1H),7.00-6.98(m,3H),4.54(t,J=3.0Hz,2H),3.78-3.86(m,2H),3.50-3.45( m, 2H), 3.47 (d, J = 9.1Hz, 2H), 2.98 (d, J = 9.1Hz, 2H), 2.59 (t, J = 7.6Hz, 4H), 1.90-1.28 (m, 24H), 0.89 (s, 12H). 13 C NMR (CDCl3): δ=142.8,128.5,128.1,125.6,99.1,77.5,61.8,39.2,36.0,34.2,32.5,30.7,25.6,24.6,23.7,19.4. C 32 H 54 HRMS calculated value of O4 (M + ):501.3943, measured value:501.3943.
[0751] 6-[3-(6-Hydroxy-5,5-dimethylhexyl)-phenyl]-2,2-dimethylhexan-1-ol (E3)
[0752] Concentrated aqueous HCl (20 mL) was added to 1,3-bis(5,5-dimethyl-6-(tetrahydropyran-2-yloxy)-hexyl]-phenylene (18.0 g, 35.7 mmol) in MeOH (200 mL). The reaction mixture was heated to reflux for 2 hours and stirred at room temperature overnight. The MeOH was evaporated in vacuo and the residue was dissolved in dichloromethane (200 mL). The solution was washed with water (100 mL), saturated NaHCO3 solution (100 mL) and brine (100 mL), and dried over MgSO4. The solvent was evaporated and the residue was purified by column chromatography (silica gel, EtOAc:hexane, 1:1) to give 6-[3-(6-hydroxy-5,5-dimethylhexyl)-phenyl]-2,2-dimethylhexan-1-ol (10.41 g, 87%, 86.4% by HPLC) as an oil. 1 H NMR (CDCl3): δ=7.21-7.19(m,1H),7.02-6.99(3H),3.32(s,4H),2.62(t,J=7.8Hz,4H),1.64-1.26(m,12H),0.89(s,12H). 13 C NMR (CDCl3): δ=142.6,128.5,128.1,125.6,71.9,38.4,35.8,35.0,32.4,23.7,23.5. C 22 H 38 HRMS calculated value of O4 (M + ): 335.2950, measured value: 335.2950.
[0753] 6-[3-(5-Carboxy-5-methylhexyl)-phenyl]-2,2-dimethylhexanoic acid
[0754] Pyridinium dichromate (74.85 g, 199 mmol) was added to a solution of 6-[3-(6-hydroxy-5,5-dimethylhexyl)-phenyl]-2,2-dimethylhexan-1-ol (8.5 g, 25.4 mmol) in DMF (200 mL) at room temperature. The reaction mixture was stirred for 30 hours and then heated to 40 ° C for 10 hours. Ethyl acetate (100 mL) was added under stirring, followed by water (200 mL) and concentrated H2SO4 (20 mL). The organic layer was separated and the aqueous layer was extracted with EtOAc (3×100 mL). The combined organic solution was washed with water (100 mL), saturated NaHCO3 solution (100 mL) and brine (2×100 mL) and dried over MgSO4. The solvent was evaporated and the residue was purified by column chromatography (silica gel, EtOAc: hexane, 1: 1). The resulting oil was stirred in Et2O: hexane (1:10, 50 mL) for 3 hours and the precipitated solid product (7.2 g, 78%, 96.1% by HPLC) was filtered (Compound I-32). Mp 99°C-101°C. Elemental analysis (C 22 H 34 O4): calculated value C, 72.89; H, 9.45; found value: C, 73.02; H, 9.57. 1 HNMR (CDCl3): δ = 7.19-7.16 (m, 1H), 6.99-6.94 (m, 3H), 2.58 (t, J = 7.1Hz, 4H), 1.63-1.56 (m, 8H), 1.32-1.22 (m, 4H), 1.18 (s, 12H). 13 C NMR (CDCl3): δ = 185.5, 142.2, 128.6, 128.3, 126.0, 42.0, 40.8, 35.7, 31.0, 25.1, 24.4. C 22 H 35 HRMS calculated value of O4 (MH + ): 363.2535, measured value: 363.2530.
[0755] Example 14: Synthesis of 5,5'-(1,2-phenylene)bis(2,2-dimethylpentanoic acid) (Compound I-61)
[0756]
[0757] 3-[2-(3-Hydroxypropyl)-phenyl]-propanol (F2)
[0758] Under Ar atmosphere, a solution of 3-[2-(2-ethoxycarbonylethyl)-phenyl]-propionic acid ethyl ester (prepared according to Fakhri, SA; Behrooz, YH Tetrahedron 2000, 56, 8301-8308; 14.5 g, 52.1 mmol) in THF (100 mL) was added dropwise to a stirred suspension of lithium aluminum hydride (3.0 g, 78.2 mmol) in anhydrous THF (100 mL) at room temperature over 50 minutes. The mixture was stirred for 2 hours, then cooled with an ice bath and carefully hydrolyzed by dropwise addition of deionized water (100 mL). The hydrolysis was completed by dropwise addition of 10% sulfuric acid at room temperature and stirring overnight. The mixture was extracted with dichloromethane (200 mL, 2×100 mL). The combined organic layers were washed with saturated sodium chloride solution (100 mL), dried over MgSO4, concentrated in vacuo, and dried under high vacuum to give 3-[2-(3-hydroxypropyl)-phenyl]-propanol (8.6 g, 85%, 87.9% pure by GC) as a cloudy oil, which was used in the next step without further purification. 1 H NMR (CDCl3): δ = 7.20-7.05 (m, 4H), 3.67 (t, 4H, J = 6.1Hz), 3.50-3.20 (m br., 2H), 2.72 (m, 4H), 1.82 (m, 4H). 13 C NMR (CDCl3): δ=139.98, 129.43, 126.24, 62.35, 34.36, 29.01. C 12 H 19 HRMS calculated value of O2 (MH + ): 195.1385, found: 195.1388. This known compound was prepared by a method different from the method described in Uenaka, M.; Kubota, B. Bull. Chem. Soc. Jpn. 1936, 11, 19-26.
[0759] 1,2-Bis-(3-bromopropyl)-benzene(F3)
[0760] A mixture of 3-[2-(3-hydroxypropyl)-phenyl]-propanol (8.6 g, 44.27 mmol), sodium bromide (18.6 g, 180.62 mmol) and water (16 mL) was heated at reflux while concentrated sulfuric acid (13.3 mL) was added dropwise over 20 minutes. The solution was heated at reflux for another 75 minutes, then cooled to room temperature and diluted with deionized water (200 mL). The mixture was extracted with dichloromethane (3×100 mL) and the combined organic layers were washed successively with water (100 mL), saturated sodium bicarbonate solution (100 mL), 10% aqueous sodium thiosulfate solution (200 mL) and saturated sodium chloride solution (100 mL). The organic layer was dried over MgSO 4 , concentrated in vacuo, and dried in high vacuum to yield the crude product (11.2 g) as a brown oil. The crude material was purified by flash chromatography (silica, hexanes, then hexanes / ethyl acetate = 90 / 10) to provide 1,2-bis-(3-bromopropyl)-benzene (8.25 g, 58%, 95.9% pure by GC) as a viscous yellow oil. 1 H NMR (CDCl3): δ = 7.16 (s, 4H), 3.33 (t, 4H, J = 6.3Hz), 2.79 (m, 4H), 2.12 (m, 4H). 13 C NMR (CDCl3): δ=138.69, 129.69, 126.66, 34.14, 33.62, 30.99. C 12 H 16 HRMS calculated value of Br2 (M + ): 317.9619, found: 317.9624. This known compound was prepared by a method different from the method described in Uenaka, M.; Kubota, B. Bull. Chem. Soc. Jpn. 1936, 11, 19-26.
[0761] 5-[2-(4-ethoxycarbonyl-4-methylpentyl)-phenyl]-2,2-dimethylpentanoic acid ethyl ester (F4)
[0762] Under Ar atmosphere, a solution of lithium diisopropylamide (2.0 M in heptane / THF / ethylbenzene, 41.2 mL, 82.48 mmol) was added dropwise to a solution of ethyl isobutyrate (8.7 g, 10.0 mL, 74.98 mmol) in anhydrous THF (100 mL) at -78 ° C for 15 minutes. After 85 minutes, a solution of 1,2-bis-(3-bromopropyl)-benzene (8.0 g, 74.98 mmol) in anhydrous THF (25 mL) was added dropwise over 10 minutes, followed by dropwise addition of DMPU (15 mL). The mixture was stirred at -78 ° C for another hour, then slowly warmed to room temperature over the next 2 hours, and stirred overnight. The reaction mixture was cooled with an ice bath and hydrolyzed by adding a saturated NH4Cl solution (100 mL) and deionized water (100 mL). The layers were separated, and the aqueous layer was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with water (100 mL), 1N hydrochloric acid (100 mL), water (100 mL) and saturated sodium chloride solution (100 mL). The organic phase was then dried over MgSO4 and concentrated in vacuo to give a crude product (14.0 g) as a light red oil. Purification by flash chromatography (silica, hexane / ethyl acetate = 95 / 5) provided 5-[2-(4-ethoxycarbonyl-4-methylpentyl)-phenyl]-2,2-dimethylpentanoic acid ethyl ester (8.2 g, 84%, 79% pure by GC) as a slightly yellowish oil. 1 H NMR (CDCl3): δ = 7.11 (s, 4H), 4.10 (q, 4H, J = 7.0Hz), 2.56 (t, 4H, J = 7.6Hz), 1.68-1.42 (m, 8H), 1.23 (t, 6H, J = 7.0Hz), 1.16 (s, 16H). 13 C NMR (CDCl3): δ = 177.95, 140.01, 129.12, 126.04, 60.34, 42.26, 40.79, 33.11, 26.75, 25.29, 14.41. C 24 H 39 HRMS calculated value of O4 (MH + ): 391.2848, measured value: 391.2846.
[0763] 5,5'-(1,2-phenylene)bis(2,2-dimethylpentanoic acid) (or 5-[2-(4-carboxy-4-methylpentyl)-phenyl]-2,2-dimethylpentanoic acid)
[0764] A solution of 5-[2-(4-ethoxycarbonyl-4-methylpentyl)-phenyl]-2,2-dimethylpentanoic acid ethyl ester (8.3 g, 21.25 mmol) and potassium hydroxide (>85%, 4.91 g, 74.38 mmol) in ethanol (20 mL) and water (10 mL) was heated at reflux for 4 hours. After cooling to room temperature, the mixture was diluted with water (50 mL) and concentrated in vacuo to a volume of approximately 60 mL. This aqueous solution was extracted with dichloromethane (2×30 mL) and then acidified to pH 1 with 1N hydrochloric acid (8 mL). The aqueous layer was extracted with dichloromethane (3×30 mL). The combined organic extracts were washed with saturated NaCl solution (30 mL), dried over MgSO4, and concentrated in vacuo to provide the crude product (5.50 g) as a white solid / viscous oil. The crude material was crystallized from heptane / dichloromethane at -5°C to provide very small white crystals, which were washed with cold heptane (10 mL) and dried in high vacuum (5.05 g, 71%, 98.3% pure by HPLC) (Compound I-61). Mp 108°C-109°C. Elemental analysis (C 20 H 30 O4): calculated value C, 71.82; H, 9.04; found value: C, 71.14; H, 9.06. 1 H NMR (DMSO-d6): δ = 12.7-11.5 (m br, 2H), 7.11 (s, 4H), 2.55 (t, 4H, J = 7.3Hz), 1.62-1.38 (m, 8H), 1.09 (s, 12H). 13 C NMR (DMSO-d6): δ = 178.83, 139.69, 128.98, 125.89, 41.25, 40.20, 32.49, 26.57, 25.04. C 20 H 31 HRMS calculated value of O4 (MH + ): 335.2222, measured value: 335.2232.
[0765] Bioassay
[0766] Example 15: Antiproliferative effects of compounds I-32, I-61, I-1 and III-1 in Hep3B and Hepa1-6 liver cancer cells
[0767] Human hepatoma cells Hep3B and mouse hepatoma cells Hepa1-6 were seeded in 96-well plates at a cell density of 3000 cells / well, respectively, with Eagle's Minimum Essential Medium (Corning) (for Hep3B cells) or Dulbecco's Modified Eagle's Medium (DMEM) high glucose (Gibco) (for Hepa1-6 cells), supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% antibiotic-antimycotic solution (Thermo-Fisher Scientific). The next day, cells were treated with 0 (vehicle control group), 0.1, 0.5, 1, 5, 10, 30, 50 or 100 μM compounds I-32, I-61, I-1 or III-1 (final concentration DMSO 0.1%) and grown at 37°C for 72 hours. On the 5th day, 10 μl of PrestoBlue TM Cell viability reagent (Invitrogen) was added to each well, and the plate was incubated for another 1-2 hours at 37° C. After incubation, the fluorescence signal was measured using a SpectraMax M5 microplate reader (Molecular Devices) at an excitation / emission wavelength of 560 / 590 nm.
[0768] The effects of compounds I-32, I-61, I-1 and III-1 on cell proliferation in Hepa1-6 cells, expressed as a percentage of vehicle control (DMSO, 0.1% final concentration), are shown in Figures 2A-2D The effects of compounds I-32, I-61, I-1 and III-1 on the proliferation of Hep3B cells are expressed as a percentage of the vehicle control (DMSO, 0.1% final concentration) and are shown in Figures 3A-3D (n=5, single experiment, error bars indicate standard deviation).
[0769] Example 16: Anti-clonogenic effects of compounds I-32, I-61, I-1 and III-1 in Hep3B and Hep1-6 liver cancer cells.
[0770] Hepatoma cell lines Hep3B (human) and Hepa1-6 (mouse) were maintained in Eagle's Minimum Essential Medium (Corning) (for Hep3B cells) or high glucose DMEM (Gibco) (for Hepa1-6 cells), supplemented with 10% FBS (Gibco) and 1% antibiotic-antimycotic (Thermo-Fisher Scientific). Each cell line was seeded in a 12-well plate at 1000 cells / well. The next day, the culture medium was replaced and treated with 0 (vehicle control, 0.1% DMSO), 1, 5, 10, 30, 50 or 100 μM compounds I-32, I-61, I-1 or III-1 (final concentration DMSO 0.1%) for 7 days. On the 9th day, the culture medium was removed, and the cells were fixed at room temperature for 10 minutes with 10% formalin (500 μl), washed with 1X PBS and stained with crystal violet. After 10 minutes, excess staining was removed by rinsing 3 times with tap water. The plates were allowed to dry overnight and the number of colonies (>50 cells) in each well was then counted using a light microscope as previously described by Villiani L.A. et al.
[0771] Effects of compounds I-32, I-61, I-1 and III-1 on clonogenicity in Hepa1-6 cells, expressed as a percentage of vehicle control (DMSO, 0.1% final concentration), are shown in Figures 4A-4D The effects of compounds I-32, I-61, I-1 and III-1 on clonogenicity in Hep3B cells, expressed as a percentage of vehicle control (DMSO, 0.1% final concentration), are shown in Figures 5A-5D (n=2, error bars indicate standard deviation).
[0772] Table 1 summarizes the biological results from Examples 15-17. ND = Not Determined.
[0773] Table 1: Effects of illustrative compounds of the invention on de novo lipogenesis (DNL), clonogenicity and cancer cell proliferation in human (h) and mouse (m) cells (IC 50 or proliferation reduction %).
[0774]
[0775] Example 17: Synergistic effect of illustrative compounds of the present invention with sorafenib or lenvatinib.
[0776] Combination studies were performed with compounds of the invention to determine the potential synergistic effects of sorafenib or lenvatinib in the presence of compound I-32 or compound I-61. In separate experiments, the IC values of sorafenib in the absence of a compound of the invention and lenvatinib in the absence of a compound of the invention for inhibiting proliferation were 50 In Hep3B cells, they were determined to be 3 μM and 0.5 μM, respectively, and in Hepa1-6 cells, they were 5 μM and 30 μM, respectively (data not shown).
[0777] Hep3B (provided by ATCC) or Hepa1-6 (provided by ATCC) cells were seeded in 96-well plates with complete medium at a density of 500 cells / well. On the 2nd day, the culture medium in each well was aspirated and replaced with 100 μl of fresh complete medium, and in the presence or absence of the compounds of the present invention, the cells were treated in a concentration-dependent manner (compound I-32 (100 μM) or compound I-61 (100 μM) alone or in combination with sorafenib (3 μM) or lenvatinib (0.5 μM)). Then, the cells were cultured in an incubator for 72 hours. On the 5th day, 10 μl of presto blue (Invitrogen, catalog number A13261) cell viability reagent was added to each 96-well plate and incubated at 37 ° C for 1-2 hours. After incubation, fluorescence was measured at an excitation / emission wavelength of 560 / 590 nm. The results are expressed as mean ± standard deviation (SD). All bar graphs and line graphs were prepared using Graph Pad Prism 8 software. Proliferation IC was calculated using the nonlinear regression mode in Graph Pad Prism 8. 50 For each cell type, the combination treatment showed a decrease in cell proliferation when compared to sorafenib or lenvatinib alone. The results in Hep3B cells are presented in Figure 6A-6B and the results in Hepa1-6 cells are presented in Figure 7A-7B middle.
[0778] Sorafenib and lenvatinib have the following structures:
[0779]
[0780]
[0781] Since further inhibition of cell proliferation was observed in the combination studies, the results were analyzed using CompuSyn software (provided by ComboSyn Inc.) to examine whether there was a synergistic or additive effect on the antiproliferative activity. Figures 8A-8D It was demonstrated that compounds I-32 and I-61 showed synergistic inhibitory effects in the presence of sorafenib or lenvatinib.
Claims
1. Have structure Use of a compound or a pharmaceutically acceptable salt thereof in the preparation of a medicament for inhibiting, reducing or delaying the development of liver fibrosis in a subject.
2. Have structure Use of a compound or a pharmaceutically acceptable salt thereof in the preparation of a medicament for inhibiting, reducing or delaying the development of liver fibrosis in a subject.
3. Have structure Use of a compound or a pharmaceutically acceptable salt thereof in preparing a medicament for treating or preventing cirrhosis.
4. Have structure Use of a compound or a pharmaceutically acceptable salt thereof in preparing a medicament for treating or preventing cirrhosis.
